[go: up one dir, main page]

US20050014786A1 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators - Google Patents

Tetrahydroquinoline derivatives as cannabinoid receptor modulators Download PDF

Info

Publication number
US20050014786A1
US20050014786A1 US10/889,274 US88927404A US2005014786A1 US 20050014786 A1 US20050014786 A1 US 20050014786A1 US 88927404 A US88927404 A US 88927404A US 2005014786 A1 US2005014786 A1 US 2005014786A1
Authority
US
United States
Prior art keywords
tetrahydroquinolin
benzyl
benzenesulfonamide
chloro
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/889,274
Inventor
Chongqing Sun
Doree Sitkoff
William Ewing
Yanting Huang
Bruce Ellsworth
Richard Sulsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US10/889,274 priority Critical patent/US20050014786A1/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUN, CHONGQING, SITKOFF, DOREE, ELLSWORTH, BRUCE A., HUANG, YANTING, EWING, WILLIAM R., SULSKY, RICHARD B.
Publication of US20050014786A1 publication Critical patent/US20050014786A1/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GERRITZ, SAMUEL, PENDRI, ANNAPURNA, EWING, WILLIAM R., HUANG, YANTING, SUN, CHONGQING, ELLSWORTH, BRUCE A., GU, ZHENGXIANG, MURUGESAN, NATESAN, SITKOFF, DOREE, SULSKY, RICHARD B.
Priority to US12/108,616 priority patent/US7884113B2/en
Priority to US12/984,628 priority patent/US8119808B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to tetrahydroquinoline containing compounds and compositions, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions in the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders.
  • Delta-9-tetrahydrocannabinol or Delta-9 THC the principle active component of Cannabis sativa (marijuana) is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression, analgesia, inflammation, emesis, anti-nocioception, sedation, and intraocular pressure.
  • cannabinoids lipophilic compounds
  • Other members of the cannabinoid family include the endogenous (arachidonic acid-derived) ligands, anandamide, 2-arachidonyl glycerol, and 2-arachidonyl glycerol ether.
  • Cannabinoids work through selective binding to and activation of G-protein coupled cannabinoid receptors.
  • Two types of cannabinoid receptors have been cloned including CB-1 (L. A. Matsuda, et al., Nature, 346, 561-564 (1990)), and CB-2 (S. Munro, et al., Nature, 365, 61-65 (1993)).
  • the CB-1 receptor is highly expressed in the central and peripheral nervous systems (M. Glass, et al., Neuroscience, 77, 299-318 (1997)), while the CB-2 receptor is highly expressed in immune tissue, particularly in spleen and tonsils.
  • the CB-2 receptor is also expressed on other immune system cells, such as lymphoid cells (S.
  • Phase IIb data reveal that SR-141716 dose-dependently reduced body weight in human subjects over a 16 week trial period. CB-1 antagonists have also been shown to promote cessation of smoking behavior. Phase II clinical data on smoking cessation were presented in September of 2002 at Sanofi-Synthelabo's Information meeting. This data showed that 30.2% of patients treated with the highest dose of SR-141716 stayed abstinent from cigarette smoke relative to 14.8% for placebo.
  • compounds which are capable of modulating the function of cannabinoid receptors.
  • the compounds are cannabinoid-1 receptor (CB-1) modulators, and have the general formula I including all pharmaceutically acceptable salts and stereoisomers, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 9 , R 10 , X and Y are described herein.
  • the present invention provides for a compound of formula I including all pharmaceutically acceptable salts and stereoisomers, wherein:
  • the present invention provides the compound of claim 1 , including all pharmaceutically acceptable salts and stereoisomers, wherein:
  • the present invention provides the compound of claim 1 , including all pharmaceutically acceptable salts and stereoisomers, wherein:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a pharmaceutical combination comprising a compound of formula I and a therapeutic agent selected from anti-obesity agents; appetite suppressants; anti-diabetic agents; anti-hyperlipidemia agents; hypolipidemic agents; hypocholesterolemic agents; lipid-modulating agents; cholesterol-lowering agents; HDL-raising agents; lipid-lowering agents; anti-hypertensive agents; agents used to treat sleep disorders; agents used to treat substance abuse and addictive disorders; anti-anxiety agents; anti-depressants; anti-psychotic agents; cognition enhancing agents; agents used to treat cognitive disorders; agents used to treat attention deficit-disorders; agents used to treat Alzheimer's disease; agents used to treat Parkinson's disease; anti-inflammatory agents; agents used to treat neurodegeneration; agents used to treat arteriosclerosis; agents used to treat respiratory conditions; agents used to treat gastrointestinal disorders including bowel and motility disorders; cardiac glycosides; and anti-tumor agents.
  • a therapeutic agent selected from anti-obesity agents; appetite suppressants
  • the present invention provides a pharmaceutical combination of a compound of formula I and another therapeutic agent wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of the pharmaceutical composition comprising a compound of formula I.
  • the present invention provides a pharmaceutical combination of a compound of formula I and an anti-obesity agent wherein the anti-obesity agent is selected from melanocortin receptor (MC4R) agonists; melanin-concentrating hormone receptor (MCHR) antagonists; growth hormone secretagogue receptor (GHSR) antagonists; orexin antagonists; galanin receptor modulators, CCK agonists; GLP-1 agonists and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonists; NPY2 and NPY4 modulators; corticotropin releasing factor agonists; histamine receptor-3 (H3) modulators; aP2 inhibitors; PPAR gamma modulators; PPAR delta modulators; acetyl-CoA carboxylase (ACC) inhibitors, adiponectin receptor modulators, 11 ⁇ -HSD inhibitors, beta 3 adrenergic agonists, including AJ9677, L750355 and
  • the present invention provides a method for the treatment or prevention of diseases and disorders associated with G-protein coupled cannabinoid receptor activity, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method for the treatment of diseases or disorders associated with the activity of the CB-1 receptor, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method for the treatment of bulimia, obesity or any disease resulting in the patient becoming overweight, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method for the treatment of metabolic disorders, eating disorders and appetitive disorders, including treatment of the conditions associated with those disorders, such as obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, reduced HDL, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive eating disorders, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • those disorders such as obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, reduced HDL, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive
  • the present invention provides a method for the treatment of obesity due to genetic or environmental causes, including overeating and bulemia, polycycstic ovary disease, craniopharyngeoma, Prader-Willi Syndrome, Frohlich's Syndrome, Type II diabetes, growth hormone deficiency, Turner's Syndrome and other pathological states characterized by reduced metabolic activity or reduced energy expenditure, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • alkyl denotes branched or unbranched hydrocarbon chains containing 1 to 20 carbons, preferably 1 to 12 carbons, and more preferably 1 to 8 carbons, in the normal chain, such as, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl and the like.
  • alkyl groups may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to hydroxyl, halo, haloalkyl, cyano, mercapto, alkylthio, heterocyclyl, aryl, heteroaryl, carboxyl, carbalkoyl, carboxamido, carbonyl, alkyl, alkenyl, alkynyl, nitro, amino, alkoxyl, aryloxyl, heteroaryloxyl, amido, and the like to form alkyl groups such as trifluoromethyl, 3-hydroxyhexyl, 2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like.
  • alkenyl refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 2 to 8 carbons with one or more double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like.
  • alkenyl groups may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to halo, haloalkyl, alkyl, alkoxy, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxyl, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, mercapto, and alkylthio.
  • alkynyl refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons with one or more triple bonds in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl,3-undecynyl, 4-dodecynyl and the like.
  • alkynyl groups may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to halo, haloalkyl, alkyl, alkoxy, alkenyl, aryl, arylalkyl, cycloalkyl, amino, hydroxyl, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, mercapto, and alkylthio.
  • halo haloalkyl
  • alkyl alkoxy
  • alkenyl aryl, arylalkyl
  • cycloalkyl amino, hydroxyl, heteroaryl, cycloheteroalkyl
  • alkanoylamino alkylamido
  • arylcarbonylamino nitro, cyano, mercapto, and alkylthio.
  • cycloalkyl as employed herein alone or as part of another group includes saturated or partially unsaturated (containing one or more double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, appended or fused, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the rings and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
  • any cycloalkyl may be optionally substituted through any available carbon atoms with one or more groups selected from hydrogen, halo, haloalkyl, alkyl, alkoxy, haloalkyloxy, hydroxyl, alkenyl, alkynyl, aryl, aryloxy, heteroaryl, heteroaryloxy, arylalkyl, heteroarylalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, mercapto, and alkylthio.
  • cycloalkylalkyl as used herein alone or as part of another group refers to alkyl groups as defined above having a cycloalkyl substituent, wherein said “cycloalkyl” and/or “alkyl” groups may optionally be substituted as defined above.
  • aryl as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl, 1-naphthyl and 2-naphthyl) and may optionally include one to three additional carbocyclic or heterocyclic fused rings, for example
  • aryl may optionally be substituted with one or more functional groups, such as halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, haloalkyl, CF 3 , hydroxy, alkoxy, haloalkoxy, OCF 3 , OCF 2 H, aryloxy, heteroaryloxy, arylalkoxy, alkylcarbonyloxy, arylcarbonyloxy, aryloxyalkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aminocarbonylaryl, heteroarylheteroaryl, nitro, cyano,
  • heteroaryl refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 heteroatoms such as nitrogen, oxygen or sulfur.
  • Such rings may be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl group and include possible N-oxides as described in Katritzky, A. R. and Rees, C. W., eds. Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds 1984, Pergamon Press, New York, N.Y.; and Katritzky, A. R., Rees, C. W., Scriven, E.
  • heteroaryl as defined herein, may optionally be substituted with one or more substituents such as the substituents included above in the definition of “substituted alkyl” and “substituted aryl”.
  • substituents include the following: and the like.
  • heteroarylalkyl as used herein alone or as part of another group refers to alkyl groups as defined above having a heteroaryl substituent, wherein said heteroaryl and/or alkyl groups may optionally be substituted as defined above.
  • heterocyclo represents an unsubstituted or substituted stable, 4 to 7-membered monocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms, with one to four heteroatoms selected from nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic groups include, but are not limited to, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl, furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl,
  • heterocycloalkyl as used herein alone or as part of another group refers to alkyl groups as defined above having a heterocyclyl substituent, wherein said heterocyclyl and/or alkyl groups may optionally be substituted as defined above.
  • arylalkyl refers to alkyl, alkenyl and alkynyl groups, respectively, as defined above having an aryl substituent as defined above.
  • Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, benzhydryl and naphthylmethyl and the like.
  • alkoxy as employed herein alone or as part of another group include, respectively, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups as defined above linked through an oxygen atom.
  • halogen or “halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with bromine, chlorine or fluorine being preferred.
  • cyano refers to a —CN group.
  • methylene refers to a —CH 2 — group.
  • nitro refers to a —NO 2 group.
  • acyl as employed herein alone or as part of another group includes, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups as defined above linked through a carbonyl group.
  • the compounds of formula I can be present as salts, which are also within the scope of this invention. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts.
  • organic carboxylic acids such as alkanecarboxylic acids of 1 to 4 carbon atoms, for example acetic acid, which are unsubstituted or substituted, for example, by a halogen as chloroacetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid or lysine or arginine, or such as benzoic acid, or with organic sulfonic acids, such as (C 1 -C 4 ) alkyl or arylsulfonic acids which are unsubstituted or substitute
  • Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the compounds of formula I having at least one acid group can form salts with bases.
  • Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethylpropylamine, or a mono, di or tri-hydroxy(lower)alkylamine, for example mono, di or triethanolamine.
  • Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds
  • Preferred salts of the compounds of formula I which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate and acetate salts.
  • Preferred salts of the compounds of formula I which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amine salts.
  • modulator refers to a chemical compound with capacity to either enhance (e.g., “agonist” activity) or partially enhance (e.g., “partial agonist” activity) or inhibit (e.g., “antagonist” activity or inverse agonist activity) a functional property or biological activity or process (e.g., enzyme activity or receptor binding); such enhancement or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway, and/or may be manifest only in particular cell types.
  • enhance e.g., “agonist” activity
  • partial agonist e.g., “partial agonist” activity
  • inhibit e.g., “antagonist” activity or inverse agonist activity
  • a functional property or biological activity or process e.g., enzyme activity or receptor binding
  • prodrug esters as employed herein includes esters and carbonates formed by reacting one or more hydroxyl group of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates and the like.
  • any compound that can be converted in vivo to provide the bioactive agent i.e., the compound of formula I
  • prodrugs Various forms of prodrugs are well known in the art. A comprehensive description of prodrugs and prodrug derivatives appears in:
  • An administration of a therapeutic agent of the invention includes administration of a therapeutically effective amount of the agent of the invention.
  • therapeutically effective amount refers to an amount of a therapeutic agent to treat or prevent a condition treatable by administration of a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or preventative or ameliorative effect. The effect may include, for example, treatment or prevention of the conditions listed herein.
  • the precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration.
  • All stereoisomers of the compounds of the instant invention are contemplated, either in mixture or in pure or substantially pure form.
  • the compounds of the present invention can have asymmetric centers at any of the carbon atoms including those within any of the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof.
  • the processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. In order to prepare diastereomeric or enantiomeric products, conventional methods for isomer separation may be employed. These include, for example, chromatographic techniques, chiral HPLC, fractional crystallization, and sequences of derivatization, separation and de-derivatization.
  • the amino group of compound II can be suitably protected by, for example, a tert-butyloxycarbonyl, or derivatized as in compound I with, for example, a arylsulfonyl group as shown in III.
  • Compound II can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art. Reduction of III via hydrogenation in the presence of a transition metal catalyst, such as platinum oxide, or palladium hydroxide on carbon affords intermediate IV.
  • compound V can be reduced via hydrogenation in the presence of a transition metal catalyst, such as platinum oxide, or palladium hydroxide on carbon to afford intermediate VI, which can be hydrolyzed to provide acid VII. Conversion of the carboxylic acid group of VII via Curtius rearrangement affords IV as free or protected amines.
  • a transition metal catalyst such as platinum oxide, or palladium hydroxide on carbon
  • Conversion of the carboxylic acid group of VII via Curtius rearrangement affords IV as free or protected amines.
  • Compound V can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • halogenated XVI and XVI′ can be prepared by treatment of intermediate IV (prepared as outlined in Scheme 1 and 2) with an appropriate bromination or clorination reagent XII. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I.
  • compounds of formula Ia can be prepared from intermediate IV (prepared as outlined in Scheme 1 and 2). It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I.
  • Treatment of IV with aldehyde XVII in the presence of triethylsilane and trifluoroacetic acid, or sodium triacetoxyborohydride affords intermediate XIX (where X ⁇ CH 2 ).
  • treatment of IV with reagent XVIII in the presence of a base provides intermediate XIX (for example, where X ⁇ SO 2 , or CO, or COO).
  • Removal of the N-protection group can be achieved by treatment of XIX with an acid (e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in methylene chloride) to provide intermediate XX.
  • an acid e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in methylene chloride
  • Treatment of XX with reagent XXI in the presence of a base provides compounds of formula Ia.
  • Reagents XVII, XVIII and XXI can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • compounds of formula Ia can be prepared as illustrated in Scheme 6. Removal of the N-protection group (e.g. Boc) of compound IV can be achieved by treatment with an acid (e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in methylene chloride) to provide intermediate XXII. Treatment of XXII with a reagent XXI in the presence of a base provides intermediate XXIII. Treatment of XXIII with an aldehyde XVII in the presence of triethylsilane and trifluoroacetic acid, or sodium triacetoxyborohydride affords compound Ia (where X ⁇ CH 2 ). Alternatively, treatment of XXIII with a reagent XVIII in the presence of a base affords compound Ia (for example, where X ⁇ SO 2 , or CO, or COO).
  • an acid e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in
  • compounds of formula Ib can be prepared from intermediate XX, which are prepared as outlined in Scheme 5. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I. Treatment of XX with a reagent XXIV in the presence of a base provides compound Ib. Alternatively, Ib can also be prepared by reaction of intermediate XXV with a primary or a secondary amine in acetonitrile in the presence of a tertiary amine (e.g. diisopropylethyiamine).
  • a tertiary amine e.g. diisopropylethyiamine
  • Intermediate XXV can be prepared by treatment of intermediate XX with the reaction adduct of 2-chloroethanol and chlorosulfonyl isocyanate according to the procedures reported by L. Ducry, et. al. ( Helv. Chim. Acta. 82, pp2432-2447, (1999)).
  • compounds of formula Ic can be prepared from intermediate XXIII (prepared as outlined in Scheme 6). It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I.
  • a reagent XXVI in the presence of a palladium catalyst (e.g. Pd(OAc) 2 and a ligand (e.g. BINAP) provides compounds of formula Ic.
  • a palladium catalyst e.g. Pd(OAc) 2
  • a ligand e.g. BINAP
  • Intermediate XXVI can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • compounds of formula Ie can be prepared via C—C bond coupling by treatment of intermediate Id with an appropriate aryl or heteroaryl boronic acid, or an aryl or heteroaryl tin reagent of formula XXVII in the presence of a palladium catalyst.
  • Compounds of formula If can be prepared via C—N or C—O bond coupling by treatment of intermediate Id with a heterocyclic (e.g. a lactam, pyridone, imidazole or pyrizole) or a hydroxyarene (e.g. phenol), or a hydroxyheteroarene of formula XXVIII in the presence of a copper catalyst.
  • Compounds of formula Ig can be prepared by treatment of intermediate Id with zinc cyanide in the presence of a palladium catalyst, e.g. Pd(Ph 3 P) 4 . It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I.
  • Reagents XXVII and XXVIII can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • compounds of formula Ih can be prepared by treatment of Ia with an alkylating reagent XXIX in the presence of a base. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R 6 , R 6a , R 7 , R 7a , R 8 as specified in the general formula I.
  • Reagent XXIX can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • reagents mentioned throughout are example reagents, not meant to be limiting. Those skilled in the art will recognize that there are many acids (trifluoroacetic acid, hydrochloric acid, polyphosphoric acid, etc.), many bases (triethylamine, sodium hydride, potassium methoxide, etc.), many oxidants (hydrogen peroxide, 3-chloroperoxybenzoic acid, etc.), many hydrogenation catalysts (palladium, platinum oxide, Raney® Nickel, etc.), and so on that may be employed to synthesize the compounds of the invention. In some cases alternative reagents known to those skilled in the art will be superior to those specifically mentioned. Alternative reagents may be found in Reagents For Organic Synthesis (Fieser and Fieser, John Wiley & Sons) and Compendium of Organic Synthetic Methods (John Wiley & Sons).
  • Standard protecting groups may be used at any stage of synthesis, for example in manipulating a functional group to convert one compound of formula I to another compound of formula I, or in manipulating a functional group to convert one protected amine, for example, amine II to another protected amine II, or to avoid undesired reaction during the conversion of amines, for example amine XX to compounds of formula I, or during the sequence of steps leading to the formation of protected amine, for example amine II.
  • Compound 2A was prepared from the (S,R) diastereomer isolated in Example 1E by procedures analogous to those described in Example 1F.
  • Compound 2B was prepared from 2A by procedures analogous to those described in Example 1G.
  • Compound 21B was prepared from 21A by procedures analogous to those described in Example 1D and 1G.
  • Compound 22B was prepared from 22A by procedures analogous to those described in Example 1D.
  • the title compound was synthesized as part of library using the following procedure in a parallel synthesis fashion using 48 well red and blue minireactors.
  • the title compound was synthesized as part of library using the following procedure in a parallel synthesis fashion using 48 well red and blue minireactors. Typical procedure: To a solution of 22B (14 mg, 0.05 mmol) in DCE (0.5 mL) at RT was added NMM (0.109 mL, 0.1 mmol), followed by addition of benzene sulfonylchloride (17.6 mg, 0.1 mmol) in DCE (0.5 uL). The reaction mixture was shaken at RT for 24 h, and treated with 100 mg of PS-Trisamine (4 mmol/g loading) for 2 h to remove excess sulfonyl chloride.
  • homochiral 87C can also be prepared from (S)-2-(tert-butyloxy carbonylamino)-3-(2-nitrophenyl)propanoic acid as described below starting from 87D.
  • the title compound may be prepared either as described in US 2004/002495 or as follows: To a solution of (S)-2-(tert-butyloxycarbonylamino)-3-(2-nitrophenyl)propanoic acid (987 mg, 3.18 mmol) in MeOH(100 mL) was added 10% palladium on carbon (300 mg), and the mixture was stirred at RT under hydrogen at 80 psi for 24 h. Filtration and solvent evaporation under vacuum provided the title compound (800 mg) as a foam.
  • the title compound was obtained via chiral chromatographic separation of racemic 87B using a Chiralpak AD column (5 ⁇ 50 cm, 20 ⁇ m chiral stationary phase) eluting with 30% isopropanol in heptane.
  • the title compound can be prepared from commercially available (R)-2-(tert-butyloxycarbonylamino)-3-(2-nitrophenyl)propanoic acid according to the procedures described in Example 87.
  • Compound 89D was prepared from 89C by procedures analogous to those described in Example 1G.
  • the title compound was obtained via chiral chromatographic separation of racemic 89D using a Chiralpak AD column (5 ⁇ 50 cm, 20 ⁇ m chiral stationary phase) eluting with 20% isopropanol in heptane.
  • the title compound was also prepared using the following procedures: To a solution of 87C (510 mg, 1.11 mmol) in THF/MeOH (2:1, 15 mL) was added phenylboronic acid (272 mg, 2.22 mmol), followed by K 2 CO 3 (613 mg, 4.44 mmol) and PXPd (30 mg, 0.056 mmol). The reaction mixture was stirred at 60° C. for 2 h, then additional amount of phenylboronic acid (54 mg, 0.44 mmol) and PXPd (16 mg, 0.028 mmol) were added. After 2 h at 60° C., same amount of phenylboronic acid and PXPd were added again to the reaction mixture to push completion of the reaction.
  • the title compound was obtained via chiral chromatographic separation of racemic 89D using a Chiralpad AD column (5 ⁇ 50 cm, 20 ⁇ m chiral stationary phase) eluting with 20% isopropanol in heptane.
  • the title compound can also be prepared from homochiral 88 using the procedures described in Example 89E.
  • the title compound can be prepared from homochiral 87C using the procedures described in Example 89E.
  • MS (ES): m/z 472 [M+1] + .
  • Compound 111A was prepared from 89A and 4-fluorophenylboronic acid, then N-boc deprotection by procedures analogous to those described in 89B and 89C.
  • Compound 111B was prepared from 111A and 3-methoxyphenylsulfonyl chloride by procedures analogous to those described in 1G.
  • Compound 113A was prepared from 87A and 4-fluorophenylboronic acid by procedures analogous to those described in 89E.
  • Compound 113B was prepared from 113A and 3-cyanobenzaldehyde by procedures analogous to those described in 22A.
  • the title compound was prepared from 4-chloro-2-nitrobenzyl chloride and diethylacetamidomalonate according to the procedures described by Davis, A. L.; et al, in Arch. Biochem. Biophys., 102, 48 (1963).
  • Compound 153A was prepared from 1D by procedures analogous to those described in Example 1G.
  • compound 155A was prepared from 1F and piperidine-1-sulfonyl chloride (prepared according to the procedures described by Padma, D. K.; Bhat, V. Subrahmanya; Murthy, A. R. Vasudeva, in J. Fluorine Chem., EN. 20, 425-438 (1982)).
  • Morpholine-4-sulfonic acid [1-(3-chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroqiuinolin-3-yl]-amide
  • compound 156A was prepared from 1D and morpholine-4-sulfonyl chloride (prepared following the procedures described by Antonio Vandi et al, in J. Org. Chem. 26, 3478-3480, (1961)).
  • 157A was prepared from 1C and benzaldehyde by procedures analogous to those described in Example 22A, followed by removal of N-Boc protecting group according to the procedures described in Example 22B.
  • Compound 165A was prepared from racemate 1G and benzaldehyde by procedures analogous to those described in Example 22A.
  • Compound 170A was prepared from 87A and phenylboronic acid by procedures analogous to those described in Example 91A.
  • Compound 170B was prepared from 170A by procedures analogous to those described in Example 1B.
  • Radioligand binding studies were conducted in membranes prepared from Chinese Hamster Ovary (CHO) cells that over-express recombinant human CB-1 (CHO-CB-1 cells). Total assay volume for the binding studies was 100 ⁇ l. 5 ug of membranes were brought up to a final volume of 95 ⁇ l with Binding Buffer (25 mM HEPES, 150 mM NaCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.25% BSA). The diluted membranes were preincubated with a compound or DMSO vehicle. The binding reaction was initiated by the addition of 2 nM final 3 H-CP-55,940 (120 Ci/mmol) and proceeded for 2.5 hours at room temperature.
  • Binding Buffer 25 mM HEPES, 150 mM NaCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.25% BSA.
  • the diluted membranes were preincubated with a
  • the binding reaction was terminated by transferring the reaction to GF/B 96 well plates (presoaked with 0.3% polyethylenimine) using a Packard Cell Harvester. The filter was washed with 0.25 ⁇ PBS, 30 ⁇ l MicroScint was added per well, and the bound radiolabel was quantitated by scintillation counting on a Packard TopCount Scintillation Counter.
  • the CB-2 radioligand binding assay was conducted identically except that the membranes from CHO-CB-2 cells were used.
  • the compound For a compound to be considered a CB-1 antagonist, the compound must possess a CB-1 receptor binding affinity Ki less than 4000 nM. As determined by the assay described above, the CB-1 receptor binding K i values of the preferred working examples fall within the range of 0.01 nM to 4000 nM.
  • Functional CB-1 inverse agonist activity of test compounds was determined in CHO-CB-1 cells using a cAMP accumulation assay.
  • CHO-CB-1 cells were grown in 96 well plates to near confluence.
  • growth medium was aspirated and 100 of Assay Buffer (PBS plus 25 mM HEPES/0.1 mM 3-isobutyl-1-methylxanthine/0.1% BSA) was added.
  • Assay Buffer PBS plus 25 mM HEPES/0.1 mM 3-isobutyl-1-methylxanthine/0.1% BSA
  • Compounds were added to the Assay buffer diluted 1:100 from 100% DMSO and allowed to preincubate for 10 minutes prior to addition of 5 uM forskolin.
  • the mixture was allowed to proceed for 15 minutes at room temperature and was terminated by the addition of 0.1 N HCl.
  • the total intracellular cAMP concentration was quantitated using the Amersham cAMP SPA kit.
  • the compounds of the present invention are cannabinoid receptor modulators, and include compounds which are, for example, selective agonists, partial agonists, inverse agonists, antagonists or partial antagonists of the cannabinoid receptor. Accordingly, the compounds of the present invention may be useful for the treatment or prevention of diseases and disorders associated with G-protein coupled cannabinoid receptor activity. Preferably, compounds of the present invention possess activity as antagonists or inverse agonists of the CB-1 receptor, and may be used in the treatment of diseases or disorders associated with the activity of the CB-1 receptor.
  • the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to metabolic and eating disorders as well as conditions associated with metabolic disorders, (e.g., obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive eating disorders) or psychiatric disorders, such as substance abuse, depression, anxiety, mania and schizophrenia.
  • metabolic disorders e.g., obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervos
  • These compounds could also be used for the improvement of cognitive function (e.g., the treatment of dementia, including Alzheimer's disease, short term memory loss and attention deficit disorders); neurodegenerative disorders (e.g., Parkinson's Disease, cerebral apoplexy and craniocerebral trauma) and hypotension (e.g., hemorrhagic and endotoxin-inducd hypotension).
  • cognitive function e.g., the treatment of dementia, including Alzheimer's disease, short term memory loss and attention deficit disorders
  • neurodegenerative disorders e.g., Parkinson's Disease, cerebral apoplexy and craniocerebral trauma
  • hypotension e.g., hemorrhagic and endotoxin-inducd hypotension.
  • These compounds could also be used for treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction (e.g., associated with valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure); and improvement of the overall pulmonary function; transplant rejection; rheumatoid arthritis; multiple sclerosis; inflammatory bowel disease; lupus; graft vs. host disease; T-cell mediated hypersensitivity disease; psoriasis; asthma; Hashimoto's thyroiditis; Guillain-Barre syndrome; cancer; contact dermatitis; allergic rhinitis; and ischemic or reperfusion injury.
  • cardiac dysfunction e.g., associated with valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure
  • improvement of the overall pulmonary function e.g., transplant rejection; rheumatoid arthritis; multiple sclerosis; inflammatory bowel disease; lupus; graft
  • appetitive disorders are understood as meaning: disorders associated with a substance and especially abuse of a substance and/or dependency on a substance, disorders of eating behaviors, especially those liable to cause excess weight, irrespective of its origin, for example: bulimia nervosa, craving for sugars.
  • the present invention therefore further relates to the use of a CB-1 receptor antagonist or inverse agonist for the treatment of bulimia and obesity, including obesity associated with type II diabetes (non-insulin-dependent diabetes), or more generally any disease resulting in the patient becoming overweight.
  • Obesity is defined by a body mass index (kg/m 2 ) of at least 26. It may be due to any cause, whether genetic or environmental, including overeating and bulemia, polycycstic ovary disease, craniopharyngeoma, Prader-Willi Syndrome, Frohlich's Syndrome, Type II diabetes, growth hormone deficiency, Turner's Syndrome and other pathological states characterized by reduced metabolic activity or reduced energy expenditure.
  • the term “treating” or “treatment” encompasses prevention, partial alleviation, or cure of the disease or disorder.
  • treatment of obesity is expected to prevent progression of medical covariants of obesity, such as arteriosclerosis, Type II diabetes, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders.
  • medical covariants of obesity such as arteriosclerosis, Type II diabetes, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders.
  • Compounds in the present invention may also be useful in treating substance abuse disorders, including substance dependence or abuse without physiological dependence.
  • Substances of abuse include alcohol, amphetamines (or amphetamine-like substances), caffeine, cannabis, cocaine, hallucinogens, inhalents, nicotine, opioids, phencyclidine (or phencyclidine-like compounds), sedative-hypnotics or benzodiazepines, and other (or unknown) substances and combinations of the above.
  • the terms “substance abuse disorders” also includes drug or alcohol withdrawal syndromes and substance-induced anxiety or mood disorder with onset during withdrawal.
  • Compounds in the present invention may be useful in treating memory impairment and cognitive disorders.
  • the condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information.
  • Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
  • Dementias are diseases that include memory loss and additional intellectual impairment separate from memory.
  • Cannabinoid receptor modulators may also be useful in treating cognitive impairments related to attentional deficits, such as attention deficit disorder.
  • Parkinsons's Disease is a neurodenerative movement disorder characterized by bradykinesia and tremor.
  • the compounds of the present invention are further useful for the treatment and prevention of respiratory diseases and disorders.
  • Respiratory diseases for which cannabinoid receptor modulators are useful include, but are not limited to, chronic pulmonary obstructive disorder, emphysema, asthma, and bronchitis.
  • cannabinoid receptor modulators block the activation of lung epithelial cells by moeties such as allergic agents, inflammatory cytokines or smoke, thereby limiting release of mucin, cytokines, and chemokines, or selectively inhibiting lung epithelial cell activation.
  • the compounds employed in the present invention may stimulate inhibitory pathways in cells, particularly in leukocytes, lung epithelial cells, or both, and are thus useful in treating such diseases.
  • Leukocyte activation is defined herein as any or all of cell proliferation, cytokine production, adhesion protein expression, and production of inflammatory mediators.
  • Epithelial cell activation is defined herein as the production of any or all of mucins, cytokines, chemokines, and adhesion protein expression.
  • transplant such as organ transplant, acute transplant, xenotransplant or heterograft or homograft (such as is employed in burn treatment)
  • protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes
  • transplantation tolerance induction arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis
  • respiratory and pulmonary diseases including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, and acute respiratory distress syndrome (ARDS); inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosis); graft vs.
  • COPD chronic obstructive pulmonary disease
  • ARDS acute respiratory distress syndrome
  • T-cell mediated hypersensitivity diseases including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenal glands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases; glomerulonephritis; serum sickness; uticaria; allergic diseases such as respiratory allergies (asthma, hayfever, allergic rhinitis) or skin allergies; scleracierma; mycosis fungoides; acute inflammatory and respiratory responses (such as acute respiratory distress syndrome and ishchemia/reperfusion
  • leukocyte activation-associated or “leukocyte-activation mediated” disease as used herein includes each of the above referenced diseases or disorders.
  • the compounds of the present invention are useful for treating the aforementioned exemplary disorders irrespective of their etiology.
  • the combined activity of the present compounds towards monocytes, macrophages, T-cells, etc. may be useful in treating any of the above-mentioned disorders.
  • Cannabinoid receptors are important in the regulation of Fc gamma receptor responses of monocytes and macrophages.
  • Compounds of the present invention inhibit the Fc gamma dependent production of TNF alpha in human monocytes/macrophages.
  • the ability to inhibit Fc gamma receptor dependent monocyte and macrophage responses results in additional anti-inflammatory activity for the present compounds. This activity is especially of value, for example, in treating inflammatory diseases such as arthritis or inflammatory bowel disease.
  • the present compounds are useful for treating autoimmune glomerulonephritis and other instances of glomerulonephritis induced by deposition of immune complexes in the kidney that trigger Fc gamma receptor responses leading to kidney damage.
  • Cannabinoid receptors are expressed on lung epithelial cells. These cells are responsible for the secretion of mucins and inflammatory cytokines/chemokines in the lung and are thus intricately involved in the generation and progression of respiratory diseases. Cannabinoid receptor modulators regulate both the spontaneous and the stimulated production of both mucins and cytokines. Thus, such compounds are useful in treating respiratory and pulmonary diseases including, COPD, ARDS, and bronchitis.
  • cannabinoid receptors may be expressed on gut epithelial cells and hence regulate cytokine and mucin production and may be of clinical use in treating inflammatory diseases related to the gut. Cannabinoid receptors are also expressed on lymphocytes, a subset of leukocytes. Thus, cannabinoid receptor modulators will inhibit B and T-cell activation, proliferation and differentiation. Thus, such compounds will be useful in treating autoimmune diseases that involve either antibody or cell mediated responses such as multiple sclerosis and lupus.
  • cannabinoid receptors regulate the Fc epsilon receptor and chemokine induced degranulation of mast cells and basophils. These play important roles in asthma, allergic rhinitis, and other allergic disease. Fc epsilon receptors are stimulated by IgE-antigen complexes. Compounds of the present invention inhibit the Fc epsilon induced degranulation responses, including the basophil cell line, RBL. The ability to inhibit Fc epsilon receptor dependent mast cell and basophil responses results in additional anti-inflammatory and anti-allergic activity for the present compounds. In particular, the present compounds are useful for treating asthma, allergic rhinitis, and other instances of allergic disease.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent.
  • compounds of the present invention can be used alone, in combination with other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-obesity agents; anti-diabetic agents, appetite suppressants; cholesterol/lipid-lowering agents, HDL-raising agents, cognition enhancing agents, agents used to treat neurodegeneration, agents used to treat respiratory conditions, agents used to treat bowel disorders, anti-inflammatory agents; anti-anxiety agents; anti-depressants; anti-hypertensive agents; cardiac glycosides; and anti-tumor agents.
  • Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the cannabinoid receptor modulators in accordance with the invention.
  • Suitable anti-obesity agents for use in combination with the compounds of the present invention include melanocortin receptor (MC4R) agonists, melanin-concentrating hormone receptor (MCHR) antagonists, growth hormone secretagogue receptor (GHSR) antagonists, galanin receptor modulators, orexin antagonists, CCK agonists, GLP-1 agonists, and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonsist, NPY2 and NPY4 modulators, corticotropin releasing factor agonists, histamine receptor-3 (H3) modulators, aP2 inhibitors, PPAR gamma modulators, PPAR delta modulators, acetyl-CoA carboxylase (ACC) inihibitors, 11- ⁇ -HSD-1 inhibitors, adinopectin receptor modulators; beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (
  • a thyroid receptor beta modulator such as a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and GB98/284425 (KaroBio), a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), serotonin receptor agonists, (e.g., BVT-933 (Biovitrum)), monoamine reuptake inhibitors or releasing agents, such as fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine or mazindol, anorectic agents such as topiramate (John
  • Suitable anti-diabetic agents for use in combination with the compounds of the present invention include: insulin secretagogues or insulin sensitizers, which may include biguanides, sulfonyl ureas, glucosidase inhibitors, aldose reductase inhibitors, PPAR ⁇ agonists such as thiazolidinediones, PPAR ⁇ agonists (such as fibric acid derivatives), PPAR ⁇ antagonists or agonists, PPAR ⁇ / ⁇ dual agonists, 11- ⁇ -HSD-1 inhibitors, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1), GLP-1 agonist, and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B inhibitor).
  • biguanides such as thiazol
  • the antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl.
  • a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl.
  • the compounds of the present invention will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.
  • the antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Pat. No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms.
  • the oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Pat. No. 4,904,769) or miglitol (disclosed in U.S. Pat. No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.
  • the compounds of the present invention may be employed in combination with a PPAR ⁇ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Pat. No.
  • a PPAR ⁇ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Pat. No.
  • Glaxo-Welcome's GL-262570 englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.
  • the compounds of the present invention may be employed with a PPAR ⁇ / ⁇ dual agonist such as MK-767/KRP-297 (Merck/Kyorin; as described in, K. Yajima, et. al., Am. J. Physiol. Endocrinol. Metab., 284: E966-E971 (2003)), AZ-242 (tesaglitazar; Astra-Zeneca; as described in B. Ljung, et. al., J. Lipid Res., 43, 1855-1863 (2002)); muraglitazar; or the compounds described in U.S. Pat. No. 6,414,002.
  • MK-767/KRP-297 Merck/Kyorin; as described in, K. Yajima, et. al., Am. J. Physiol. Endocrinol. Metab., 284: E966-E971 (2003)
  • AZ-242 tesaglitazar; Astra-Zen
  • the compounds of the present invention may be employed in combination with anti-hyperlipidemia agents, or agents used to treat arteriosclerosis.
  • An example of an hypolipidemic agent would be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Pat. No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Pat. No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Pat. No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Pat. Nos. 4,448,784 and 4,450,171.
  • HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Pat. No. 5,354,772, cerivastatin disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Pat. Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pitavastatin (Nissan/Sankyo's nisvastatin (NK-104) or itavastatin), disclosed in U.S. Pat. No.
  • phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.
  • the squalene synthetase inhibitors suitable for use herein include, but are not limited to, ⁇ -phosphono-sulfonates disclosed in U.S. Pat. No. 5,712,396, those disclosed by Biller, et al, J. Med. Chem., 31, 1869-1871 (1998) including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Pat. No. 4,871,721 and 4,924,024 and in Biller, S. A., Neuenschwander, K., Ponpipom, M. M., and Poulter, C. D., Current Pharmaceutical Design, 2, 1-40 (1996).
  • squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano, et al, J. Med. Chem., 20, 243-249 (1977), the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 98, 1291-1293 (1976), phosphinylphosphonates reported by McClard, R. W. et al., J. Am. Chem. Soc., 109, 5544 (1987) and cyclopropanes reported by Capson, T. L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.
  • hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Pat. No.
  • bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (SECHOLEX, POLICEXIDE) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphos-phorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, aci
  • the other hypolipidemic agent may be an ACAT inhibitor (which also has anti-atherosclerosis activity) such as disclosed in, Drugs of the Future, 24, 9-15 (1999), (Avasimibe); “The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Nicolosi et al, Atherosclerosis (Shannon, Irel), 137 (1), 77-85 (1998); “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein”, Ghiselli, Giancarlo, Cardiovasc.
  • ACAT inhibitor which also has anti-atherosclerosis activity
  • the hypolipidemic agent may be an upregulator of LDL receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).
  • the hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).
  • the other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as well as CETi-1 and JTT-705.
  • CETP cholesteryl transfer protein inhibitor
  • the hypolipidemic agent may be an ileal Na + /bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).
  • the ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Pat. No. 5,447,954.
  • the other lipid agent also includes a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as an isoflavone such as genistein, daidzein, glycitein or equol, or phytosterols, phytostanol or tocotrienol as disclosed in WO 2000/015201; a beta-lactam cholesterol absorption inhibitor such as disclosed in EP 675714; an HDL upregulator such as an LXR agonist, a PPAR ⁇ -agonist and/or an FXR agonist; an LDL catabolism promoter such as disclosed in EP 1022272; a sodium-proton exchange inhibitor such as disclosed in DE 19622222; an LDL-receptor inducer or a steroidal glycoside such as disclosed in U.S.
  • a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as
  • Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, pitavastatin and rosuvastatin, as well as niacin and/or cholestagel.
  • the compounds of the present invention may be employed in combination with anti-hypertensive agents.
  • suitable anti-hypertensive agents for use in combination with the compounds of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and/or T-type; e.g.
  • diltiazem verapamil, nifedipine, amiodipine and mybefradil
  • diuretics e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisino
  • Dual ET/AII antagonist e.g., compounds disclosed in WO 00/01389
  • neutral endopeptidase (NEP) inhibitors neutral endopeptidase (NEP) inhibitors
  • vasopepsidase inhibitors dual NEP-ACE inhibitors
  • omapatrilat and gemopatrilat e.g., omapatrilat and gemopatrilat
  • Cannbinoid receptor modulators could be useful in treating other diseases associated with obesity, including sleep disorders. Therefore, the compounds described in the present invention could be used in combination with therapeutics for treating sleep disorders. Examples of suitable therapies for treatment of sleeping disorders for use in combination with the compounds of the present invention include melatonin analogs, melatonin receptor antagonists, ML 1 B agonists, GABA receptor modulators; NMDA receptor modulators, histamine-3 (H3) receptor modulators, dopamine agonists and orexin receptor modulators.
  • Cannabinoid receptor modulators may reduce or ameliorate substance abuse or addictive disorders. Therefore, combination of cannabinoid receptor modulators with agents used to treat addictive disorders may reduce the dose requirement or improve the efficacy of current addictive disorder therapeutics. Examples of agents used to treat substance abuse or addictive disorders are: selective serotonin reuptake inhibitors (SSRI), methadone, buprenorphine, nicotine and bupropion.
  • SSRI selective serotonin reuptake inhibitors
  • methadone methadone
  • buprenorphine nicotine and bupropion.
  • Cannabinoid receptor modulators may reduce anxiety or depression; therefore, the compounds described in this application may be used in combination with anti-anxiety agents or antidepressants.
  • suitable anti-anxiety agents for use in combination with the compounds of the present invention include benzodiazepines (e.g., diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam), 5HT1A receptor agonists (e.g., buspirone, flesinoxan, gepirone and ipsapirone), and corticotropin releasing factor (CRF) antagonists.
  • benzodiazepines e.g., diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and
  • SSRIs selective
  • the combination of a conventional antipsychotic drug with a CB-1 receptor antagonist could also enhance symptom reduction in the treatment of psychosis or mania. Further, such a combination could enable rapid symptom reduction, reducing the need for chronic treatment with antipsychotic agents. Such a combination could also reduce the effective antipsychotic dose requirement, resulting in reduced probability of developing the motor dysfunction typical of chronic antipsychotic treatment.
  • Suitable antipsychotic agents for use in combination with the compounds of the present invention include the phenothiazine (chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine), thioxanthine (chlorprothixene, thiothixene), heterocyclic dibenzazepine (clozapine, olanzepine and aripiprazole), butyrophenone (haloperidol), dipheyylbutylpiperidine (pimozide) and indolone (molindolone) classes of antipsychotic agents.
  • Other antipsychotic agents with potential therapeutic value in combination with the compounds in the present invention include loxapine, sulpiride and risperidone.
  • schizophrenic disorders include paranoid, disorganized, catatonic, undifferentiated and residual schizophrenia, schizophreniform disorder, shcizoaffective disorder, delusional disorder, brief psychotic disorder and psychotic disorder not specified.
  • Suitable antipsychotic drugs for combination with the compounds in the present invention include the antipsychotics mentioned above, as well as dopamine receptor antagonists, muscarinic receptor agonists, 5HT2A receptor antagonists and 5HT2A/dopamine receptor antagonists or partial agonists (e.g., olanzepine, aripiprazole, risperidone, ziprasidone).
  • the compounds described in the present invention could be used to enhance the effects of cognition-enhancing agents, such as acetylcholinesterase inhibitors (e.g., tacrine), muscarinic receptor-1 agonists (e.g., milameline), nicotinic agonists, glutamic acid receptor (AMPA and NMDA) modulators, and nootropic agents (e.g., piracetam, levetiracetam).
  • cognition-enhancing agents such as acetylcholinesterase inhibitors (e.g., tacrine), muscarinic receptor-1 agonists (e.g., milameline), nicotinic agonists, glutamic acid receptor (AMPA and NMDA) modulators, and nootropic agents (e.g., piracetam, levetiracetam).
  • Suitable therapies for treatment of Alzheimer's disease and cognitive disorders for use in combination with the compounds of the present invention include donepezil, tacrine, revastigraine, 5HT6, gamma secretase inhibitors, beta secretase inhibitors, SK channel blockers, Maxi-K blockers, and KCNQs blockers.
  • agents used to treat Parkinson's Disease include: levadopa with or without a COMT inhibitor, antiglutamatergic drugs (amantadine, riluzole), alpha-2 adrenergic antagonists such as idazoxan, opiate antagonists, such as naltrexone, other dopamine agonists or transportor modulators, such as ropinirole, or pramipexole or neurotrophic factors such as glial derived neurotrophic factor (GDNF).
  • antiglutamatergic drugs amantadine, riluzole
  • alpha-2 adrenergic antagonists such as idazoxan
  • opiate antagonists such as naltrexone
  • other dopamine agonists or transportor modulators such as ropinirole, or pramipexole
  • neurotrophic factors such as glial derived neurotrophic factor (GDNF).
  • GDNF glial derived neurotrophic factor
  • suitable anti-inflammatory agents include prednisone, dexamethasone, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, aspirin, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha-4 beta-7 integrin antagonists, cell adhesion inhibitors, interferon gamma antagonists, ICAM-1, tumor necrosis factor (TNF) antagonists (e.g., infliximab, OR1384, including TNF-alpha inhibitors, such as tenidap, anti-TNF antibodies or soluble TNF-alpha inhibitors, such as tenidap, anti-TNF antibodies or soluble TNF-alpha inhibitors
  • cyclosporins e.g., cyclosporin A
  • Anti-Tac anti-IL-2 receptor
  • Anti-CD45RB anti-CD2, anti-CD3 (OKT-3)
  • anti-CD4, anti-CD80 anti-CD86
  • monoclonal antibody OKT3 agents blocking the interaction between CD40 and gp39, such as antibodies specific for CD40 and/or gp39 (i.e., CD154), fusion proteins constructed from CD40 and gp39 (CD40Ig and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG), gold compounds, antiproliferative agents such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil, cytotoxic drugs such as azathiprine and cyclophosphamide, anticytokines
  • the compounds of formula I of the invention can be administered orally or parenterally, such as subcutaneously or intravenously, as well as by nasal application, rectally or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, in an effective amount up to 1 gram, preferably up to 200 mg, more preferably to 50 mg in a regimen of single, two or four divided daily doses.
  • the compounds of the formula I can be administered for any of the uses described herein by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
  • suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.
  • the present compounds can, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
  • the present compounds can also be administered liposomally.
  • compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.
  • the compounds of formula I can also be delivered through the oral cavity by sublingual and/or buccal administration.
  • Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used.
  • Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG).
  • Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934).
  • HPC hydroxy propyl cellulose
  • HPMC hydroxy propyl methyl cellulose
  • SCMC sodium carboxy methyl cellulose
  • maleic anhydride copolymer e.g., Gantrez
  • agents to control release such as polyacrylic copolymer (e.g. Carbopol 934).
  • Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
  • compositions for nasal aerosol or inhalation administration include solutions in saline which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor.
  • suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor.
  • compositions for rectal administration include suppositories which can contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
  • a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides for compounds of formula I
Figure US20050014786A1-20050120-C00001
 wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Description

    RELATED APPLICATIONS
  • This application claims priority benefit under Title 35 § 119(e) of U.S. provisional Application No. 60/486,774, filed Jul. 11, 2003, the contents of which are herein incorporated by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to tetrahydroquinoline containing compounds and compositions, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions in the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders.
    • BACKGROUND OF THE INVENTION
  • Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression, analgesia, inflammation, emesis, anti-nocioception, sedation, and intraocular pressure. Other members of the cannabinoid family include the endogenous (arachidonic acid-derived) ligands, anandamide, 2-arachidonyl glycerol, and 2-arachidonyl glycerol ether. Cannabinoids work through selective binding to and activation of G-protein coupled cannabinoid receptors. Two types of cannabinoid receptors have been cloned including CB-1 (L. A. Matsuda, et al., Nature, 346, 561-564 (1990)), and CB-2 (S. Munro, et al., Nature, 365, 61-65 (1993)). The CB-1 receptor is highly expressed in the central and peripheral nervous systems (M. Glass, et al., Neuroscience, 77, 299-318 (1997)), while the CB-2 receptor is highly expressed in immune tissue, particularly in spleen and tonsils. The CB-2 receptor is also expressed on other immune system cells, such as lymphoid cells (S. Galiegue, et al., Eur J Biochem, 232, 54-61 (1995)). Agonist activation of cannabinoid receptors results in inhibition of cAMP accumulation, stimulation of MAP kinase activity, and closure of calcium channels.
  • There exists substantial evidence that cannabinoids regulate appetitive behavior. Stimulation of CB-1 activity by anandamide or Delta-9 THC results in increased food intake and weight gain in multiple species including humans (Williams and Kirkham, Psychopharm., 143, 315-317 (1999)). Genetic knock-out of CB-1 result in mice that were hypophagic and lean relative to wild-type litter mates (DiMarzo, et al., Nature, 410, 822-825 (2001)). Published studies with CB-1 small molecule antagonists have demonstrated decreased food intake and body weight in rats (Trillou, et. al., Am. J. Physiol. Regul. Integr. Comp. Physiol., R345-R353, (2003)). Chronic administration of the CB-1 antagonist AM-251 for two weeks resulted in substantial body weight reduction and decreased adipose tissue mass (Hildebrandt, et. al., Eur. J. Pharm, 462, 125-132 (2003)). There are multiple studies that have assessed the anorexic effect of the Sanofi CB-1 antagonist, SR-141716 (Rowland, et. al., Pyschopharm., 159, 111-116 (2001); Colombo, et. al., Life Sci., 63, 113-117 (1998)). There are at least two CB-1 antagonists in clinical trials for regulation of appetite, Sanofi's SR-141716 and Solvay's SLV-319. Published Phase IIb data reveal that SR-141716 dose-dependently reduced body weight in human subjects over a 16 week trial period. CB-1 antagonists have also been shown to promote cessation of smoking behavior. Phase II clinical data on smoking cessation were presented in September of 2002 at Sanofi-Synthelabo's Information meeting. This data showed that 30.2% of patients treated with the highest dose of SR-141716 stayed abstinent from cigarette smoke relative to 14.8% for placebo.
  • Compounds that reportedly bind to the cannabinoid G-protein receptors are disclosed in European Patent Documents Nos. EP 0570920 and EP 0444451; International Publications Nos. WO 9729079, WO 9902499, WO 9841519, WO 9412466, WO 03007887, WO 03027069, WO 03027114, WO 03020217, WO 03027076, WO 03035005, WO 03051850, WO 03051851; U.S. Pat. Nos. 4,371,720, 5,081,122, 5,292,736, and 5,013,387; and French Patent No. FR 2,735,774, each of which is incorporated herein by reference.
    • SUMMARY OF THE INVENTION
  • In accordance with illustrative embodiments and demonstrating features of the present invention, compounds are provided which are capable of modulating the function of cannabinoid receptors. Preferably the compounds are cannabinoid-1 receptor (CB-1) modulators, and have the general formula I
    Figure US20050014786A1-20050120-C00002
    including all pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R9, R10, X and Y are described herein.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Thus, in a first embodiment, the present invention provides for a compound of formula I
    Figure US20050014786A1-20050120-C00003
    including all pharmaceutically acceptable salts and stereoisomers,
    wherein:
      • R1 is selected from the group consisting of hydrogen, alkyl, halo and CN;
      • R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, halo, CF3, CN, nitro, OR11, NR12R12a, COOR12 and CONR12R12a;
      • R3 is selected from the group consisting of hydrogen, alkyl, halo and CN;
      • R4 is selected from the group consisting of hydrogen, alkyl, halo and CN;
      • R5 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, COOR13 and CONR13R13a;
      • R6 and R6a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
      • R7 and R7a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
      • R8 is selected from the group consisting of hydrogen and alkyl;
      • R9 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • R10 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • R11 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, CHF2 and CF3;
      • R12 and R12a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • or R12 and R12a taken together can form cycloalkyl or heterocyclyl;
      • R13 and R13a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • or R13 and R13a taken together can form cycloalkyl or heterocyclyl;
      • X is selected from the group consisting of (CR14R14n)n, CO, COO, S(O)2, SO2N(R12) and CON(R12);
      • or R5 and R12 taken together can form cycloalkyl or heterocyclyl;
      • Y is selected from the group consisting of S(O)2, SO2N(R15) and C(O)C(O);
      • R14 and R14a are each independently selected from the group consisting of hydrogen, alkyl;
      • R15 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
      • n is an integer of 0, 1, or 2.
  • In a preferred embodiment, the present invention provides the compound of claim 1, including all pharmaceutically acceptable salts and stereoisomers, wherein:
      • R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, halo, CN;
      • R5 is selected from the group consisting of alkenyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
      • R6 and R6a are each independently selected from the group consisting of hydrogen and alkyl;
      • R7 and R7a are each independently selected from the group consisting of hydrogen and alkyl;
      • R8 is hydrogen;
      • R9 is hydrogen;
      • R11 is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CHF2 and CF3;
      • X is CH2;
      • Y is selected from the group consisting of S(O)2, and SO2N(R15);
      • R15 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
      • n is an integer of 0, or 1.
  • In a more preferred embodiment, the present invention provides the compound of claim 1, including all pharmaceutically acceptable salts and stereoisomers, wherein:
      • R1 is hydrogen;
      • R2 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo and CN;
      • R3 is hydrogen;
      • R4 is hydrogen;
      • R5 is selected from the group consisting of aryl and heteroaryl;
      • R6 and R6a are each hydrogen;
      • R7 and R7a are each hydrogen;
      • R10 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
      • R15 is selected from the group consisting of hydrogen, alkyl;
      • or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
      • n is an integer of 1.
  • In a second embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent.
  • In a third embodiment, the present invention provides a pharmaceutical combination comprising a compound of formula I and a therapeutic agent selected from anti-obesity agents; appetite suppressants; anti-diabetic agents; anti-hyperlipidemia agents; hypolipidemic agents; hypocholesterolemic agents; lipid-modulating agents; cholesterol-lowering agents; HDL-raising agents; lipid-lowering agents; anti-hypertensive agents; agents used to treat sleep disorders; agents used to treat substance abuse and addictive disorders; anti-anxiety agents; anti-depressants; anti-psychotic agents; cognition enhancing agents; agents used to treat cognitive disorders; agents used to treat attention deficit-disorders; agents used to treat Alzheimer's disease; agents used to treat Parkinson's disease; anti-inflammatory agents; agents used to treat neurodegeneration; agents used to treat arteriosclerosis; agents used to treat respiratory conditions; agents used to treat gastrointestinal disorders including bowel and motility disorders; cardiac glycosides; and anti-tumor agents.
  • In a preferred embodiment, the present invention provides a pharmaceutical combination of a compound of formula I and another therapeutic agent wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of the pharmaceutical composition comprising a compound of formula I.
  • In another preferred embodiment, the present invention provides a pharmaceutical combination of a compound of formula I and an anti-obesity agent wherein the anti-obesity agent is selected from melanocortin receptor (MC4R) agonists; melanin-concentrating hormone receptor (MCHR) antagonists; growth hormone secretagogue receptor (GHSR) antagonists; orexin antagonists; galanin receptor modulators, CCK agonists; GLP-1 agonists and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonists; NPY2 and NPY4 modulators; corticotropin releasing factor agonists; histamine receptor-3 (H3) modulators; aP2 inhibitors; PPAR gamma modulators; PPAR delta modulators; acetyl-CoA carboxylase (ACC) inhibitors, adiponectin receptor modulators, 11 β-HSD inhibitors, beta 3 adrenergic agonists, including AJ9677, L750355 and CP331648 or other known beta 3 agonists; thyroid receptor beta modulator; lipase inhibitors, including orlistat and ATL-962; serotonin receptor agonists, including BVT-933; monoamine reuptake inhibitors or releasing agents, including fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine and mazindol; anorectic agents, including topiramate; ciliary neurotrophic factor, including Axokine; brain-derived neurotrophic factor; leptin and leptin modulators; other cannabinoid-1 receptor antagonists, including SR-141716 and SLV-319.
  • In a fourth embodiment, the present invention provides a method for the treatment or prevention of diseases and disorders associated with G-protein coupled cannabinoid receptor activity, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • In a preferred embodiment, the present invention provides a method for the treatment of diseases or disorders associated with the activity of the CB-1 receptor, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • In another preferred embodiment, the present invention provides a method for the treatment of bulimia, obesity or any disease resulting in the patient becoming overweight, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • In another preferred embodiment, the present invention provides a method for the treatment of metabolic disorders, eating disorders and appetitive disorders, including treatment of the conditions associated with those disorders, such as obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, reduced HDL, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive eating disorders, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • In another preferred embodiment, the present invention provides a method for the treatment of obesity due to genetic or environmental causes, including overeating and bulemia, polycycstic ovary disease, craniopharyngeoma, Prader-Willi Syndrome, Frohlich's Syndrome, Type II diabetes, growth hormone deficiency, Turner's Syndrome and other pathological states characterized by reduced metabolic activity or reduced energy expenditure, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I.
  • The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.
  • As used herein, the term “alkyl” denotes branched or unbranched hydrocarbon chains containing 1 to 20 carbons, preferably 1 to 12 carbons, and more preferably 1 to 8 carbons, in the normal chain, such as, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl and the like. Further, alkyl groups, as defined herein, may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to hydroxyl, halo, haloalkyl, cyano, mercapto, alkylthio, heterocyclyl, aryl, heteroaryl, carboxyl, carbalkoyl, carboxamido, carbonyl, alkyl, alkenyl, alkynyl, nitro, amino, alkoxyl, aryloxyl, heteroaryloxyl, amido, and the like to form alkyl groups such as trifluoromethyl, 3-hydroxyhexyl, 2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like.
  • Unless otherwise indicated, the term “alkenyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 2 to 8 carbons with one or more double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like. Further, alkenyl groups, as defined herein, may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to halo, haloalkyl, alkyl, alkoxy, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxyl, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, mercapto, and alkylthio.
  • Unless otherwise indicated, the term “alkynyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons with one or more triple bonds in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl,3-undecynyl, 4-dodecynyl and the like. Further, alkynyl groups, as defined herein, may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to halo, haloalkyl, alkyl, alkoxy, alkenyl, aryl, arylalkyl, cycloalkyl, amino, hydroxyl, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, mercapto, and alkylthio.
  • Unless otherwise indicated, the term “cycloalkyl” as employed herein alone or as part of another group includes saturated or partially unsaturated (containing one or more double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, appended or fused, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the rings and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
    Figure US20050014786A1-20050120-C00004
  • Further, any cycloalkyl may be optionally substituted through any available carbon atoms with one or more groups selected from hydrogen, halo, haloalkyl, alkyl, alkoxy, haloalkyloxy, hydroxyl, alkenyl, alkynyl, aryl, aryloxy, heteroaryl, heteroaryloxy, arylalkyl, heteroarylalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, mercapto, and alkylthio.
  • The term “cycloalkylalkyl” as used herein alone or as part of another group refers to alkyl groups as defined above having a cycloalkyl substituent, wherein said “cycloalkyl” and/or “alkyl” groups may optionally be substituted as defined above.
  • Unless otherwise indicated, the term “aryl” as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl, 1-naphthyl and 2-naphthyl) and may optionally include one to three additional carbocyclic or heterocyclic fused rings, for example
    Figure US20050014786A1-20050120-C00005
  • Further, “aryl”, as defined herein, may optionally be substituted with one or more functional groups, such as halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, haloalkyl, CF3, hydroxy, alkoxy, haloalkoxy, OCF3, OCF2H, aryloxy, heteroaryloxy, arylalkoxy, alkylcarbonyloxy, arylcarbonyloxy, aryloxyalkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aminocarbonylaryl, heteroarylheteroaryl, nitro, cyano, arylazo, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl or aryl), alkylcarbonylamino, arylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, arylthio, alkoxyarylthio, heteroarylthio, arylsulfinyl, alkylsulfonyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl, alkylsulfonylalkyl, or arylsulfonaminocarbonyl.
  • Unless otherwise indicated, the term “heteroaryl” as used herein alone or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 heteroatoms such as nitrogen, oxygen or sulfur. Such rings may be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl group and include possible N-oxides as described in Katritzky, A. R. and Rees, C. W., eds. Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds 1984, Pergamon Press, New York, N.Y.; and Katritzky, A. R., Rees, C. W., Scriven, E. F., eds. Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982-1995 1996, Elsevier Science, Inc., Tarrytown, N.Y.; and references therein. Further, “heteroaryl”, as defined herein, may optionally be substituted with one or more substituents such as the substituents included above in the definition of “substituted alkyl” and “substituted aryl”. Examples of heteroaryl groups include the following:
    Figure US20050014786A1-20050120-C00006
    and the like.
  • The term “heteroarylalkyl” as used herein alone or as part of another group refers to alkyl groups as defined above having a heteroaryl substituent, wherein said heteroaryl and/or alkyl groups may optionally be substituted as defined above.
  • The term “heterocyclo”, “heterocycle”, “heterocyclyl” or “heterocyclic ring”, as used herein, represents an unsubstituted or substituted stable, 4 to 7-membered monocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms, with one to four heteroatoms selected from nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include, but are not limited to, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl, furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, oxadiazolyl and other heterocycles described in Katritzky, A. R. and Rees, C. W., eds. Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds 1984, Pergamon Press, New York, N.Y.; and Katritzky, A. R., Rees, C. W., Scriven, E. F., eds. Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982-1995 1996, Elsevier Science, Inc., Tarrytown, N.Y.; and references therein.
  • The term “heterocycloalkyl” as used herein alone or as part of another group refers to alkyl groups as defined above having a heterocyclyl substituent, wherein said heterocyclyl and/or alkyl groups may optionally be substituted as defined above.
  • The terms “arylalkyl”, “arylalkenyl” and “arylalkynyl” as used alone or as part of another group refer to alkyl, alkenyl and alkynyl groups, respectively, as defined above having an aryl substituent as defined above. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, benzhydryl and naphthylmethyl and the like.
  • The terms “alkoxy”, “aryloxy”, “heteroaryloxy”, “arylalkyloxy” or “heteroarylalkyloxy” as employed herein alone or as part of another group include, respectively, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups as defined above linked through an oxygen atom.
  • The term “halogen” or “halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with bromine, chlorine or fluorine being preferred.
  • The term “cyano,” as used herein alone or as part of another group, refers to a —CN group.
  • The term “methylene,” as used herein alone or as part of another group, refers to a —CH2— group.
  • The term “nitro,” as used herein alone or as part of another group, refers to a —NO2 group.
  • The term “acyl”, as employed herein alone or as part of another group includes, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups as defined above linked through a carbonyl group.
  • The compounds of formula I can be present as salts, which are also within the scope of this invention. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms, for example acetic acid, which are unsubstituted or substituted, for example, by a halogen as chloroacetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid or lysine or arginine, or such as benzoic acid, or with organic sulfonic acids, such as (C1-C4) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by a halogen, for example methanesulfonic acid or p-toluenesulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH) can form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethylpropylamine, or a mono, di or tri-hydroxy(lower)alkylamine, for example mono, di or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of formula I or their pharmaceutically acceptable salts, are also included.
  • Preferred salts of the compounds of formula I which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate and acetate salts.
  • Preferred salts of the compounds of formula I which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amine salts.
  • The term “modulator” refers to a chemical compound with capacity to either enhance (e.g., “agonist” activity) or partially enhance (e.g., “partial agonist” activity) or inhibit (e.g., “antagonist” activity or inverse agonist activity) a functional property or biological activity or process (e.g., enzyme activity or receptor binding); such enhancement or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway, and/or may be manifest only in particular cell types.
  • The term “prodrug esters” as employed herein includes esters and carbonates formed by reacting one or more hydroxyl group of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates and the like.
  • Any compound that can be converted in vivo to provide the bioactive agent (i.e., the compound of formula I) is a prodrug within the scope and spirit of the invention.
  • Various forms of prodrugs are well known in the art. A comprehensive description of prodrugs and prodrug derivatives appears in:
      • The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996);
      • Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003);
      • i Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985);
      • A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pp. 113-191 (Harwood Academic Publishers, 1991). Said references are incorporated herein by reference.
  • An administration of a therapeutic agent of the invention includes administration of a therapeutically effective amount of the agent of the invention. The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent to treat or prevent a condition treatable by administration of a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or preventative or ameliorative effect. The effect may include, for example, treatment or prevention of the conditions listed herein. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration.
  • All stereoisomers of the compounds of the instant invention are contemplated, either in mixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including those within any of the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. In order to prepare diastereomeric or enantiomeric products, conventional methods for isomer separation may be employed. These include, for example, chromatographic techniques, chiral HPLC, fractional crystallization, and sequences of derivatization, separation and de-derivatization.
  • The compounds of formula I of the invention can be prepared as shown below in the following descriptions and reaction schemes, as well as by using relevant published literature procedures that may be used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.
  • The following abbreviations may be employed in the descriptions, schemes, working Examples and elsewhere herein:
      • Ac=acetyl
      • AcCN or MeCN=acetonitrile
      • AcOH=acetic acid
      • Boc=tert-butoxycarbonyl
      • BINAP=2,2′-bis(diphenylphosphino)-1,1′-binaphthyl
      • Brine=saturated aqueous sodium chloride solution
      • Chiralpak®=Trademark of Chiral Technologies, Inc. Eaton, Pa.
      • DCE=1,2-dichloroethane
      • DCM=dichloromethane
      • DIPEA=N,N-diisopropylethylamine
      • DMF=N,N-dimethylformamide
      • EDAC=1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
      • EtOAc=ethyl acetate
      • Et3N=triethylamine
      • Et2O=diethyl ether
      • Et3SiH=triethylsilane
      • HOBt=1-hydroxybenzotriazole hydrate
      • HPLC=high performance liquid chromatography
      • LAH=lithium aluminum hydride
      • LG=leaving group such as chloride, bromide, methanesulfonate or trifluoromethanesulfonate.
      • MeOH=methanol
      • MS or Mass Spec=mass spectrometry
      • NaB(OAc)3H=sodium triacetoxyborohydride
      • NaOH=sodium hydroxide
      • NMM=N-methylmorpholine
      • PG=protecting group
      • PXPd=dichlorobis(chlorodi-tert-butylphosphine)palladium
      • RT=room temperature
      • SEM=2-(trimethylsilyl)ethoxymethyl
      • TFA=trifluoroacetic acid
      • THF=tetrahydrofuran
      • THQ=tetrahydroquinoline
      • mp=melting point
      • min=minute(s)
      • h=hour(s)
      • L=liter(s)
      • mL=milliliter(s)
      • μL=microliter(s)
      • g=gram(s)
      • mg=milligram(s)
      • mol=mole(s)
      • mmol=millimole(s)
      • nM=nanomolar
  • Compounds of the present invention may be prepared by procedures illustrated in the accompanying schemes.
    Figure US20050014786A1-20050120-C00007
  • As illustrated in Scheme 1, the amino group of compound II can be suitably protected by, for example, a tert-butyloxycarbonyl, or derivatized as in compound I with, for example, a arylsulfonyl group as shown in III. Compound II can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art. Reduction of III via hydrogenation in the presence of a transition metal catalyst, such as platinum oxide, or palladium hydroxide on carbon affords intermediate IV.
    Figure US20050014786A1-20050120-C00008
  • As illustrated in Scheme 2, compound V can be reduced via hydrogenation in the presence of a transition metal catalyst, such as platinum oxide, or palladium hydroxide on carbon to afford intermediate VI, which can be hydrolyzed to provide acid VII. Conversion of the carboxylic acid group of VII via Curtius rearrangement affords IV as free or protected amines. Compound V can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
    Figure US20050014786A1-20050120-C00009
  • As illustrated in Scheme 3, reduction of o-nitrophenylalanine derivative VIII via hydrogenation in the presence of a palladium catalyst in an alcoholic solvent, e.g. MeOH, affords cyclized compound IX. Compound VIII in either a racemic or a homochiral form can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art. It is understood that non-aromatic carbons of the THQ ring system can optionally be substituted with R7, R7a, R8 as specified in the general formula I. Reaction of IX with an alkylating reagent, such as a bromide in the presence of a base, e.g. cesium carbonate, provides compound X, which can be reduced to XI with a reduing agent, e.g. borane/THF complex. Treatment of XI with an appropriate bromination or chlorination reagent XII in the presence of a base provides compound XIII (Z=Br or Cl). Alternatively, treatment of intermediate IX with a halogenation reagent XII provides compound XIV, which can be converted, upon alkylation and reduction to compound XIII. Bromination or clorination reagents XII can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art. Compounds IX, X, XIV and XV may also be prepared following the procedures and methods disclosed in US 2004/002495 or references contained therein, or by analogy to the procedures and methods disclosed in US 2004/002495 or references contained therein.
    Figure US20050014786A1-20050120-C00010
  • As illustrated in Scheme 4, halogenated XVI and XVI′ can be prepared by treatment of intermediate IV (prepared as outlined in Scheme 1 and 2) with an appropriate bromination or clorination reagent XII. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I.
    Figure US20050014786A1-20050120-C00011
  • As illustrated in Scheme 5, compounds of formula Ia can be prepared from intermediate IV (prepared as outlined in Scheme 1 and 2). It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I. Treatment of IV with aldehyde XVII in the presence of triethylsilane and trifluoroacetic acid, or sodium triacetoxyborohydride affords intermediate XIX (where X═CH2). Alternatively, treatment of IV with reagent XVIII in the presence of a base provides intermediate XIX (for example, where X═SO2, or CO, or COO). Removal of the N-protection group (e.g. Boc) can be achieved by treatment of XIX with an acid (e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in methylene chloride) to provide intermediate XX. Treatment of XX with reagent XXI in the presence of a base provides compounds of formula Ia. Reagents XVII, XVIII and XXI can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
    Figure US20050014786A1-20050120-C00012
  • Alternatively, compounds of formula Ia can be prepared as illustrated in Scheme 6. Removal of the N-protection group (e.g. Boc) of compound IV can be achieved by treatment with an acid (e.g. hydrochloric acid in dioxane, or trifluoroacetic acid in methylene chloride) to provide intermediate XXII. Treatment of XXII with a reagent XXI in the presence of a base provides intermediate XXIII. Treatment of XXIII with an aldehyde XVII in the presence of triethylsilane and trifluoroacetic acid, or sodium triacetoxyborohydride affords compound Ia (where X═CH2). Alternatively, treatment of XXIII with a reagent XVIII in the presence of a base affords compound Ia (for example, where X═SO2, or CO, or COO).
    Figure US20050014786A1-20050120-C00013
  • As illustrated in Scheme 7, compounds of formula Ib can be prepared from intermediate XX, which are prepared as outlined in Scheme 5. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I. Treatment of XX with a reagent XXIV in the presence of a base provides compound Ib. Alternatively, Ib can also be prepared by reaction of intermediate XXV with a primary or a secondary amine in acetonitrile in the presence of a tertiary amine (e.g. diisopropylethyiamine). Intermediate XXV can be prepared by treatment of intermediate XX with the reaction adduct of 2-chloroethanol and chlorosulfonyl isocyanate according to the procedures reported by L. Ducry, et. al. (Helv. Chim. Acta. 82, pp2432-2447, (1999)).
    Figure US20050014786A1-20050120-C00014
  • As illustrated in Scheme 8, compounds of formula Ic can be prepared from intermediate XXIII (prepared as outlined in Scheme 6). It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I. Treatment of XXIII with a reagent XXVI in the presence of a palladium catalyst (e.g. Pd(OAc)2 and a ligand (e.g. BINAP) provides compounds of formula Ic. Intermediate XXVI can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
    Figure US20050014786A1-20050120-C00015
  • As illustrated in Scheme 9, compounds of formula Ie can be prepared via C—C bond coupling by treatment of intermediate Id with an appropriate aryl or heteroaryl boronic acid, or an aryl or heteroaryl tin reagent of formula XXVII in the presence of a palladium catalyst. Compounds of formula If can be prepared via C—N or C—O bond coupling by treatment of intermediate Id with a heterocyclic (e.g. a lactam, pyridone, imidazole or pyrizole) or a hydroxyarene (e.g. phenol), or a hydroxyheteroarene of formula XXVIII in the presence of a copper catalyst. Compounds of formula Ig can be prepared by treatment of intermediate Id with zinc cyanide in the presence of a palladium catalyst, e.g. Pd(Ph3P)4. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I. Reagents XXVII and XXVIII can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
    Figure US20050014786A1-20050120-C00016
  • As illustrated in Scheme 10, compounds of formula Ih can be prepared by treatment of Ia with an alkylating reagent XXIX in the presence of a base. It is understood that each of the non-aromatic carbons of the THQ ring system can optionally be substituted with R6, R6a, R7, R7a, R8 as specified in the general formula I. Reagent XXIX can be obtained commercially, or can be prepared by methods known in the literature, or can be readily prepared by one skilled in the art.
  • It is understood that the reagents mentioned throughout are example reagents, not meant to be limiting. Those skilled in the art will recognize that there are many acids (trifluoroacetic acid, hydrochloric acid, polyphosphoric acid, etc.), many bases (triethylamine, sodium hydride, potassium methoxide, etc.), many oxidants (hydrogen peroxide, 3-chloroperoxybenzoic acid, etc.), many hydrogenation catalysts (palladium, platinum oxide, Raney® Nickel, etc.), and so on that may be employed to synthesize the compounds of the invention. In some cases alternative reagents known to those skilled in the art will be superior to those specifically mentioned. Alternative reagents may be found in Reagents For Organic Synthesis (Fieser and Fieser, John Wiley & Sons) and Compendium of Organic Synthetic Methods (John Wiley & Sons).
  • In general, the interchange of functional groups within all the various R groups may be accomplished according to the methods and procedures described in Compendium of Organic Synthetic Methods (John Wiley & Sons) and Comprehensive Organic Transformations—A Guide To Functional Group Preparations (R. C. Larock, VCH Publishers, 1989). It is understood that during the course of manipulating any functional group within any of the various R groups, standard protecting groups, as described in Protective Groups in Organic Synthesis, may be employed to avoid undesired reaction of any other functional group.
  • Standard protecting groups may be used at any stage of synthesis, for example in manipulating a functional group to convert one compound of formula I to another compound of formula I, or in manipulating a functional group to convert one protected amine, for example, amine II to another protected amine II, or to avoid undesired reaction during the conversion of amines, for example amine XX to compounds of formula I, or during the sequence of steps leading to the formation of protected amine, for example amine II.
  • The following examples serve to better illustrate, but not limit, some of the preferred embodiments of the invention.
    • EXAMPLE 1 (S)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00017
    • 1A. tert-Butyl 1,2,3,4-tetrahydroquinolin-3-yl-carbamate
  • Figure US20050014786A1-20050120-C00018
  • To a solution of 3-aminoquinoline (4.32 g, 30 mmol) in anhydrous THF (100 mL) under argon at RT was added dropwise sodium bis(trimethylsilyl)amide (1 M solution in THF, 63 mL, 63 mmol). The resulting dark brown mixture was treated with di-tert-butyl dicarbonate (7.2 g, 33 mmol). After stirring at RT for 2 h, the reaction was quenched with water (30 mL), and 1N aqueous HCl (45 mL). The aqueous layer was separated and extracted with EtOAc (2×70 mL). The combined organics were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (0 to 50%) in hexane to give 3-quinolinylcarbamic acid, 1,1-dimethylethyl ester (6.5 g, 89% yield) as an off-white solid.
  • To a solution of 3-quinolinylcarbamic acid, 1,1-dimethylethyl ester (6.0 g, 24.56 mmol) in MeOH (150 mL) was added acetic acid (18 mL). The mixture was bubbled with argon for 15 min, then palladium hydroxide (20 weight % palladium on carbon) (1.2 g) was added. The resulting suspension was subjected to hydrogenation under 45 psi of pressure for 16 h., then filtered. The filtrate was concentrated and the residue taken in CH2Cl2. The resulting CH2Cl2 solution was washed with saturated aqueous NaHCO3, brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (0 to 50%) in hexane to give 1A (4.6 g, 75% yield) as a white solid.
    • 1B. (6-Bromo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00019
  • To a solution of 1A (2.7 g, 10.9 mmol) in THF (50 mL) at RT was added dropwise a solution of pyridinium tribromide (3.83 g, 0.41 mmol) in THF (50 mL). After addition, the reaction mixture was stirred for 15 min, then water (60 mL) and ether (60 mL) added. The aqueous layer was separated, and extracted with EtOAc (2×50 mL). The combined organics were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (0 to 50%) in hexane to give the title compound (2.5 g, 70% yield) as a white solid.
    • —1C. (6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-carbaniic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00020
  • A solution of 1B (250 mg, 0.76 mmol) and zinc cyanide (88 mg, 0.75 mmol) in DMF (2.5 mL) was bubbled with argon for 10 min, then tetrakis-(triphenylphosphine)palladium(0) (65 mg, 0.057 mmol) was added and the solution was deoxygenated. The reaction mixture was then heated at 90° C. for 4 h, cooled to RT, and partitioned between EtOAc and water. The aqueous layer was separated and extracted with EtOAc (2×20 mL). The combined EtOAc extracts were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (0 to 60%) in hexane to give the title compound (140 mg, 67% yield) as a white solid.
    • 1D. 3-Amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile, dihydrochloride
  • Figure US20050014786A1-20050120-C00021
  • To a solution of IC (546 mg, 2 mmol) in CH2Cl2 (5 mL) at 0° C. was added 4 M HCl in dioxane (4 mL, 16 mmol). After addition, the reaction mixture was stirred at RT for 2 h, then concentrated. The residue was stripped with ether (3×), and the resulting off-white solid dried in vacuo to afford the title compound (490 mg, 100%).
    • 1E. (S)—N-((S)-6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-2-hydroxy-2-phenylacetamide
  • Figure US20050014786A1-20050120-C00022
  • To a solution of 1D (10.03 g, 40.7 mmol) in DMF (100 mL) was added (S)-(+)-mandelic acid (7.45 g, 48.9 mmol), followed by EDAC (9.37 g, 48.9 mmol), HOBt (7.49 g, 48.9 mmol) and NMM (16.1 mL, 146.1 mmol). The reaction mixture was stirred at RT overnight, then diluted with EtOAc (200 mL), washed with water (50 mL×3), IN aqueous HCl (50 mL), water (50 mL) and brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc/hexane (2:1), and the purified compound crystallized from acetone (3×) to give the title compound as the (S,S) diastereoisomer (2.54 g, 20% yield).
    • 1F. (S)-3-Amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile
  • Figure US20050014786A1-20050120-C00023
  • To a solution of 1E (2.5 g, 8.14 mmol) in EtOH (25 mL) was added 15% aqueous sulfuric acid (25 mL). The resulting mixture was refluxed overnight, then cooled to RT. After removal of most of the EtOH, the mixture was diluted with water (200 mL), extracted with CH2Cl2 (3×50 mL). The aqueous layer was basified with 4N NaOH to pH=10, then extracted with CH2Cl2 (3×50 mL). The combined organics were washed with brine, dried (Na2SO4) and concentrated. The residue was crystallized from EtOAc/hexane to afford the title compound (1.026 g, 73% yield).
    • 1G. (S)—N-(6-Cyano-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00024
  • To a suspension of 1F (103.9 mg, 0.6 mmol) in CH3CN (3 mL) at RT under argon was added DIPEA (0.11 mL, 0.66 mmol), followed by dropwise addition of benzene sulfonylchloride (0.08 mL, 0.63 mmol). The reaction mixture was stirred at RT for 1.5 h, then concentrated under reduced pressure. The residue was taken into EtOAc, washed with water, brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (30-50%) in hexane to give the title compound (170 mg, 90%). HPLC: 99% at 5.2 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 314 [M+H]+.
    • 1H. (S)-N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
  • To a solution of 1G (94 mg, 0.3 mmol) and thiazole-5-carbaldehyde (67.9 mg, 0.6 mmol) (prepared following the procedures described in Alessandro Dondoni, et al, Synthesis, 11, 998-1001, (1987)) in a mixed solvents of TFA (0.75 mL) and CH2Cl2 (0.75 mL) was added Et3SiH (0.096 mL, 0.6 mmol). The resulting mixture was stirred at RT under argon for 18 h, then concentrated under reduced pressure. The residue was diluted with saturated aqueous NaHCO3, then extracted with EtOAc (3×20 mL). The combined EtOAc extracts were washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (50-90%) in hexane to give the title compound as an off-white solid (70 mg, 57%). HPLC: 99% at 5.43 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4), Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 411 [M+H]+; Chiral HPLC 100% e.e.; retention time=32.9 min; Conditions: AD (4.6×250 mm); Eluted with 40% isopropanol in hexane for 50 min at 1 mL/min.
    • EXAMPLE 2 (R)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00025
    • 2A. (R)-3-Amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile
  • Figure US20050014786A1-20050120-C00026
  • Compound 2A was prepared from the (S,R) diastereomer isolated in Example 1E by procedures analogous to those described in Example 1F.
    • 2B. (R)—N-(6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00027
  • Compound 2B was prepared from 2A by procedures analogous to those described in Example 1G.
    • 2C. (R)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • The title compound was prepared from 2B by procedures analogous to those described in Example 1H. HPLC: 99% at 5.45 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4), Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 411 [M+H]+; Chiral HPLC 100% e.e.; retention time=29.4 min; Conditions: AD (4.6×250 mm); Eluted with 40% isopropanol in hexane for 50 min at 1 mL/min.
    • EXAMPLE 3 (S)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-N-methyl-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00028
  • To a solution of 1G (50 mg, 0.12 mmol) in ethylene glycol dimethyl ether (1.5 mL) at RT was added NaH (5.1 mg, 0.13 mmol). The resulting mixture was heated at reflux under argon for 1 h, then cooled to RT, iodomethane (27 uL, 0.42 mmol) was added. The reaction was heated at reflux for 4 h. After cooling to RT, the reaction was quenched with water, then extracted with EtOAc (3×10 mL). The combined EtOAc extracts were washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (50-80%) in hexane to give the title compound as a white foam (25 mg, 49%). HPLC: 98% at 5.8 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 425 [M+1]+. Chiral HPLC 100% e.e.; retention time=39.2 min; Conditions: OD (4.6×250 mm); Eluted with 40% isopropanol in hexane for 50 min at 1 mL/min.
    • EXAMPLE 4 (R)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahvdroquinolin-3-yl)-N-methyl-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00029
  • The title compound was prepared from 2C by procedures analogous to those described in Example 3. HPLC: 98% at 5.8 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 425 [M+1]+. Chiral HPLC 100% e.e.; retention time=25.3 min; Conditions: OD (4.6×250 mm); Eluted with 40% isopropanol in hexane for 50 min at 1 mL/min.
    • EXAMPLE 5 TO 14
  • Additional compounds of the present invention were prepared by procedures analogous to those described in Example 1. The compounds of Examples 5 to 14 have the following structure,
    Figure US20050014786A1-20050120-C00030
  • where the group XR5, the stereochemistry, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 1. The chromatography techniques used to determine the compound retention times of Table 1 are as follows: HPLC (purity) conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). LC-MS conditions: Phenom. Luna C18, 4.6×50 mm eluting with 10-90% MeOH/H2O over 4 minutes containing 0.1% TFA; 4 mL/min, monitoring at 220 nm. The molecular mass of the compounds listed in Table 1, where provided, were determined by MS (ES) by the formula m/z.
    TABLE 1
    Retention Time
    Ex. No. XR5 Compound Name (min.)/m/z See Ex.
    5a
    Figure US20050014786A1-20050120-C00031
         		(S)-N-(1-Benzyl-6-cyano- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 6.87 LCMS/404 [M + H]+ 1H
    5b
    Figure US20050014786A1-20050120-C00032
         		(R)-N-(1-Benzyl-6-cyano- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 6.90 LCMS/404 [M + H]+ 22A
    6
    Figure US20050014786A1-20050120-C00033
         		(S)-N-[1-(2-Chloro-benzyl)-6- cyano-1,2,3,4- tetrahydroquinolin-3-yl]- benzenesulfonamide 7.27 LCMS/438 [M + H]+ 1H
    7a
    Figure US20050014786A1-20050120-C00034
         		(S)-N-[1-(3-Chloro-benzyl)-6- cyano-1,2,3,4- tetrahydroquinolin-3-yl]- benzenesulfonamide 7.12 LCMS/438 [M + H]+ 1H
    7b
    Figure US20050014786A1-20050120-C00035
         		(R)-N-[1-(3-Chloro-benzyl)-6- cyano-1,2,3,4- tetrahydroquinolin-3-yl]- benzenesulfonamide 7.20 LCMS/438 [M + H]+ 22A
    8
    Figure US20050014786A1-20050120-C00036
         		(S)-N-[1-(4-Chloro-benzyl)-6- cyano-1,2,3,4- tetrahydroquinolin-3-yl]- benzenesulfonamide 7.20 LCMS/438 [M + H]+ 1H
    9
    Figure US20050014786A1-20050120-C00037
         		(S)-N-(6-Cyano-1-pyridin-2- ylmethyl-1,2,3,4- tetrahydroquinolin-3-yl)- benzensulfonamide 4.75 LCMS/405 [M + H]+ 1H
    10
    Figure US20050014786A1-20050120-C00038
         		(S)-N-(6-Cyano-1-pyridin-3- ylmethyl-1,2,3,4- tetrahydroquinolin-3-yl)- benzenesulfonamide 3.95 LCMS/405 [M + H]+ 1H
    11
    Figure US20050014786A1-20050120-C00039
         		(S)-N-(6-Cyano-1-pyridin-4- tetrahydroquinolin-3-yl)- benzenesulfonamide 3.88 LCMS/405 [M + H]+ 1H
    12
    Figure US20050014786A1-20050120-C00040
         		N-[6-Cyano-1-(1-phenylethyl)- 1,2,3,4-tetrahydroquinolin-3-tetrahydroquinolin-3- yl]-benzenesulfonamide 7.04 LCMS/418 [M + H]+ 1H
    13
    Figure US20050014786A1-20050120-C00041
         		N-(6-Cyano-1-phenethyl- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 7.23 LCMS/418 [M + H]+ 22A
    14
    Figure US20050014786A1-20050120-C00042
         		(S)-N-(6-Cyano-1- cyclohexylmethyl-1,2,3,4- tetrahydroquinolin-3-yl)- benzenesulfonamide 7.70 LCMS/410 [M + H]+ 22A
    • EXAMPLE 15 TO 20
  • Additional compounds also prepared by procedures analogous to those described in Example 1. The compounds of Examples 15 to 20 have the following structure,
    Figure US20050014786A1-20050120-C00043
  • where the group R10, the stereochemistry, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 2. The chromatography techniques used to determine the compound retention times of Table 2 are as follows: HPLC (purity) conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). LC-MS conditions: Phenom. Luna C18, 4.6×50 mm eluting with 10-90% MeOH/H2O over 4 minutes containing 0.1% TFA; 4 mL/min, monitoring at 220 nm. The molecular mass of the compounds listed in Table 2, where provided, were determined by MS (ES) by the formula m/z.
    Retention
    Ex. Time See
    No. R10 Compound Name (min.)/m/z Ex.
    15
    Figure US20050014786A1-20050120-C00044
         		Pyridine-3-sulfonic acid[1-(3- chlorobenzyl)-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl)-amide 6.60 LCMS/ 439 [M + H]+ 1
    16
    Figure US20050014786A1-20050120-C00045
         		Pyridine-2-sulfonic acid[1-(3- chlorobenzyl)-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl)-amide 6.60 LCMS/ 439 [M + H]+ 1
    17
    Figure US20050014786A1-20050120-C00046
         		Thiophene-2-sulfonic acid[1- (3-chlorobenzyl-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl)-amide 6.95 LCMS/ 444 [M + H]+ 1
    18
    Figure US20050014786A1-20050120-C00047
         		(S)-2-Chloro-N-[1-(3- chlorobenzyl)-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl]-benzenesulfonamide 7.23 LCMS/ 472 [M + H]+ 1
    19
    Figure US20050014786A1-20050120-C00048
         		(S)-3-Chloro-N-[1-(3- chlorobenzyl)-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl]-benzenesulfonamide 7.52 LCMS/ 472 [M + H]+ 1
    20
    Figure US20050014786A1-20050120-C00049
         		(S)-4-Chloro-N-[1-(3- chlorobenzyl)-6-cyano- 1,2,3,4- tetrahydroquinolin-3- yl]-benzenesulfonamide 7.54 LCMS/ 472 [M + H]+ 1
    • EXAMPLE 21 N-(6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00050
    • 21A. tert-Butyl 6-chloro-1,2,3,4-tetrahydroquinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00051
  • To a solution of 1A (28.3 g, 114 mmol) in acetonitrile (240 mL) at RT was added dropwise a solution of N-chlorosuccinimide (15.22 g, 114 mmol) in acetonitrile (240 mL). After addition, the reaction mixture was stirred for 6 h, then water (500 mL) added. The mixture was extracted with EtOAc (2×500 mL). The combined organics were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc/hexane 1:5 to give the title compound (10.6 g, 58% yield) as a white solid.
    • 21B. N-(6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Compound 21B was prepared from 21A by procedures analogous to those described in Example 1D and 1G.
    • EXAMPLE 22 1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-amine, dihydrochloride
  • Figure US20050014786A1-20050120-C00052
    • 22A. tert-Butyl 1-benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00053
  • To a solution of 21A (310 mg, 1.096 mmol) in 1,2-dichloroethane (7 mL) was added benzaldehyde (235 mg, 2.193 mmol), followed by sodium triacetoxyborohydride (650 mg, 3.069 mmol) and AcOH (200 mg, 3.29 mmol). The reaction mixture was stirred at RT for 4 h, then diluted with EtOAc, washed with saturated aqueous NaHCO3, water, brine, dried (Na2SO4) and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc/hexane 1:5 to give the title compound as light yellow foam (325 mg, 80%).
    • 22B. 1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-amine, dihydrochloride
  • Compound 22B was prepared from 22A by procedures analogous to those described in Example 1D.
    • EXAMPLE 23 N-(6-Chloro-1-(pyrazin-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00054
  • The title compound was synthesized as part of library using the following procedure in a parallel synthesis fashion using 48 well red and blue minireactors.
  • Typical procedure: To a solution of 21B (21 mg, 0.05 mmol) in DCE (1 mL) at RT was added 2-pyrazinecarboxaldehyde (10.8 mg, 0.1 mmol) followed by addition of scandium triflate (25 mg, 0.1 mmol) and sodium cyanoborohydride (6.2 mg, 0.1 mmol). The reaction mixture was shaken at RT for 48 h, and treated with 1.0 mL methanol for 30 min. Contents were flitered into a synthesis tube rack and the solvent was dried in a speedvac. The resulting residue was chromatographed using Prep HPLC (conditions: Xterra MS-C18 (30×50 mm); Eluted with 10% to 100% B, 6 min gradient. (A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 30 mL/min. UV detection at 220 nm) to give the title compound 23 (6.4 mg, 20%). HPLC: 99% at 1.47 min (retention time) (Conditions: Xterra MS-C18 (2.1×50 mm); Eluted with 0% to 100% B, 2.75 min gradient. (A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 1 mL/min. UV detection at 220 nm) MS (ES): m/z 415.07 [M+H]+.
    • EXAMPLE 24-49
  • Additional compounds of the present invention were prepared by procedures described in Example 23. The compounds of Examples 24 to 49 have the following structure,
    Figure US20050014786A1-20050120-C00055
  • where XR5, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 3. The chromatography techniques used to determine the compound retention times of Table 3 are as follows: HPLC (purity) conditions: Xterra MS-C18 (2.1×50 mm); Eluted with 0% to 100% B, 2.75 min gradient. (A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 1 mL/min. UV detection at 220 nm). The molecular mass of the compounds listed in Table 3, where provided, were determined by MS (ES) by the formula m/z using Waters LCT Time of flight mass spec, with a mux 4-way source.
    TABLE 3
    Retention Time
    Ex. No. XR5 Compound Name (min.)/m/z See Ex.
    24
    Figure US20050014786A1-20050120-C00056
         		N-(6-Chloro-1-(thiazol-4- ylmethyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.57 LCMS/420 [M + H]+ 23
    25
    Figure US20050014786A1-20050120-C00057
         		N-(6-Chloro-1-(thiozol-5- ylmethyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.39 LCMS/420 [M + H]+ 23
    26
    Figure US20050014786A1-20050120-C00058
         		N-(6-Chloro-1-((6- methoxypyridin-3- yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.59 LCMS/444 [M + H]+ 23
    27
    Figure US20050014786A1-20050120-C00059
         		N-(6-Chloro-1-((1-ethyl- 1H-pyrazol-4-yl)methyl)- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.49 LCMS/431 [M + H]+ 23
    28
    Figure US20050014786A1-20050120-C00060
         		N-(6-Chloro-1-((4- hydroxy-3- phenylisothiazol-5- yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.60 LCMS/512 [M + H]+ 23
    29
    Figure US20050014786A1-20050120-C00061
         		N-(6-Chloro-1-((2,4- dimethylthiazol-5- yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.47 LCMS/448 [M + H]+ 23
    30
    Figure US20050014786A1-20050120-C00062
         		N-(6-Chloro-1- ((tetrahydrofuran-3- yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.44 LCMS/407 [M + H]+ 23
    31
    Figure US20050014786A1-20050120-C00063
         		N-(6-Chloro-1- ((tetrahydro-2H-pyran-4- yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.50 LCMS/421 [M + H]+ 23
    32
    Figure US20050014786A1-20050120-C00064
         		N-(1-Benzo[d][1,3]dioxol-5-ylmethyl)-6- chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.68 LCMS/457 [M + H]+ 23
    33
    Figure US20050014786A1-20050120-C00065
         		N-(6-Chloro-1-((2,3- dihydrobenzo[b][1,4]diox in-5-yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.71 LCMS/471 [M + H]+ 23
    34
    Figure US20050014786A1-20050120-C00066
         		N-(6-Chloro-1-((2,3- dihydrobenzo[b][1,4]diox in-6-yl)methyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.77 LCMS/471 [M + H]+ 23
    35
    Figure US20050014786A1-20050120-C00067
         		N-(1-(3-Fluorobenzyl)-6- Chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.77 LCMS/431 [M + H]+ 23
    36
    Figure US20050014786A1-20050120-C00068
         		N-(1-(3-Chloro-2- fluorobenzyl)-6-chloro- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.84 LCMS/465 [M + H]+ 23
    37
    Figure US20050014786A1-20050120-C00069
         		N-(1-(3,5- Difluorobenzyl)-6- Chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.95 LCMS/449 [M + H]+ 23
    38
    Figure US20050014786A1-20050120-C00070
         		N-(1-(2,4-Difluorobenzyl)- 6-chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.76 LCMS/449 [M + H]+ 23
    39
    Figure US20050014786A1-20050120-C00071
         		N-(1-(5-Fluoro-2- methoxybenzyl)-6-chloro- 1,2,3,4-tetrahydro quinolin-3-yl) benzenesulfonamide 1.81 LCMS/461 [M + H]+ 23
    40
    Figure US20050014786A1-20050120-C00072
         		N-(1-(3-Cyanobenzyl)-6- chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.62 LCMS/438 [M + H]+ 23
    41
    Figure US20050014786A1-20050120-C00073
         		N-(1-(2-Cyanobenzyl)-6- chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.60 LCMS/438 [M + H]+ 23
    42
    Figure US20050014786A1-20050120-C00074
         		N-(1-(4- Cyanomethyl)benzyl)-6- chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.67 LCMS/452 [M + H]+ 23
    43
    Figure US20050014786A1-20050120-C00075
         		N-(6-Chloro-1-(2-cyano- 2-phenylethyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.67 LCMS/452 [M + H]+ 23
    44
    Figure US20050014786A1-20050120-C00076
         		N-(1-(4-(3- (Dimethylamino)propoxy) benzyl)-6-chloro-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.28 LCMS/514 [M + H]+ 23
    45
    Figure US20050014786A1-20050120-C00077
         		N-(6-Chloro-1- (cyclohexylmethyl)- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 2.11 LCMS/419 [M + H]+ 23
    46
    Figure US20050014786A1-20050120-C00078
         		N-(6-Chloro-1- (cyclopentylmethyl)- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.9o8 LCMS/405 [M + H]+ 23
    47
    Figure US20050014786A1-20050120-C00079
         		N-(6-Chloro-1- (cyclopropylmethyl)- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.74 LCMS/377 [M +H]+ 23
    48
    Figure US20050014786A1-20050120-C00080
         		N-(6-Chloro-1-isopentyl- 1,2,3,4- tetrahydroguinolin-3- yl)benzenesulfonamide 2.04 LCMS/393 [M +H]+ 23
    49
    Figure US20050014786A1-20050120-C00081
         		N-(6-Chloro-1-butyl- 1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 1.79 LCMS/379 [M + H]+ 23
    • EXAMPLE 50 N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00082
  • The title compound was synthesized as part of library using the following procedure in a parallel synthesis fashion using 48 well red and blue minireactors. Typical procedure: To a solution of 22B (14 mg, 0.05 mmol) in DCE (0.5 mL) at RT was added NMM (0.109 mL, 0.1 mmol), followed by addition of benzene sulfonylchloride (17.6 mg, 0.1 mmol) in DCE (0.5 uL). The reaction mixture was shaken at RT for 24 h, and treated with 100 mg of PS-Trisamine (4 mmol/g loading) for 2 h to remove excess sulfonyl chloride. Contents were flitered into a synthesis tube rack (STR) and the solvent was dried in a speed vac. The resulting residue was chromatographed using Prep HPLC (conditions: Xterra MS-C18 (30×50 mm); Eluted with 10% to 100% B, 6 min gradient.(A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 30 mL/min. UV detection at 220 nm) to give compound 50 (13.8 mg, 69%). HPLC: 99% at 1.74 min (retention time) (Conditions: Xterra MS-C18 (2.1×50 mm); Eluted with 0% to 100% B, 2.75 min gradient. (A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 1 mL/min. UV detection at 220 nm). MS (ES): m/z 413 [M+H]+.
    • EXAMPLE 51-86
  • Additional compounds were prepared by procedures described in Example 50. The compounds of example 51-86 have the following structure,
    Figure US20050014786A1-20050120-C00083
  • where the group A, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 4. The chromatography techniques used to determine the compound retention times of Table 4 are as follows: HPLC (purity) conditions: Xterra MS-C18 (2.1×50 mm); Eluted with 0% to 100% B, 2.75 min gradient (A=100% water—0.1% TFA and B=acetonitrile with 0.1% TFA); Flow rate at 1 mL/min. UV detection at 220 nm). The molecular mass of the compounds listed in Table 4, where provided, were determined by MS (ES) by the formula m/z. using Waters LCT Time of flight mass spec, with a mux 4-way source.
    TABLE 4
    Retention
    Ex. Time See
    No. A Compound Name (min.)/m/z Ex.
    51
    Figure US20050014786A1-20050120-C00084
         		N,N-Dimethylamino-1- sulfonic acid (1-benzyl-6- chloro-1,2,3,4-tetra hydroquinolin-3-yl)-amide 1.63 LCMS/ 380 [M+H]+ 50
    52
    Figure US20050014786A1-20050120-C00085
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)ethanesulfonamide 1.54 LCMS/ 365 [M+H]+ 50
    53
    Figure US20050014786A1-20050120-C00086
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-2,2,2- trifluoroethanesulfonamide 1.70 LCMS/ 419 [M+H]+ 50
    54
    Figure US20050014786A1-20050120-C00087
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-2-(naphthalen-1-yl) ethanesulfonamide 1.99 LCMS/ 491 [M+H]+ 50
    55
    Figure US20050014786A1-20050120-C00088
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4- propylbenzenesulfonamide 2.04 LCMS/ 455 [M+H]+ 50
    56
    Figure US20050014786A1-20050120-C00089
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4- ethylbenzenesulfonamide 1.97 LCMS/ 441 [M+H]+ 50
    57
    Figure US20050014786A1-20050120-C00090
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4-(2-cyanoethoxy) benzenesulfonamide 1.67 LCMS/ 482 [M+H]+ 50
    58
    Figure US20050014786A1-20050120-C00091
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4- bromobenzenesulfonamide 1.94 LCMS/ 492 [M+H]+ 50
    59
    Figure US20050014786A1-20050120-C00092
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-2,5- dimethylbenzenesulfonamide 1.94 LCMS/ 441 [M+H]+ 50
    60
    Figure US20050014786A1-20050120-C00093
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-2-(trifluoromethoxy) benzenesulfonamide 1.91 LCMS/ 497 [M+H]+ 50
    61
    Figure US20050014786A1-20050120-C00094
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-2- cyanobenzenesulfonamide 1.72 LCMS/ 438 [M+H]+ 50
    62
    Figure US20050014786A1-20050120-C00095
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3- cyanobenzenesulfonamide 1.69 LCMS/ 438 [M+H]+ 50
    63
    Figure US20050014786A1-20050120-C00096
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3- fluorobenzenesulfonamide 1.79 LCMS/ 431 [M+H]+ 50
    64
    Figure US20050014786A1-20050120-C00097
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4- fluorobenzenesulfonamide 1.77 LCMS/ 431 [M+H]+ 50
    65
    Figure US20050014786A1-20050120-C00098
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3,5- difluorobenzenesulfonamide 1.83 LCMS/ 449 [M+H]+ 50
    66
    Figure US20050014786A1-20050120-C00099
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3,5- dichlorobenzenesulfonamide 2.06 LCMS/ 483 [M+H]+ 50
    67
    Figure US20050014786A1-20050120-C00100
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3,4-dimethoxyl benzenesulfonamide 1.66 LCMS/ 473 [M+H]+ 50
    68
    Figure US20050014786A1-20050120-C00101
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3- methylbenzenesulfonamide 1.83 LCMS/ 427 [M+H]+ 50
    69
    Figure US20050014786A1-20050120-C00102
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4-methylsulfonyl) benzenesulfonamide 1.6 LCMS/ 491 [M+H]+ 50
    70
    Figure US20050014786A1-20050120-C00103
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4-acetamido) benzenesulfonamide 1.52 LCMS/ 470 [M+H]+ 50
    71
    Figure US20050014786A1-20050120-C00104
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4-(pyrrolidine-1- carboxamido) benzenesulfonamide 1.57 LCMS/ 525 [M+H]+ 50
    72
    Figure US20050014786A1-20050120-C00105
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)benzo(c)[1,2,5]thiazole-4- sulfonamide 1.76 LCMS/ 471 [M+H]+ 50
    73
    Figure US20050014786A1-20050120-C00106
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3-(5-methyl-1,3,4- oxadizol-2-yl)benzene sulfonamide 1.62 LCMS/ 495 [M+H]+ 50
    74
    Figure US20050014786A1-20050120-C00107
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-5-bromothiophene-2- sulfonamide 1.92 LCMS/ 499 [M+H]+ 50
    75
    Figure US20050014786A1-20050120-C00108
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4,5-dibromothiophene-2- sulfonamide 2.06 LCMS/ 576 [M+H]+ 50
    76
    Figure US20050014786A1-20050120-C00109
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-4,5-dichlorothiophene-2- sulfonamide 2.05 LCMS/ 488 [M+H]+ 50
    77
    Figure US20050014786A1-20050120-C00110
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-1-methyl-1H-imidazole- 4-sulfonamide 1.4 LCMS/ 417 [M+H]+ 50
    78
    Figure US20050014786A1-20050120-C00111
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-1,2-dimethyl-1H- imidazole-4-sulfonamide 1.44 LCMS/ 431 [M+H]+ 50
    79
    Figure US20050014786A1-20050120-C00112
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-5-chloro-1,3-dimethyl- 1H-pyrazole-4-sulfonamide 1.67 LCMS/ 465 [M+H]+ 50
    80
    Figure US20050014786A1-20050120-C00113
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-3,5-dimethyisoxazole-4- sulfonamide 1.74 LCMS/ 432 [M+H]+ 50
    81
    Figure US20050014786A1-20050120-C00114
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-thiophene-3-sulfonamide 1.71 LCMS/ 419 [M+H]+ 50
    82
    Figure US20050014786A1-20050120-C00115
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-thiophene-2-sulfonamide 1.72 LCMS/ 419 [M+H]+ 50
    83
    Figure US20050014786A1-20050120-C00116
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-5-(oxazol-5-yl)thiophene- 2-sulfonamide 1.69 LCMS/ 486 [M+H]+ 50
    84
    Figure US20050014786A1-20050120-C00117
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-5-(pyridin-2- yl)thiophene-2-sulfonamide 1.85 LCMS/ 496 [M+H]+ 50
    85
    Figure US20050014786A1-20050120-C00118
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-5-bromo-6-chloro pyridine-3-sulfonamide 1.92 LCMS/ 527 [M+H]+ 50
    86
    Figure US20050014786A1-20050120-C00119
         		N-(1-Benzyl-6-chloro- 1,2,3,4-tetrahydroquinolin-3- yl)-6-morpholino chloro pyridine-3-sulfonamide 1.67 LCMS/ 499 [M+H]+ 50
    • EXAMPLE 87 (S)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00120
    • 87A. N-(6-Bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00121
  • Compound 1A was treated with 4N HCl in dioxane, and the resulting product was reacted with benzene sulfonylchloride following the procedures described in Example 1D and 1G to give compound 87A.
    • 87B. N-(1-benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00122
  • The title compound was prepared from 87A and benzaldehyde by procedures analogous to those described in Example 22A.
    • 87C. (S)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • The title compound was obtained via chiral chromatographic separation of racemic 87B using a Chiralpak AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 30% isopropanol in heptane. HPLC: 99% at 8.01 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mumin. UV detection at 220 nm). MS (ES): m/z 458 [M+1]+. Chiral HPLC 100% e.e.; retention time=17.97 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
  • Alternatively, homochiral 87C can also be prepared from (S)-2-(tert-butyloxy carbonylamino)-3-(2-nitrophenyl)propanoic acid as described below starting from 87D.
    • 87D. (S)-(2-Oxo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00123
  • The title compound may be prepared either as described in US 2004/002495 or as follows: To a solution of (S)-2-(tert-butyloxycarbonylamino)-3-(2-nitrophenyl)propanoic acid (987 mg, 3.18 mmol) in MeOH(100 mL) was added 10% palladium on carbon (300 mg), and the mixture was stirred at RT under hydrogen at 80 psi for 24 h. Filtration and solvent evaporation under vacuum provided the title compound (800 mg) as a foam.
    • 87E. (S)-(6-Bromo-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00124
  • To a solution of 87D (750 mg, 2.42 mmol) in MeOH (12 mL) and CH2Cl2 (12 mL) stirring at RT under argon was added CaCO3 (484 mg, 4.83 mmol) and benzyltrimethylammonium tribromide (1.885 g, 4.83 mmol). After 18 h, 10% aqueous NaHSO3 (5 mL) was added to the reaction mixture, and stirring was continued for 30 min. Partial evaporation under vacuum was performed to remove nearly all of the organic solvents before the mixture was extracted twice with CH2Cl2. The combined extracts were washed with water, dried (MgSO4), and evaporated under vacuum. The resulting residue was chromatographed on silica gel eluted with 25% Et2O in CH2Cl2 to obtain the title compound (746 mg) as a white foam.
    • 87F. (S)-(1-Benzyl-6-bromo-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00125
  • A stirring mixture of 87E (0.60 g, 1.76 mmol), K2CO3 (0.49 g, 3.52 mmol), and benzyl bromide (0.36 g, 2.11 mmol) in acetone (15 mL) was heated to reflux under argon for 16 h. The mixture was then cooled to RT and the solvent was evaporated under vacuum. The resulting residue was partitioned between water and EtOAc. The EtOAc layer was washed with brine, dried (Na2SO4), and evaporated. The resulting crude product was chromatographed on silica gel eluted with 10-20% EtOAc in hexane (step-wise gradient) to obtain the title compound (0.72 g) as a solid.
    • 87G. (S)-3-Amino-1-benzyl-6-bromo-2-oxo-1,2,3,4-tetrahydroquinoline, hydrochloric acid salt
  • Figure US20050014786A1-20050120-C00126
  • The title compound was prepared from 87F according to the procedures described in Example 1D.
    • 87H. (S)—N-(1-Benzyl-6-bromo-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00127
  • The title compound was prepared from 87G according to the procedures described in Example 1G.
    • 87C. (S)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • The title compound was prepared from 87H according to the procedures described in Example 148I.
    • EXAMPLE 88 (R)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00128
  • The title compound was obtained via chiral chromatographic separation of racemic 87B using a Chiralpak AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 30% isopropanol in heptane.
  • Alternatively, the title compound can be prepared from commercially available (R)-2-(tert-butyloxycarbonylamino)-3-(2-nitrophenyl)propanoic acid according to the procedures described in Example 87. HPLC: 99% at 8.01 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 458 [M+1]+. Chiral HPLC 100% e.e.; retention time=11.50 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1mL/min.
    • EXAMPLE 89 (S) N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00129
    • 89A. (1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00130
  • To a solution of 1B (1.636 g, 5 mmol) in DCE (16 mL) at RT was added benzaldehyde (1 mL, 10 mmol), followed by NaB(OAc)3H (2.97 g, 14 mmol) and AcOH (0.6 mL, 10 mmol). The reaction mixture was stirred at RT for 16 h, then quenched with aqueous NaHCO3 (40 mL) and extracted with CH2Cl2 (50 mL×3). The combined extracts were washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with 0-20% of EtOAc in hexane to give the title compound (1.70 g, 81%) as a white foam.
    • 89B. (1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester
  • Figure US20050014786A1-20050120-C00131
  • Compound 89A (150 mg, 0.36 mmol), phenylboronic acid (57 mg, 0.47 mmol) and 2N aqueous Na2CO3 (1.25 mL, 2.5 mmol) in a mixed solvent of toluene (1.5 mL) and EtOH (0.5 mL) were stirred at RT for 30 min while N2 was allowed to bubble through the mixture, and then tetrakis(triphenylphosphine)-palladium (0) (30 mg) was added. The mixture was stirred at 90° C. under N2 for 1 h. After cooling to RT, the mixture was extracted with EtOAc (15 mL×3), and organic extracts were washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (10-50%) in hexane to give the title compound (80 mg, 67%) as a white foam.
    • 89C. 1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-ylamine, trifluoroacetic acid salt
  • Figure US20050014786A1-20050120-C00132
  • To a solution of compound 89B (44 mg, 0.106 mmol) in CH2Cl2 (0.5 mL) at RT was added trifluoroacetic acid (0.5 mL). After stirring at RT for 1.5 h, the reaction mixture was concentrated, and the resulting residue stripped with toluene, dried in vacuo to give the title compound as an oil (46 mg, 100%).
    • 89D. N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00133
  • Compound 89D was prepared from 89C by procedures analogous to those described in Example 1G. HPLC: 96% at 8.3 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 455 [M+1]+.
    • 89E. (S) N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • The title compound was obtained via chiral chromatographic separation of racemic 89D using a Chiralpak AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 20% isopropanol in heptane.
  • The title compound was also prepared using the following procedures: To a solution of 87C (510 mg, 1.11 mmol) in THF/MeOH (2:1, 15 mL) was added phenylboronic acid (272 mg, 2.22 mmol), followed by K2CO3 (613 mg, 4.44 mmol) and PXPd (30 mg, 0.056 mmol). The reaction mixture was stirred at 60° C. for 2 h, then additional amount of phenylboronic acid (54 mg, 0.44 mmol) and PXPd (16 mg, 0.028 mmol) were added. After 2 h at 60° C., same amount of phenylboronic acid and PXPd were added again to the reaction mixture to push completion of the reaction. After stirring at 60° C. for one more hour, the reaction was allowed to cool to RT and concentrated. The residue was partitioned between water and CH2Cl2, and the aqueous phase extracted with CH2Cl2 (50 mL×2). The combined organics were washed with brine, dried (Na2SO4) and concentrated. The residue was purified using chromatography (silica gel) eluting with EtOAc/hexane (0-60%) to afford the title compound (260 mg, 51%) as a white solid.
  • HPLC: 99% at 8.35 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 455 [M+1]+. Chiral HPLC: 100% e.e.; retention time=17.20 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
    • EXAMPLE 90 (R) N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00134
  • The title compound was obtained via chiral chromatographic separation of racemic 89D using a Chiralpad AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 20% isopropanol in heptane.
  • The title compound was also prepared from 88 using the procedures analogous to those described in Example 89E.
  • HPLC: 99% at 8.35 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 455 [M+1]+. Chiral HPLC: 100% e.e.; retention time=14.85 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
    • EXAMPLE 91 (R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydrouuinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00135
    • 91A. N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00136
  • To a solution of 87B (3.648 g, 8.0 mmol) and 4-fluorobenzene boronic acid (2.24 g, 16.0 mmol) in a mixed solvent of MeOH-THF (80 mL, 1:1 ratio) was added K2CO3 (4.423 g, 32.0 mmol), followed by PXPd (215 mg, 0.40 mmol). The resulting suspension was vigorously stirred in a 70° oil bath for 35 min. After cooling down to RT, the dark brown solution was diluted with water (200 mL), and extracted with with EtOAc (200 mL×2). The combined EtOAc extracts were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc/hexane (0-30%) to afford the title compound (2.977 g, 79%) as a light brown solid.
    • 91B. (R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • The title compound was obtained via chiral chromatographic separation of racemic 91A using a Chiralpad AD column (5×50 cm, 20 μm chiral stationary phase) eluting with a mixed solvent (isopropanol-methanol-heptane=1:1:2) The title compound can also be prepared from homochiral 88 using the procedures described in Example 89E. HPLC: 99% at 8.46 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 473 [M+1]+. Chiral HPLC: 99% e.e.; retention time=10.02 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1mL/min.
    • EXAMPLE 92 (S) N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00137
  • The title compound was obtained via chiral chromatographic separation of racemic 91A using a Chiralpad AD column (5×50 cm, 20 μm chiral stationary phase) eluting with a mixed solvent (isopropanol-methanol-heptane=1:1:2).
  • Alternatively, the title compound can be prepared from homochiral 87C using the procedures described in Example 89E. HPLC: 99% at 8.34 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 473 [M+1]+. Chiral HPLC: 99% e.e.; retention time=17.84 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
    • EXAMPLE 93 N-(1-Benzyl-6-(2-oxopyridin-1(2H)-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00138
  • To a suspension of 87B (229 mg, 0.5 mmol), 2-hydroxypyridine (71.3 mg, 0.75 mmol), K2CO3 (138.2 mg, 1.0 mmol) and copper iodide (47.6 mg, 0.25 mmol) in DMF (i.o mL) was added N,N′-dimethylethylenediamine (27 μL, 025 mmol). The resulting blue suspension was shaken at 110° for 2 h. After cooling to RT, the reaction mixture was partitioned between EtOAc and water, and the aqueous layer was extracted with EtOAc (3×). The combined EtOAc extracts were washed with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc/hexane (30-60%) to afford 93 (45 mg, 19%) as an off-white solid. HPLC: 99% at 6.72 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mumin. UV detection at 220 nm). MS (ES): m/z 472 [M+1]+.
    • EXAMPLE 94 TO 108
  • Additional compounds were prepared by procedures analogous to those described in Example 89 and 93. The compounds of Examples 94 to 108 have the following structure,
    Figure US20050014786A1-20050120-C00139
  • where the group R2, the stereochemistry, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 5. The chromatography techniques used to determine the compound retention times of Table 5 are as follows: HPLC (purity) conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm) (Note: retention time*=4 min gradient). LC-MS conditions: Phenom. Luna C18, 4.6×50 mm eluting with 10-90% MeOH/H2O over 4 minutes containing 0.1% TFA; 4 mL/min, monitoring at 220 nm. The molecular mass of the compounds listed in Table 5, where provided, were determined by MS (ES) by the formula m/z.
    TABLE 5
    Retention Time
    Ex. No. R2 Compound Name (min.)/m/z See Ex.
    94
    Figure US20050014786A1-20050120-C00140
         		N-(1-Benzyl-6-pyridin-2-yl- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 5.37 LCMS/456 [M + H]+ 89B
    95
    Figure US20050014786A1-20050120-C00141
         		N-(1-Benzyl-6-pyridin-3-yl- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 5.66 LCMS/456 [M + H]+ 89E
    96
    Figure US20050014786A1-20050120-C00142
         		N-(1-Benzyl-6-pyridin-4-yl- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 5.50 LCMS/456 [M + H]+ 89E
    97
    Figure US20050014786A1-20050120-C00143
         		N-[1-Benzyl-6-(3-fluoro- phenyl)-1,2,3,4- tetrahydroquinolin-3-yl]- benzenesulfonamide 8.37 LCMS/456 [M + H]+ 89E
    98
    Figure US20050014786A1-20050120-C00144
         		N-(1-Benzyl-6-thiophen-2- yl-1,2,3,4-tetrahydro quinolin-3-yl)-benzene sulfonamide 8.26 LCMS/461 [M + H]+ 89B
    99
    Figure US20050014786A1-20050120-C00145
         		N-(1-Benzyl-6-thiophen-3-yl- 1,2,3,4-tetrahydroquinolin-3- yl)-benzenesulfonamide 8.18 LCMS/461 [M + H]+ 89E
    100
    Figure US20050014786A1-20050120-C00146
         		N-(1-Benzyl-6-vinyl-1,2,3,4- tetrahydroquinolin-3-yl)- benzenesulfonamide 7.94 LCMS/405 [M + H]+ 89B
    101
    Figure US20050014786A1-20050120-C00147
         		N-(6-Allyl-1-benzyl-1,2,3,4- tetrahydroquinolin-3-yl)- benzenesulfonamide 8.28 LCMS/419 [M + H]+ 89B
    102
    Figure US20050014786A1-20050120-C00148
         		N-(1-Benzyl-6-(4- (trifluoromethoxy)phenyl)- 1,2,3,4-tetrahydroquinolin-3- yl)benzenesulfonamide 4.32* LCMS/539 [M + H]+ 89E
    103
    Figure US20050014786A1-20050120-C00149
         		N-(1-Benzyl-6-(6- methoxypyridin-3-yl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 3.90* LCMS/486 [M + H]+ 89E
    104
    Figure US20050014786A1-20050120-C00150
         		N-(1-Benzyl-6-(4- (benzyloxy)-3-fluorophenyl)- 1,2,3,4-tetrahydroquinolin-3- yl)benzenesulfonamide 4.39* LCMS/579 [M + H]+ 89E
    105
    Figure US20050014786A1-20050120-C00151
         		N-(1-Benzyl-6-(2- oxopyrrolidin-1-yl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 6.85 LCMS/462 [M + H]+ 93
    106
    Figure US20050014786A1-20050120-C00152
         		N-(1-Benzyl-6-(2- oxopiperidin-1-yl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 6.98 LCMS/476 [M + H]+ 93
    107
    Figure US20050014786A1-20050120-C00153
         		N-(1-Benzyl-6-(1H-imidazol- 1-yl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 5.21 LCMS/445 [M + H]+ 93
    108
    Figure US20050014786A1-20050120-C00154
         		N-(1-Benzyl-6-(1H-pyrazol- 1-yl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 7.18 LCMS/445 [M + H]+ 93
    • EXAMPLE 109 N-(1-Benzyl-6-(3-fluoro-4-hydroxyphenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00155
  • To a 2-neck round-bottom flask was added 104 (12 mg, 0.0207 mmol), EtOAc (2 ml), ethanol (2 ml), 5% Pd/C (5 mg). The resulting suspension was stirred under hydrogen balloon for 5 hours. The reaction mixture was filtered through a pad of Celite, and the filtrate concentrated in vacuo. The resulting residue was purified using prep HPLC (Conditions: Phenomenex Luna 5μ C18 21.2×100 mm); Eluted with 0% to 100% B, 10 min gradient (A=90% H2O—10% MeOH and B=10% H2O—90% MeOH); Flow rate at 20 mL/min, UV detection at 220 nm) to give the title compound (6 mg, 60%) as an off-white solid. HPLC: 99% at 3.777 min (retention time) (Conditions: YMC S5 ODS CombiScreen 4.6×50 mm); Eluted with 0% to 100% B, 4 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 4 mL/min, UV detection at 220 nm). MS (ES): m/z=489 [M+1]+.
    • EXAMPLE 110 N-(1-Benzyl-6-(6-hydroxypyridin-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00156
  • To a round-bottom flask was added 103 (10 mg, 0.0206 mmol), acetic acid (1 ml) and 40% HBr in H2O. The reaction mixture was stirred at 90° C. for 10 hours. After cooling to RT, the reaction mixture was treated with 1N aqueous NaOH (10 ml), then extracted with EtOAc(2×10 ml). The combined organics were washed with water (5 ml), brine (10 ml), dried (MgSO4) and concentrated. The residue was purified using prep HPLC (Conditions: Phenomenex Luna 5μ C18 21.2×100 mm); Eluted with 0% to 100% B, 10 min gradient (A=90% H2O—10% MeOH and B=10% H2O—90% MeOH); Flow rate at 20 mL/min, UV detection at 220 nm) to give the title compound (4 mg, 42%) as a white solid. HPLC: 99% at 3.410 min (retention time) (Conditions: YMC S5 ODS CombiScreen 4.6×50 mm); Eluted with 0% to 100% B, 4 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 4 mlimin, UV detection at 220 nm). MS (ES): m/z =472 [M+1]+.
    • EXAMPLE 111 (R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-hydroxybenzenesulfonamide
  • Figure US20050014786A1-20050120-C00157
    • 111A. 1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-amine, trifluoroacetic acid salt
  • Figure US20050014786A1-20050120-C00158
  • Compound 111A was prepared from 89A and 4-fluorophenylboronic acid, then N-boc deprotection by procedures analogous to those described in 89B and 89C.
    • 111B. N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-methoxybenzenesulfonamide
  • Figure US20050014786A1-20050120-C00159
  • Compound 111B was prepared from 111A and 3-methoxyphenylsulfonyl chloride by procedures analogous to those described in 1G.
    • 111C. (R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-hydroxybenzenesulfonamide
  • To a solution of 111B (3.9 g, 7.8 mmol) in CH2Cl2 (100 mL) at −78° C. was added BBr3 (1.47 mL, 15.5 mmol). The reaction solution was stirred at −78° C. for 15 min and at 0° C. for 2 h. The reaction was quenched with methanol (100 mL) and the solvents were removed in vacuo. The residue was redissolved in methanol (100 mL) and glacial acetic acid (1 mL). The mixture was heated to reflux for 1 h and the solvents were removed in vacuo. The residue was chromatographed (silica gel) eluting with EtOAc/hexanes (0-100%) over 20 min. The fractions containing product were combined and evaporated to give 2.5 g of product as a yellow solid. Chiral separation of 0.7 g of product was performed using Chiracel AD column 5×50 cm, flow rate: 40 mL/min; UV detection at 256 nm; solvent: 50% heptane, 25% methanol, 25% isopropanol to afford (R)-isomer (240 mg beige solid) and (S)-isomer (235 mg light yellow solid). HPLC: 4.06 min, column: 4.6×50 mm Phenomenex LUNA C-18 (S-5); flow rate 2.5 mL/min; gradient: 0-100% B over 4 min, hold 100% B for 1 min. Solvent A: (90% H2O—10% MeOH—0.1% H3PO4 and Solvent B (10% H2O—90% MeOH—0.1% H3PO4); MS (ES): m/z=489 [M+1]+.
    • EXAMPLE 112 (R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-(dihydrogen phosphate)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00160
  • To a solution of 111C (0.1 g, 0.22 mmol) in acetonitrile (2.2 mL) at −10° C. was added carbon tetrachloride (0.1 mL, 1.1 mmol), diisopropylethylamine (0.08 mL, 0.46 mmol), and 4-N,N-dimethylaminopyridine (3 mg, 0.02 mmol). Dibenzyl phosphite (0.085 g, 0.32 mmol) was added dropwise to the reaction solution, and the temperature was maintained at −10° C. for 45 min. The reaction was quenched with 1 mL of 0.5 M aqueous KH2PO4 and the mixture was stirred at RT. The mixture was diluted with EtOAc (10 mL) and the layers were separated. The organic layer was washed with water (10 mL), brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified via flash chromatography (silica gel) eluting with 0-60% ethyl acetate/hexanes to give 67 mg of a yellow oil. The yellow oil (67 mg, 0.1 mmol) was stirred in CH2Cl2 (0.5 mL) and trifluoroacetic acid (0.5 mL) for 2 h and the solvents were evaporated in vacuo. The residue was purified via preparative reverse-phase HPLC (column: 21×100 mm Phenomenex LUNA C-18 (S-5); flow rate 20 mL/min; gradient: 40-100% B over 12 min, hold 100% B for 8 min. Solvent A: 10% methanol/water+0.1% TFA. Solvent B: 90% methanol/water+0.1% TFA) to give the title compound (56 mg) as a grey solid. HPLC: 4.77 min, column: 4.6×50 mm Phenomenex LUNA C-18 (S-5); flow rate 2.5 mL/min; gradient: 0-100% B over 4 min, hold 100% B for 1 min. Solvent A: 10%methanol/water+0.2% H3PO4. Solvent B: 90% methanol/water+0.2% H3PO4. MS (ES): m/z =568 [M+1]+.
    • EXAMPLE 113 N-(1-(3-Cyanobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00161
    • 113A. N-(6-(4-Fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzene sulfonamide
  • Figure US20050014786A1-20050120-C00162
  • Compound 113A was prepared from 87A and 4-fluorophenylboronic acid by procedures analogous to those described in 89E.
    • 113B. N-(1-(3-Cyanobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Compound 113B was prepared from 113A and 3-cyanobenzaldehyde by procedures analogous to those described in 22A. HPLC: 96% at 6.25 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 498 [M+1]+.
    • EXAMPLE 114-141
  • Additional compounds were prepared by procedures analogous to those described in Example 113. The compounds of Examples 114 to 141 have the following structure,
    Figure US20050014786A1-20050120-C00163
  • where the group A and group R, the compound name, retention time, molecular mass, and the procedure employed, are set forth in Table 6. The chromatography techniques used to determine the compound retention times of Table 6 are as follows: HPLC (purity) conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MEOH—0.1% H3PO4 and B=IO% H2O—90% MEOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). (Note: retention time*=4 min gradient). LC-MS conditions: Phenom. Luna C 18, 4.6×50 mm eluting with 10-90% MeOH/H2O over 4 minutes containing 0.1% TFA; 4 mL/min, monitoring at 220 nm. The molecular mass of the compounds listed in Table 6, where provided, were determined by MS (ES) by the formula m/z.
    TABLE 6
    Retention Time
    Ex. No. R A Compound Name (min.)/m/z See No.
    114 H
    Figure US20050014786A1-20050120-C00164
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-2- acetarnido-4-methyl thiazole-5-sulfonamide 3.33* LCMS/551 [M + H]+ 111B
    115 H
    Figure US20050014786A1-20050120-C00165
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-1- methyl-1H-imidazole-4- sulfonamide 3.32* LCMS/477 [M + H]+ 111B
    116 H
    Figure US20050014786A1-20050120-C00166
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-1- methyl-1H-imidazole-4- sulfonamide 3.32* LCMS/477 [M + H]+ 111B
    117 H
    Figure US20050014786A1-20050120-C00167
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-5- chloro-1,2-dimethyl-1H- imidazole-4-sulfonamide 3.64* LCMS/525 [M + H]+ 111B
    118 H
    Figure US20050014786A1-20050120-C00168
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)- 1,2-dimethyl-1H-imidazole- 4-sulfonamide 3.30* LCMS/491 [M + H]+ 111B
    119 H
    Figure US20050014786A1-20050120-C00169
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)- (oxazol-5-yl)-thiophene- 2-sulfonamide 4.25* LCMS/546 [M + H]+ 111B
    120 H
    Figure US20050014786A1-20050120-C00170
         		N-(1-Benzyl-6-(4-fluoro phenyl)-1,2,3,4-tetrahydro quinolin-3-yl)-5-(isoxazole- 3-yl)thiophene-2- sulfonamide 3.68* LCMS/546 [M + H]+ 111B
    121 H
    Figure US20050014786A1-20050120-C00171
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-5- chlorothiophene-2- sulfonamide 3.51* LCMS/513 [M + H]+ 111B
    122 H
    Figure US20050014786A1-20050120-C00172
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-5- methyl-2-(trifluoromethyl) furan-3-sulfonamide 3.55* LCMS/545 [M + H]+ 111B
    123 H
    Figure US20050014786A1-20050120-C00173
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)pyridine-2-sulfonamide 7.96 LCMS/474 [M + H]+ 111B
    124 H
    Figure US20050014786A1-20050120-C00174
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)pyridine-3-sulfonamide 7.97 LCMS/474 [M + H]+ 111B
    125 H
    Figure US20050014786A1-20050120-C00175
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-5- sulfonamide 4.30* LCMS/576 [M + H]+ 111B
    126 H
    Figure US20050014786A1-20050120-C00176
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-3- fluorobenzene sulfonamide 8.40 LCMS/491 [M + H]+ 111B
    127 H
    Figure US20050014786A1-20050120-C00177
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-3- chlorobenzene sulfonamide 8.60 LCMS/508 [M + H]+ 111B
    128 H
    Figure US20050014786A1-20050120-C00178
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-3- methylbenzene sulfonamide 8.54 LCMS/487 [M + H]+ 111B
    129 H
    Figure US20050014786A1-20050120-C00179
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-3- cyanobenzene sulfonamide 8.17 LCMS/498 [M + H]+ 111B
    130 H
    Figure US20050014786A1-20050120-C00180
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)- 3,5-difluorobenzene sulfonamide 8.60 LCMS/509 [M + H]+ 111B
    131 H
    Figure US20050014786A1-20050120-C00181
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)(phenyl)methane sulfonamide 8.37 LCMS/487 [M + H]+ 111B
    132 H
    Figure US20050014786A1-20050120-C00182
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)(pyridin-3-yl)methane sulfonamide 7.43 LCMS/488 [M +H]+ 111B
    133 H
    Figure US20050014786A1-20050120-C00183
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)(pyridin-4-yl)methane sulfonamide 7.17 LCMS/488 [M + H]+ 111B
    134 H
    Figure US20050014786A1-20050120-C00184
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)(pyridin-2-yl)methane sulfonamide 7.17 LCMS/488 [M + H]+ 111B
    135 H
    Figure US20050014786A1-20050120-C00185
         		N-(1-Benzyl-6-(4- fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl)-2- phenylethene sulfonamide 8.55 LCMS/499 [M + H]+ 111B
    136 Cl
    Figure US20050014786A1-20050120-C00186
         		N-(1-(3-Chlorobenzyl)-6- (4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 7.05 LCMS/507 [M + H]+ 113
    137 F
    Figure US20050014786A1-20050120-C00187
         		N-(1-(3-Fluorobenzyl)-6- (4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 6.79 LCMS/491 [M + H]+ 113
    138 CH3
    Figure US20050014786A1-20050120-C00188
         		N-(1-(3-Methylbenzyl)-6- (4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 7.67 LCMS/487 [M + H]+ 113
    139 OCH3
    Figure US20050014786A1-20050120-C00189
         		N-(1-(3-Methoxylbenzyl)- 6-(4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3- yl)benzenesulfonamide 7.13 LCMS/503 [M + H]+ 113
    140 Cl
    Figure US20050014786A1-20050120-C00190
         		N-(1-(3-Chlorobenzyl)-6- 4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl))- 3,5-difluorobenzene sulfonamide 4.4* LCMS/543 [M + H]+ 113
    141 Cl
    Figure US20050014786A1-20050120-C00191
         		N-(1-(3-Chlorobenzyl)-6- (4-fluorophenyl)-1,2,3,4- tetrahydroquinolin-3-yl))- 3-cyanobenzene sulfonamide 4.2* LCMS/533 [M + H]+ 113
    • EXAMPLE 142 3-Benzenesulfonylamino-1-benzyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid amide
  • Figure US20050014786A1-20050120-C00192
  • To a solution of racemate 5 (100 mg, 0.25 mmol) in MeOH (2 mL) at RT was added 1N aqueous NaOH (0.13 mL), followed by 30% hydrogen peroxide (0.1 mL). The mixture was stirred at 65° C. for 24 h, cooled to RT and concentrated. The residue was partitioned between H2O and CH2Cl2, and the separated CH2Cl2 layer was concentrated. The crude product was purified using preparative HPLC (YMC S5 ODS 20×100 mm) eluting with MeOH (50-80%) in H2O for 8 min, and then 80% MeOH in H2O for 7 min to give the title compound (64 mg, 62%) as a white solid. HPLC: 99% at 6.05 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 422 [M+H]+.
    • EXAMPLE 143 3-Benzenesulfonylamino-1-benzyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid
  • Figure US20050014786A1-20050120-C00193
  • To a solution of racemate 5 (188 mg, 0.47 mmol) in EtOH (4 mL) at RT was added 20% aqueous NaOH (2 mL). The mixture was stirred at 80° C. for 60 h, cooled to RT, adjusted to pH 7 with 1N aqeous HCl and extracted with CH2Cl2 (15 mL×3). The combined CH2Cl2 extracts were washed with brine, dried (Na2SO4), and concentrated. The crude product was purified using preparative HPLC as described in 142 to give the title compound (84 mg, 43%) as a white solid. HPLC: 99% at 6.61 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 423 [M+H]+.
    • EXAMPLE 144 N-[1-Benzyl-6-(morpholine-4-carbonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00194
  • To a solution of compound 143 (74 mg, 0.175 mmol) in anhydrous DMF (2 mL) was added morpholine (27 mg, 0.31 mmol), followed by EDAC (72 mg, 0.375 mmol), HOBt (58 mg, 0.3765 mmol) and NMM (89 mg, 0.88 mmol). The mixture was stirred at RT for 2 h, then partitioned between H2O (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (15 mL×2 ) and the combined EtOAc extracts were washed with brine, dried (Na2SO4) and concentrated. The crude product was chromatographed (silica gel) eluting with EtOAc-hexane to give the title compound (65 mg, 75%) as a white solid. HPLC: 99% at 6.58 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 492 [M+H]+.
    • EXAMPLE 145 N-[1-Benzyl-6-(Piperidine-1-carbonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00195
  • The title compound was prepared from 143 and piperidine by procedure analogous to those described in Example 144. HPLC: 99% at 7.37 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 490 [M+H]+.
    • EXAMPLE 146 N-[1-Benzyl-6-(pyrrolidine-1-carbonyl)-1,2,3,4-tetrahydroquinolin-3yl]-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00196
  • The title compound was prepared from 143 and pyrrolidine by procedure analogous to those described in Example 144. HPLC: 99% at 7.01 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 476 [M+H]+.
    • EXAMPLE 147 N-(1-Benzyl-6-(4-fluorophenyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00197
    • 147A. 6-Chloro-4-(trifluoromethyl)-3-aminoquinoline
  • Figure US20050014786A1-20050120-C00198
  • To a solution of 6-chloro-3-nitro-4-(trifluoromethyl)quinoline (5.53 g, 20 mmol) (prepared according to the procedures described by Tarby, C. M., in WO 2003062238) in EtOAc (100 mL) was added SnCl22H2O (18 g, 80 mmol). The resulting mixture was stirred at RT for 18 h, then at 80° C. for 6 h. After cooling to RT, saturated aqueous K2CO3 (5 mL) was added. The reaction mixture was stirred at RT for 30 min, and then solid K2CO3 (16.6 g, 120 mmol) was added stirring was continued at RT for 4 more hours. EtOAc (200 mL) was added, the resulting mixture was filtered, and the filtrate concentrated in vacuo to give the title compound (4.8 g, 97% yield) as an off-white solid.
    • 147B. 6-(4-Fluorophenyl)-4-(trifluoromethyl)-3-aminoquinoline
  • Figure US20050014786A1-20050120-C00199
  • The title compound was prepared from 147A using the procedures analogous to those described in Example 89E.
    • 147C. 6-(4-Fluorophenyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-amine
  • Figure US20050014786A1-20050120-C00200
  • To a solution of 147B (400 mg, 1.3 mmol) in EtOAc (5 mL)-MeOH (15 mL) was bubbled with N2 for 15 min, then palladium hydroxide (20 weight % palladium on carbon) (200 mg) was added. The resulting suspension was subjected to hydrogenation under 80 psi of pressure for 16 h., then filtered. The filtrate was concentrated. The residue was chromatographed (silica gel) eluting with 20% EtOAc in hexane (100 mL), 50% EtOAc in hexane (100 mL), 100% ETOAc (100 mL), 5% MeOH in EtOAc (150 mL) to give title compound (62 mg, 15% yield) as a white foam.
    • 147D. N-(6-(4-Fluorophenyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00201
  • The title compound was prepared from 147C using the procedures analogous to those described in Example 1G.
    • 147E. N-(1-Benzyl-6-(4-fluorophenyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • The title compound was prepared from 147D using the procedures analogous to those described in Example 22A. HPLC: 99% at 8.30 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 541 [M+1]+.
    • EXAMPLE 148 N-(1-Benzyl-6-(4-fluorophenyl)-3-methyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00202
    • 148A. Ethyl-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate
  • Figure US20050014786A1-20050120-C00203
  • The title compound was prepared following the procedures described by Turconi, M., et al.,in Bioorganic & Medicinal Chemistry, 2, 1375-1383 (1994).
    • 148B. Ethyl 6-bromo-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate
  • Figure US20050014786A1-20050120-C00204
  • The title compound was prepared from 148A using the procedures analogous to those described in Example 87E.
    • 148C. 6-Bromo-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylic acid
  • Figure US20050014786A1-20050120-C00205
  • The title compound was prepared from 148B using the procedures analogous to those described in Example 149D.
    • 148D. Benzyl-6-bromo-3-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00206
  • The title compound was prepared from 148C using the procedures analogous to those described in Example 149E.
    • 148E. Benzyl 1-benzyl-6-bromo-3-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00207
  • The title compound was prepared from 148D using the procedures analogous to those described in Example 87F.
    • 148F. Benzyl 1-benzyl-6-(4-fluorophenyl)-3-methyl-2-oxo-1,2,3,4-tetrahydro quinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00208
  • The title compound was prepared from 148E using the procedures analogous to those described in Example 89E.
    • 148G. 1-Benzyl-6-(4-fluorophenyl)-3-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-amine
  • Figure US20050014786A1-20050120-C00209
  • To a solution of 148F (340 mg, 0.69 mmol) in MeOH (8 mL) was added 5% palladium on carbon (200 mg). The resulting suspension was hydrogenated under hydrogen balloon for 1 h., then filtered. The filtrate was concentrated to give title compound (235 mg, 94% yield) as an off-white foam.
    • 148H. N-(1-benzyl-6-(4-fluorophenyl)-3-methyl-2-oxo-1,2,3,4-tetrahydro quinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00210
  • The title compound was prepared from 148G using the procedures analogous to those described in Example 1G.
    • 148I. N-(1-benzyl-6-(4-fluorophenyl)-3-methyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00211
  • To compound 148H ((75 mg, 0.15 mmol) was added BH3 THF (1M, 1.5 mL, 1.5 mmol) at RT under Argon. After addition, the reaction was stirred at RT for 24 h, then quenched by carefully adding MeOH (1 mL). The resulting mixture was stirred at RT for 2 h, then partitioned between saturated aqueous Na2CO3 (10 mL) and EtOAc. The aqueous layer was extracted with EtOAc (15 mL×3) and the combined EtOAc extracts washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (0-40%) in hexane to give the title compound as an off-white solid (40 mg,55%). HPLC: 99% at 8.50 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4), Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 487 [M+H]+.
    • EXAMPLE 149 (S)—N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00212
    • 149A. Ethyl 4-chloro-6-(trifluoromethyl)quinoline-3-carboxylate
  • Figure US20050014786A1-20050120-C00213
  • The title compound was prepared from ethyl 4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate according to the procedures described in U.S. Pat. No. 4,343,804.
    • 149B. Ethyl 6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-3-carboxylate
  • Figure US20050014786A1-20050120-C00214
  • The title compound was prepared from 149A using the procedures analogous to those described in Example 1A.
    • 149C. Ethyl 1-benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-3-carboxylate
  • Figure US20050014786A1-20050120-C00215
  • The title compound was prepared from 149B using the procedures analogous to those described in Example 22A.
    • 149D. 1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-3-carboxylic acid
  • Figure US20050014786A1-20050120-C00216
  • To a solution of 149C (825 mg, 2.27 mmol) in a mixed solvent of MeOH-THF-H2O (20 mL at ratio of 2:2:1)was added lithium hydroxide monohydrate (400 mg, 11.35 mmol).The mixture was stirred at RT for 2 h, then extracted with ether (20 mL). The aqueous layer was acidified to pH 4-5 using 3N aqueous HCl, then extracted with CH2Cl2 (3×). The combined CH2Cl2 extracts were washed with water, brine, dried (Na2SO4), and concentrated in vacuo to afford compound 149D as light yellow foam (735 mg, 97%).
    • 149E. Benzyl 1-benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-ylcarbamate
  • Figure US20050014786A1-20050120-C00217
  • To a solution of 149D (345 mg, 1.029 mmol) in dioxane (3.5 mL) was added diphenylphosphoryl azide (244 μL, 1.133 mmol) and triethylamine (170 μL, 1.236 mmol). The reaction mixture was stirred at RT for 20 min, then benzylalcohol (130 μL, 1.236 mmol) was added. The reaction was heated at 100° C. for 7 h. After cooling to RT, the reaction mixture was concentrated in vacuo, and the residue partitioned between EtOAc and water. The separated organic layer was washed with brine, dried (Na2SO4), and concentrated in vacuo. The residue was chromatographed (silica gel) eluting with EtOAc/hexane 0-40% to afford 149E as a clear oil (390 mg, 86%).
    • 149F. 1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-amine
  • Figure US20050014786A1-20050120-C00218
  • A suspension of 149E (740 mg, 1.682 mmol) and 5% Pd/C (Degussa type, 300 mg) in a mixed solvent of MeOH-THF (20 mL, 1:1 ratio) was hydrogenated ar RT under hydrogen balloon for 1 h. After filtration to remove the catalyst, the filtrate was concentrated and the residue dried in vacuo to afford compound 149F as a clear oil (465 mg, 90%).
    • 149G. N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00219
  • The title compound was prepared from 149F using the procedures analogous to those described in Example 1G.
    • 149H. (S)—N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • The title compound was separated from 149G using a Chiralpak AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 30% isopropanol in heptane. HPLC: 99% at 7.81 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 447 [M+1]+. Chiral HPLC 99% e.e.; retention time=10.1 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
    • EXAMPLE 150 (R)—N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00220
  • The title compound was obtained via chiral chromatographic separation of racemic 149G using a Chiralpak AD column (5×50 cm, 20 μm chiral stationary phase) eluting with 30% isopropanol in heptane. HPLC: 99% at 7.82 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 447 [M+1]+. Chiral HPLC 99% e.e.; retention time=5.49 min; Conditions: AD (4.6×250 mm); Eluted with 30% isopropanol in heptane for 30 min at 1 mL/min.
    • EXAMPLE 151 N-(1-Benzyl-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00221
  • The title compound was prepared from ethyl 4-hydroxy-7-(trifluoromethyl)quinoline-3-carboxylate by the procedures analogous to those described in Example 149. HPLC: 97% at 7.75 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 447 [M+1]+.
    • EXAMPLE 152 N-(1-Benzyl-7-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluorobenzenesulfonamide
  • Figure US20050014786A1-20050120-C00222
    • 152A. 2-Amino-3-(4-chloro-2-nitrophenyl)propanoic acid
  • Figure US20050014786A1-20050120-C00223
  • The title compound was prepared from 4-chloro-2-nitrobenzyl chloride and diethylacetamidomalonate according to the procedures described by Davis, A. L.; et al, in Arch. Biochem. Biophys., 102, 48 (1963).
    • 152B. 3-Amino-7-chloro-3,4-dihydroquinolin-2(1H)-one
  • Figure US20050014786A1-20050120-C00224
  • To a solution of 152A (1.0 g, 4.1 mmol) in 50% aqueous EtOH (40 mL), 10% Pt/C (100 mg) was added under argon and the mixture was hydrogenated at 35 psi for 1 h. The reaction mixture was filtered via a pad of celite and the filtrate was concentrated. The residue was dissolved in conc. HCl (10 mL) and stirred at RT for 6 h. The mixture was then concentrated and dissolved in 100 mL of saturated aqueous sodium bicarbonate. The white solid was filtered and dried to afford 0.44 g of 152B.
    • 152C. 7-Chloro-N-(1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluoro-benzene-sulfonamide
  • Figure US20050014786A1-20050120-C00225
  • To a solution of 152B (50 mg, 0.22 mmol) in 1 mL THF, lithium aluminum hydride (81 mg, 2.2 mmol) was added and the mixture refluxed under argon for 16 h. Excess LAH was quenched with MeOH and the mixture partitioned between saturated aqueous NaHCO3 and EtOAc. The organic layer was separated, washed with water, brine, dried (MgSO4) and evaporated to afford 21 mg of a colorless gum. To a solution of this material in 1 mL of DCM was added triethylamine (0.24 mL, 0.96 mmol), followed by 3,5-difluorobenzenesulfonylchloride (20.4 mg, 0.09 mmol). The mixture was stirred at RT for 1.5 h, then concentrated in vacuo. The residue was taken into EtOAc (30 mL), washed with water, brine, dried (MgSO4) and concentrated to give 37 mg of 152C.
    • 152D. N-(1-Benzyl-7-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluoro-benzenesulfonamide
  • The title compound was prepared from 152C and 3-chlorobenzaldehyde by procedures analogous to those described in Example 22A. HPLC: 99% at 4.20 min (retention time) (Conditions: Phenom Prime S5, C18 (4.6×50 mm); Eluted with 0% to 100% B, 4 min gradient (A=90% H2O—10% MeOH—0.1% TFA and B=10% H2O—90% MeOH—0.1% TFA); Flow rate at 4.0 mL/min, UV detection at 220 nm). MS (ES): m/z 484 [M+H]+.
    • EXAMPLE 153 N-(6-Cyano-1-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00226
    • 153A. N-(6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00227
  • Compound 153A was prepared from 1D by procedures analogous to those described in Example 1G.
    • 153B. N-(6-Cyano-1-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • To a s mixture of 153A (235 mg, 0.75 mmol), Pd(OAc)2 (8.4 mg, 0.0375 mmol), BINAP (25.7 mg, 0.041 mmol), bromobenzene (94.2 mg, 0.6 mmol) in toluene (1.5 mL) was added KOtBu (98 mg, 0.88 mmol) at RT under argon. The resulting mixture was stirred at 100° C. under argon for 16 h. After cooling to RT, residue was diluted with 5% citric acid, then extracted with EtOAc (3×10 mL). The combined EtOAc extracts were washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (50-90%) in hexane to give the title compound as a white foam (25 mg, 8.6%). HPLC: 99% at 6.9 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 390 [M+1]+.
    • EXAMPLE 154 N-(1-(3-Chlorophenyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00228
    • 154A. N-(6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-N-(2-(trimethylsilyl)ethoxy)methyl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00229
  • To a solution of 153A (627 mg, 2 mmol) in DMF (5 mL) at RT was added NaH (96 mg, 2.4 mmol) in portions. After addition, the reaction was stirred at RT for 30 min, and then 2-(trimethylsilyl)ethoxymethyl chloride (0.37 mL, 2. 10 mmol) was added dropwise. After addition, the reaction was stirred at RT for 1 h, then quenched carefully with water. The mixture was extracted with EtOAc (3×30 mL), and the combined extracts washed with brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with EtOAc (0-60%) in hexane to give the title compound as a white powder (620 mg, 70%).
    • 154B. N-(1-(3-Chlorophenyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-N-(2-(trimethylsilyl)ethoxy)methyl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00230
  • The title compound was prepared from 154A and 1-chloro-3-iodobenzene by procedures analogous to those described in Example 153B.
    • 154C. N-(1-(3-Chlorophenyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • To a solution of 154B (100 mg, 0.18 mmol) in THF (1 mL) at RT was added 1.0 M solution of tetrabutylammonium fluoride in THF (2 mL, 2 mmol). The resulting solution was stirred at RT under argon for 24 h. The reaction was diluted with water, then extracted with EtOAc (3×15 mL). The combined EtOAc extracts were washed with 1.0 M aqueous HCl, saturated aqueous NaHCO3, brine, dried (Na2SO4), and concentrated. The resulting residue was chromatographed (silica gel) eluting with lo EtOAc (0-50%) in hexane to give the title compound as a white foam (25 mg, 33%). HPLC: 99% at 7.3 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min, UV detection at 220 nm). MS (ES): m/z 424 [M+1]+.
    • EXAMPLE 155 (S)-Piperidine-1-sulfonic acid (1-benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
  • Figure US20050014786A1-20050120-C00231
    • 155A. (S)-Piperidine-1-sulfonic acid-(6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
  • Figure US20050014786A1-20050120-C00232
  • Using procedures analogous to those described in Example 1G, compound 155A was prepared from 1F and piperidine-1-sulfonyl chloride (prepared according to the procedures described by Padma, D. K.; Bhat, V. Subrahmanya; Murthy, A. R. Vasudeva, in J. Fluorine Chem., EN. 20, 425-438 (1982)).
    • 155B. (S)-Piperidine-1-sulfonic acid-(1-benzyl-6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl)amide
  • The title compound was prepared from 155A and benzaldehyde by procedures analogous to those described in Example 22A. HPLC: 99% at 7.2 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 411 [M+1]+. Chiral HPLC 100% e.e.; retention time=29.7 min; Conditions: AD (4.6×250 mm); Eluted with 25% isopropanol in hexane for 60 min at 1 mL/min.
    • EXAMPLE 156 Morpholine-4-sulfonic acid [1-(3-chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroqiuinolin-3-yl]-amide
  • Figure US20050014786A1-20050120-C00233
    • 156A. Morpholine-4-sulfonic acid-(6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
  • Figure US20050014786A1-20050120-C00234
  • Using procedures analogous to those described in Example 1F, compound 156A was prepared from 1D and morpholine-4-sulfonyl chloride (prepared following the procedures described by Antonio Vandi et al, in J. Org. Chem. 26, 3478-3480, (1961)).
    • 156B. Morpholine-4-sulfonic acid-[1-(3-chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-amide
  • The title compound was prepared from 156A and 3-chlorobenzaldehyde by procedures analogous to those described in Example 22A. HPLC: 99% at 6.7min(retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 447 [M+1]+.
    • EXAMPLE 157 N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-2-oxooxazolidine-3-sulfonamide
  • Figure US20050014786A1-20050120-C00235
    • 157A. 3-Amino-1-benzyl-1,2,3,4-tetrahydroquinoline-6-carbonitrile
  • Figure US20050014786A1-20050120-C00236
  • 157A was prepared from 1C and benzaldehyde by procedures analogous to those described in Example 22A, followed by removal of N-Boc protecting group according to the procedures described in Example 22B.
    • 157B. N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-2-oxooxazolidine-3-sulfonamide
  • The title compound was prepared from 157A according to the procedures described by Ducry, L., et al., in Helv. Chim Acta, 82, 2432-2447, (1999). HPLC: 99% at 6.11 min(retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 413 [M+1]+.
    • EXAMPLE 158 N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-cyclohexylamino-3-sulfonamide
  • Figure US20050014786A1-20050120-C00237
  • To a solution of 157B (41.2 mg, 0.1 mmol) in acetonitril (0.5 mL) was added cyclohexylamine (14 μL, 0.12 mmol), followed by diisopropylethylamine (120 μL) the mixture was shaken at 80° for 16 h. After cooling to RT, the reaction mixture was partitioned between EtOAc and water. The separated organic layer was washed with saturated aqueous ammonium chloride (2×), dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel) eluing with EtOAc/hexane (0-60%) to afford the title compound (28 mg, 66%) as a white solid. HPLC: 99% at 7.34 min(retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 425 [M+1]+.
    • EXAMPLE 159 N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-anilinyl-3-sulfonamide
  • Figure US20050014786A1-20050120-C00238
  • The title compound was prepared from 157B with aniline according to the procedures described in 158. HPLC: 99% at 6.92 min(retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 419 [M+1]+.
    • EXAMPLE 160 (S)—N-(1-Benzoyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzene-sulfonamide
  • Figure US20050014786A1-20050120-C00239
  • To a solution of 1G (62 mg, 0.2 mmol) in CH2Cl2 (1 mL) was added pyridine (0.049 mL, 0.6 mmol), followed by addition of benzoyl chloride (42 mg, 0.3 mmol). The resulting mixture was stirred at RT under argon for 6 h, then loaded on a silica gel cartridge (10 g), eluting with EtOAc (25-50%) in hexane to give the title compound as a white solid (72 mg, 88%). m.p. 174-175° C., HPLC: 99% at 3.01 min (retention time, Phenom. Luna C18, 4.6×50 mm eluting with 10-90% MeOH/H2O over 4 minutes containing 0.1% TFA; 4 mL/min, monitoring at 220 nm). MS (ES): m/z=418 [M+1]+. Chiral HPLC 100% e.e.; retention time=34.8 min; Conditions: OD (4.6×250 mm); Eluted with 40% isopropanol in hexane at ImL/min.
    • EXAMPLE 161 (S)—N-[1-(3-Chloro-benzoyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00240
  • The title compound was prepared from 1G and 3-chlorobenzoyl chloride by procedures analogous to those described in Example 160. HPLC: 100% at 6.3 min(retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mljmin, UV detection at 220 nm). MS (ES): m/z 452 [M+1]+. Chiral HPLC 100% e.e.; retention time=50.4 min; Conditions: AD (4.6×250 mm); Eluted with 25% isopropanol in hexane for 70 min at 1 mL/min.
    • EXAMPLE 162 N-[1-(3-Chloro-benzyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00241
    • 162A. N-(2-Oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonaniide
  • Figure US20050014786A1-20050120-C00242
  • To a suspension of 3-amino-3,4-dihydro-1H-quinolin-2-one (177.6 mg, 0.59 mmol) (prepared according to the procedures by Davis, A. L.; et al, Arch. Biochem. Biophys., 102, 48 (1963)) in CH3CN (5 mL) was added DIPEA (0.24 mL, 1.44 mmol), followed by addition of benzene sulfonylchloride (0.09 mL, 0.71 mmol). The mixture was stirred at RT for 1.5 h, then concentrated in vacuo. The residue was taken into EtOAc (30 mL), washed with water, brine, dried (MgSO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (50-90%) in hexane to give the title compound (140 mg, 78%).
    • 162B. N-(1,2,3,4-Tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00243
  • To a solution of LAH (1.0 mL, 1.0 M solution in Et2O) cooled at 0° C. was added dropwise a solution of 162A (120 mg, 0.4 mmol) in THF (5 ML) in 5 min. After addition, the reaction mixture was stirred at RT for 4 h, then quenched by slow addition of EtOAc (2.0 mL), followed by water (15 mL). The mixture was extracted with EtOAc (2×20 mL). The combined EtOAc extracts were washed with water, brine, dried (MgSO4) and concentrated. The residue was chromatographed (silica gel) eluting with EtOAc (30-60%) in hexane to give the title compound (84 mg, 73%).
    • 162C. N-[1-(3-Chlorobenzyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
  • The title compound was prepared from 162B and 3-chlorobenzaldehyde by procedures analogous to those described in Example 22A. HPLC: 99% at 3.94 min (retention time) (Conditions: Phenom Prime S5, C18 (4.6×50 mm); Eluted with 0% to 100% B, 4 min gradient (A=90% H2O—10% MeOH—0.1% TFA and B=10% H2O—90% MeOH—0.1% TFA); Flow rate at 4.0 mL/min, UV detection at 220 nm). MS (ES): m/z 413 [M+H]+.
    • EXAMPLE 163 N-(1-Benzoyl-8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00244
    • 163A. N-(8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzene-sulfonamide
  • Figure US20050014786A1-20050120-C00245
  • To a suspension of racemate 1G (313.4 mg, 1 mmol) in a mixed solvent of acetic acid (3 mL), THF (3 mL) and CH2Cl2 (3 mL) at RT was added benzyltrimethylammonium tetrachloroiodate (419 mg, 1 mmol). After addition, the mixture was stirred at RT for 30 min to become a clear yellow solution which was concentrated in vacuo. The residue was triturated with CH2Cl2 and H2O and the resultant solid filtered and washed with CH2Cl2 and H2O, dried in vacuo to give the title compound as an off-white solid (204 mg, 59%).
    • 163B. N-(1-Benzoyl-8-chloo-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • To a solution of compound 163A (164 mg, 0.472 mmol) in pyridine (1 mL) and CH2Cl2 (1 mL) at RT was added benzoyl chloride (82 μL, 0.71 mmol), and the mixture was then stirred at 50° C. for 16 h. After cooling to RT, the reaction was concentrated in vacuo and the resultant residue was taken into MeOH (4 mL), and Et3N (1 mL) added. The reaction was stirred at 70° C. for 1 h. After cooling to RT, the reaction was concentrated. The residue was diluted with 10% aqueous citric acid, then extracted with EtOAc (3×15 mL). The combined EtOAc extracts were concentrated. The resulting residue was purified using preparative HPLC (YMC S5 ODS 20×100 mm) eluting with MeOH (50-80%) in H2O for 8 min, and then 80% MeOH in H2O for 7 min to give the title compound (60 mg, 28%) as a white solid. HPLC: 99% at 6.2 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 muLmin. UV detection at 220 nm). MS (ES): m/z 452 [M+H]+.
    • EXAMPLE 164 N-(1-Benzoyl-8-bromo-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00246
    • 164A. N-(8-Bromo-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00247
  • To a suspension of racemate 1G (323 mg, 1.03 mmol) in mixed solvents of MeOH (3 mL), CH2Cl2 (3 mL) and THF (3 mL) at RT was added CaCO3 (103 mg, 1.03 mmol), followed by benzyltriethylammonium tribromide (445 mg, 1.03 mmol). After addition, the mixture was stirred at RT for 45 min. The resultant precipitate was collected by filtration, washed with 0.2 N aqueous HCl, H2O, then dried to provide the title compound (311 mg, 77%) as a white solid.
    • 164B. N-(1-Benzoyl-8-bromo-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • The title compound was prepared from 164A by procedures analogous to those described in Example 163B. HPLC: 99% at 6.3 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 496 [M+H]+.
    • EXAMPLE 165 N-(1-Benzyl-8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00248
    • 165A. N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00249
  • Compound 165A was prepared from racemate 1G and benzaldehyde by procedures analogous to those described in Example 22A.
    • 165B. N-(1-Benzyl-8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • To a solution of compound 165A (121 mg, 0.3 mmol) in acetic acid (2 mL) at RT was added benzyltrimethylammonium tetrachloroiodate (125.7 mg, 0.3 mmol). The reaction mixture was stirred at RT for 30 min, and then concentrated under reduced pressure. The resultant residue was partitioned between saturated aqueous NaHCO3 solution and CH2Cl2. The separated aqueous layer was extracted with CH2Cl2 (15 mL×2). The combined CH2Cl2 extracts were washed with brine, dried (Na2SO4) and concentrated. The residue was purified using preparative HPLC (YMC S5 ODS 20×100 mm) eluting with MeOH (50-80%) in H2O for 8 min, and then 80% MeOH in H2O for 7 min to give the title compound (108 mg, 82%) as a white solid. HPLC: 99% at 7.65 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 438 [M+H]+.
    • EXAMPLE 166 N-(1-Benzyl-8-bromo-6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00250
  • The title compound was prepared from 165A by procedures analogous to those described in Example 164A. HPLC: 99% at 7.73 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 483 [M+H]+.
    • EXAMPLE 167 N-(1-Benzenesulfonyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00251
  • To a solution of compound 87A (98 mg, 0.299 mmol) in pyridine (3 mL) was added benzenesulfonyl chloride (0.042 mL, 0.33 mmol). The mixture was stirred at RT overnight, then concentrated. The residue was chromatographed (10 g silica gel) eluting with EtOAc (0-60%) in hexane to give the title compound (140 mg, 93%) as a white foam. HPLC: 99% at 7.06 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 529 [M+Na]+.
    • EXAMPLE 168 N-(1-Benzenesulfonyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
  • Figure US20050014786A1-20050120-C00252
  • To a solution of compound 167 (51 mg, 0.1 mmol) in THF-MeOH (1:1) (2 mL) was added benzeneboronic acid (24 mg, 0.2 mmol), followed by K2CO3 (55 mg, 0.4 mmol) and PXPd (3.2 mg, 0.006 mmol). The mixture was heated at 62° C. overnight. After cooling to RT, the reaction was concentrated and MeOH (2 mL) added. The resulting suspension was filtered and the filtrate purified using preparative HPLC (Phenomenex Luna, 5μ, 30×100 mm column), eluting with 80-90% MeOH/H2O to give the title compound (42 mg, 85%) as a white foam. HPLC: 99% at 7.443 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 505 [M+1]+.
    • EXAMPLE 169 N-(1-Benzyl-6-phenoxy-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00253
  • A suspension of 87B (55 mg, 0.12 mmol), phenol (33.9 mg, 0.36 mmol), K2CO3 (50 mg, 0.36 mmol) and copper iodide (17.1 mg, 0.09 mmol) in DMF (1.0 mL) was heated at 200° C. in a sealed tube with stirring for 16 h. After cooling to RT, the reaction mixture was filtered, the filtrate purified using preparative HPLC (YMC S5 ODS 20×100 mm) eluting with MeOH (70-100%) in H2O for 8 min, and then 100% MeOH in H2O for 7 min to give the title compound (4 mg) as a light brownish solid. HPLC: 91% at 6.99 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 471 [M+H]+.
    • EXAMPLE 170 N-(8-Phenoxy-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00254
    • 170A. N-(6-Phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00255
  • Compound 170A was prepared from 87A and phenylboronic acid by procedures analogous to those described in Example 91A.
    • 170B. N-(8-Bromo-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
  • Figure US20050014786A1-20050120-C00256
  • Compound 170B was prepared from 170A by procedures analogous to those described in Example 1B.
    • 170C. N-(8-Phenoxy-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzene sulfonamide
  • The title compound was prepared as an off-white powder from 170B by procedures described in Example 169. HPLC: 98% at 8.07 min (retention time) (Conditions: Zorbax SB C18 (4.6×75 mm); Eluted with 0% to 100% B, 8 min gradient. (A=90% H2O—10% MeOH—0.1% H3PO4 and B=10% H2O—90% MeOH—0.1% H3PO4); Flow rate at 2.5 mL/min. UV detection at 220 nm). MS (ES): m/z 457 [M+H]+.
    • EXAMPLE 171 N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-2-oxo-2-phenylacetamide
  • Figure US20050014786A1-20050120-C00257
  • To a solution of 35 mg (0.06 mmol) of 89C in CH2Cl2 (0.6 mL) was added EDAC (13 mg, 0.07 mmol), HOBt (11 mg, 0.07 mmol), DIPEA (0.03 mL, 0.18 mmol) and benzoylformic acid (11 mg, 0.07 mmol). The reaction was stirred at RT overnight, and the solution was loaded directly onto silica gel column for purification. The product was purified via flash chromatography using EtOAc/hexanes to give 13 mg of a yellow oil. HPLC: 4.24 min, column: 4.6×50 mm Phenomenex LUNA C-18 (S-5); flow rate 2.5 mL/min; gradient: 0-100% B over 4 min, hold 100% B for 1 min. Solvent A: 10% MeOH-90% H2O—0.2% H3PO4. Solvent B: 90% MeOH—10% H2O—0.2% H3PO4. MS (ES): m/z 465 [M+1]+.
    • EXAMPLE 172 Ethyl 2-(1-benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroauinolin-3-ylamino)-2-oxoacetate
  • Figure US20050014786A1-20050120-C00258
  • To a solution of 89C (60 mg, 0.11 mmol) in CH2Cl2 (1.5 mL) and added Et3N (0.06 mL, 0.44 mmol), followed by ethyl chlorooxoacetate (0.024 mL, 0.22 mmol). The reaction was stirred at RT for 1 h and the solution was loaded directly onto silica gel column for purification. The product was purified via flash chromatography using EtOAc/hexanes to give 40 mg of the title compound as a yellow solid. HPLC: 4.10 min, column: 4.6×50 mm Phenomenex LUNA C-18 (S-5); flow rate 2.5 mL/min; gradient: 0-100% B over 4 min, hold 100% B for 1 min. Solvent A: 10% MeOH—90% H2O—0.2% H3PO4. Solvent B: 90% MeOH—10% H2O—0.2% H3PO4 MS (ES): m/z 433 [M+1]+.
    • Biological Evaluation
  • Cannabinoid Receptor Binding Assay
  • Radioligand binding studies were conducted in membranes prepared from Chinese Hamster Ovary (CHO) cells that over-express recombinant human CB-1 (CHO-CB-1 cells). Total assay volume for the binding studies was 100 μl. 5 ug of membranes were brought up to a final volume of 95 μl with Binding Buffer (25 mM HEPES, 150 mM NaCl, 2.5 mM CaCl2, 1 mM MgCl2, 0.25% BSA). The diluted membranes were preincubated with a compound or DMSO vehicle. The binding reaction was initiated by the addition of 2 nM final 3H-CP-55,940 (120 Ci/mmol) and proceeded for 2.5 hours at room temperature. The binding reaction was terminated by transferring the reaction to GF/B 96 well plates (presoaked with 0.3% polyethylenimine) using a Packard Cell Harvester. The filter was washed with 0.25×PBS, 30 μl MicroScint was added per well, and the bound radiolabel was quantitated by scintillation counting on a Packard TopCount Scintillation Counter. The CB-2 radioligand binding assay was conducted identically except that the membranes from CHO-CB-2 cells were used.
  • For a compound to be considered a CB-1 antagonist, the compound must possess a CB-1 receptor binding affinity Ki less than 4000 nM. As determined by the assay described above, the CB-1 receptor binding Ki values of the preferred working examples fall within the range of 0.01 nM to 4000 nM.
  • Cannabinoid Receptor Functional Activity Assay
  • Functional CB-1 inverse agonist activity of test compounds was determined in CHO-CB-1 cells using a cAMP accumulation assay. CHO-CB-1 cells were grown in 96 well plates to near confluence. On the day of the functional assay, growth medium was aspirated and 100 of Assay Buffer (PBS plus 25 mM HEPES/0.1 mM 3-isobutyl-1-methylxanthine/0.1% BSA) was added. Compounds were added to the Assay buffer diluted 1:100 from 100% DMSO and allowed to preincubate for 10 minutes prior to addition of 5 uM forskolin. The mixture was allowed to proceed for 15 minutes at room temperature and was terminated by the addition of 0.1 N HCl. The total intracellular cAMP concentration was quantitated using the Amersham cAMP SPA kit.
    • Utilities & Combinations
  • A. Utilities
  • The compounds of the present invention are cannabinoid receptor modulators, and include compounds which are, for example, selective agonists, partial agonists, inverse agonists, antagonists or partial antagonists of the cannabinoid receptor. Accordingly, the compounds of the present invention may be useful for the treatment or prevention of diseases and disorders associated with G-protein coupled cannabinoid receptor activity. Preferably, compounds of the present invention possess activity as antagonists or inverse agonists of the CB-1 receptor, and may be used in the treatment of diseases or disorders associated with the activity of the CB-1 receptor.
  • Accordingly, the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to metabolic and eating disorders as well as conditions associated with metabolic disorders, (e.g., obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive eating disorders) or psychiatric disorders, such as substance abuse, depression, anxiety, mania and schizophrenia. These compounds could also be used for the improvement of cognitive function (e.g., the treatment of dementia, including Alzheimer's disease, short term memory loss and attention deficit disorders); neurodegenerative disorders (e.g., Parkinson's Disease, cerebral apoplexy and craniocerebral trauma) and hypotension (e.g., hemorrhagic and endotoxin-inducd hypotension). These compounds could also be used for treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction (e.g., associated with valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure); and improvement of the overall pulmonary function; transplant rejection; rheumatoid arthritis; multiple sclerosis; inflammatory bowel disease; lupus; graft vs. host disease; T-cell mediated hypersensitivity disease; psoriasis; asthma; Hashimoto's thyroiditis; Guillain-Barre syndrome; cancer; contact dermatitis; allergic rhinitis; and ischemic or reperfusion injury.
  • Compounds useful in the treatment of appetitive or motivational disorders regulate desires to consume sugars, carbohydrates, alcohol or drugs and more generally to regulate the consumption of ingredients with hedonic value. In the present description and in the claims, appetitive disorders are understood as meaning: disorders associated with a substance and especially abuse of a substance and/or dependency on a substance, disorders of eating behaviors, especially those liable to cause excess weight, irrespective of its origin, for example: bulimia nervosa, craving for sugars. The present invention therefore further relates to the use of a CB-1 receptor antagonist or inverse agonist for the treatment of bulimia and obesity, including obesity associated with type II diabetes (non-insulin-dependent diabetes), or more generally any disease resulting in the patient becoming overweight. Obesity, as described herein, is defined by a body mass index (kg/m2) of at least 26. It may be due to any cause, whether genetic or environmental, including overeating and bulemia, polycycstic ovary disease, craniopharyngeoma, Prader-Willi Syndrome, Frohlich's Syndrome, Type II diabetes, growth hormone deficiency, Turner's Syndrome and other pathological states characterized by reduced metabolic activity or reduced energy expenditure. As used with reference to the utilities described herein, the term “treating” or “treatment” encompasses prevention, partial alleviation, or cure of the disease or disorder. Further, treatment of obesity is expected to prevent progression of medical covariants of obesity, such as arteriosclerosis, Type II diabetes, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders.
  • Compounds in the present invention may also be useful in treating substance abuse disorders, including substance dependence or abuse without physiological dependence. Substances of abuse include alcohol, amphetamines (or amphetamine-like substances), caffeine, cannabis, cocaine, hallucinogens, inhalents, nicotine, opioids, phencyclidine (or phencyclidine-like compounds), sedative-hypnotics or benzodiazepines, and other (or unknown) substances and combinations of the above. The terms “substance abuse disorders” also includes drug or alcohol withdrawal syndromes and substance-induced anxiety or mood disorder with onset during withdrawal.
  • Compounds in the present invention may be useful in treating memory impairment and cognitive disorders. The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline. Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. Cannabinoid receptor modulators may also be useful in treating cognitive impairments related to attentional deficits, such as attention deficit disorder.
  • Compounds in the present invention may also be useful in treating diseases associated with dysfunction of brain dopaminergic systems, such as Parkinson's Disease and substance abuse disorders. Parkinsons's Disease is a neurodenerative movement disorder characterized by bradykinesia and tremor.
  • As modulators of the cannabinoid receptor, the compounds of the present invention are further useful for the treatment and prevention of respiratory diseases and disorders. Respiratory diseases for which cannabinoid receptor modulators are useful include, but are not limited to, chronic pulmonary obstructive disorder, emphysema, asthma, and bronchitis. In addition, cannabinoid receptor modulators block the activation of lung epithelial cells by moeties such as allergic agents, inflammatory cytokines or smoke, thereby limiting release of mucin, cytokines, and chemokines, or selectively inhibiting lung epithelial cell activation.
  • Moreover, the compounds employed in the present invention may stimulate inhibitory pathways in cells, particularly in leukocytes, lung epithelial cells, or both, and are thus useful in treating such diseases. “Leukocyte activation” is defined herein as any or all of cell proliferation, cytokine production, adhesion protein expression, and production of inflammatory mediators. “Epithelial cell activation” is defined herein as the production of any or all of mucins, cytokines, chemokines, and adhesion protein expression.
  • Use of the compounds of the present invention for treating leukocyte activation-associated disorders is exemplified by, but is not limited to, treating a range of disorders such as: transplant (such as organ transplant, acute transplant, xenotransplant or heterograft or homograft (such as is employed in burn treatment)) rejection; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis; respiratory and pulmonary diseases including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, and acute respiratory distress syndrome (ARDS); inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosis); graft vs. host disease; T-cell mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenal glands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases; glomerulonephritis; serum sickness; uticaria; allergic diseases such as respiratory allergies (asthma, hayfever, allergic rhinitis) or skin allergies; scleracierma; mycosis fungoides; acute inflammatory and respiratory responses (such as acute respiratory distress syndrome and ishchemia/reperfusion injury); dermatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis palmoplanteris; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic schlerosis; and morphea. The term “leukocyte activation-associated” or “leukocyte-activation mediated” disease as used herein includes each of the above referenced diseases or disorders. In a particular embodiment, the compounds of the present invention are useful for treating the aforementioned exemplary disorders irrespective of their etiology. The combined activity of the present compounds towards monocytes, macrophages, T-cells, etc. may be useful in treating any of the above-mentioned disorders.
  • Cannabinoid receptors are important in the regulation of Fc gamma receptor responses of monocytes and macrophages. Compounds of the present invention inhibit the Fc gamma dependent production of TNF alpha in human monocytes/macrophages. The ability to inhibit Fc gamma receptor dependent monocyte and macrophage responses results in additional anti-inflammatory activity for the present compounds. This activity is especially of value, for example, in treating inflammatory diseases such as arthritis or inflammatory bowel disease. In particular, the present compounds are useful for treating autoimmune glomerulonephritis and other instances of glomerulonephritis induced by deposition of immune complexes in the kidney that trigger Fc gamma receptor responses leading to kidney damage.
  • Cannabinoid receptors are expressed on lung epithelial cells. These cells are responsible for the secretion of mucins and inflammatory cytokines/chemokines in the lung and are thus intricately involved in the generation and progression of respiratory diseases. Cannabinoid receptor modulators regulate both the spontaneous and the stimulated production of both mucins and cytokines. Thus, such compounds are useful in treating respiratory and pulmonary diseases including, COPD, ARDS, and bronchitis.
  • Further, cannabinoid receptors may be expressed on gut epithelial cells and hence regulate cytokine and mucin production and may be of clinical use in treating inflammatory diseases related to the gut. Cannabinoid receptors are also expressed on lymphocytes, a subset of leukocytes. Thus, cannabinoid receptor modulators will inhibit B and T-cell activation, proliferation and differentiation. Thus, such compounds will be useful in treating autoimmune diseases that involve either antibody or cell mediated responses such as multiple sclerosis and lupus.
  • In addition, cannabinoid receptors regulate the Fc epsilon receptor and chemokine induced degranulation of mast cells and basophils. These play important roles in asthma, allergic rhinitis, and other allergic disease. Fc epsilon receptors are stimulated by IgE-antigen complexes. Compounds of the present invention inhibit the Fc epsilon induced degranulation responses, including the basophil cell line, RBL. The ability to inhibit Fc epsilon receptor dependent mast cell and basophil responses results in additional anti-inflammatory and anti-allergic activity for the present compounds. In particular, the present compounds are useful for treating asthma, allergic rhinitis, and other instances of allergic disease.
  • B. Combinations
  • The present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent. Optionally, compounds of the present invention can be used alone, in combination with other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-obesity agents; anti-diabetic agents, appetite suppressants; cholesterol/lipid-lowering agents, HDL-raising agents, cognition enhancing agents, agents used to treat neurodegeneration, agents used to treat respiratory conditions, agents used to treat bowel disorders, anti-inflammatory agents; anti-anxiety agents; anti-depressants; anti-hypertensive agents; cardiac glycosides; and anti-tumor agents.
  • Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the cannabinoid receptor modulators in accordance with the invention.
  • Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include melanocortin receptor (MC4R) agonists, melanin-concentrating hormone receptor (MCHR) antagonists, growth hormone secretagogue receptor (GHSR) antagonists, galanin receptor modulators, orexin antagonists, CCK agonists, GLP-1 agonists, and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonsist, NPY2 and NPY4 modulators, corticotropin releasing factor agonists, histamine receptor-3 (H3) modulators, aP2 inhibitors, PPAR gamma modulators, PPAR delta modulators, acetyl-CoA carboxylase (ACC) inihibitors, 11-β-HSD-1 inhibitors, adinopectin receptor modulators; beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, a thyroid receptor beta modulator, such as a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and GB98/284425 (KaroBio), a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), serotonin receptor agonists, (e.g., BVT-933 (Biovitrum)), monoamine reuptake inhibitors or releasing agents, such as fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine or mazindol, anorectic agents such as topiramate (Johnson & Johnson), CNTF (ciliary neurotrophic factor)/Axokine® (Regeneron), BDNF (brain-derived neurotrophic factor), leptin and leptin receptor modulators, or cannabinoid-1 receptor antagonists, such as SR-141716 (Sanofi) or SLV-319 (Solvay).
  • Examples of suitable anti-diabetic agents for use in combination with the compounds of the present invention include: insulin secretagogues or insulin sensitizers, which may include biguanides, sulfonyl ureas, glucosidase inhibitors, aldose reductase inhibitors, PPAR γ agonists such as thiazolidinediones, PPAR α agonists (such as fibric acid derivatives), PPAR δ antagonists or agonists, PPAR α/γ dual agonists, 11-β-HSD-1 inhibitors, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1), GLP-1 agonist, and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B inhibitor).
  • The antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl. Where the antidiabetic agent is a biguanide, the compounds of the present invention will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.
  • The antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Pat. No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms. The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Pat. No. 4,904,769) or miglitol (disclosed in U.S. Pat. No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.
  • The compounds of the present invention may be employed in combination with a PPAR γ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Pat. No. 5,594,016), Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.
  • The compounds of the present invention may be employed with a PPARα/γ dual agonist such as MK-767/KRP-297 (Merck/Kyorin; as described in, K. Yajima, et. al., Am. J. Physiol. Endocrinol. Metab., 284: E966-E971 (2003)), AZ-242 (tesaglitazar; Astra-Zeneca; as described in B. Ljung, et. al., J. Lipid Res., 43, 1855-1863 (2002)); muraglitazar; or the compounds described in U.S. Pat. No. 6,414,002.
  • The compounds of the present invention may be employed in combination with anti-hyperlipidemia agents, or agents used to treat arteriosclerosis. An example of an hypolipidemic agent would be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Pat. No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Pat. No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Pat. No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Pat. Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Pat. No. 5,354,772, cerivastatin disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Pat. Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pitavastatin (Nissan/Sankyo's nisvastatin (NK-104) or itavastatin), disclosed in U.S. Pat. No. 5,011,930, Shionogi-Astra/Zeneca rosuvastatin (visastatin (ZD4522)) disclosed in U.S. Pat. No. 5,260,440, and related statin compounds disclosed in U.S. Pat. No. 5,753,675, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Pat. No. 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivatives thereof as disclosed in U.S. Pat. No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Pat. No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Pat. No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No.0,142,146 A2, and quinoline and pyridine derivatives disclosed in U.S. Pat. Nos. 5,506,219 and 5,691,322. In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.
  • The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α-phosphono-sulfonates disclosed in U.S. Pat. No. 5,712,396, those disclosed by Biller, et al, J. Med. Chem., 31, 1869-1871 (1998) including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Pat. No. 4,871,721 and 4,924,024 and in Biller, S. A., Neuenschwander, K., Ponpipom, M. M., and Poulter, C. D., Current Pharmaceutical Design, 2, 1-40 (1996).
  • In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano, et al, J. Med. Chem., 20, 243-249 (1977), the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 98, 1291-1293 (1976), phosphinylphosphonates reported by McClard, R. W. et al., J. Am. Chem. Soc., 109, 5544 (1987) and cyclopropanes reported by Capson, T. L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.
  • Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Pat. No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (SECHOLEX, POLICEXIDE) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphos-phorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Pat. No. 4,027,009, and other known serum cholesterol lowering agents.
  • The other hypolipidemic agent may be an ACAT inhibitor (which also has anti-atherosclerosis activity) such as disclosed in, Drugs of the Future, 24, 9-15 (1999), (Avasimibe); “The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Nicolosi et al, Atherosclerosis (Shannon, Irel), 137 (1), 77-85 (1998); “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein”, Ghiselli, Giancarlo, Cardiovasc. Drug Rev., 16 (1), 16-30 (1998); “RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor”, Smith, C., et al, Bioorg. Med. Chem. Lett, 6 (1), 47-50 (1996); “ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals”, Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways, 173-98 (1995), Publisher: CRC, Boca Raton, Fla.; “ACAT inhibitors: potential anti-atherosclerotic agents”, Sliskovic et al, Curr. Med. Chem., 1 (3), 204-25 (1994); “Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N′-[(1-phenylcyclopentyl)-methyl]ureas with enhanced hypocholesterolemic activity”, Stout et al, Chemtracts: Org. Chem., 8 (6), 359-62 (1995), or TS-962 (Taisho Pharmaceutical Co. Ltd), as well as F-1394, CS-505, F-12511, HL-004, K-10085 and YIC-C8-434.
  • The hypolipidemic agent may be an upregulator of LDL receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly). The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).
  • The other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as well as CETi-1 and JTT-705.
  • The hypolipidemic agent may be an ileal Na+/bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999). The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Pat. No. 5,447,954.
  • The other lipid agent also includes a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as an isoflavone such as genistein, daidzein, glycitein or equol, or phytosterols, phytostanol or tocotrienol as disclosed in WO 2000/015201; a beta-lactam cholesterol absorption inhibitor such as disclosed in EP 675714; an HDL upregulator such as an LXR agonist, a PPAR α-agonist and/or an FXR agonist; an LDL catabolism promoter such as disclosed in EP 1022272; a sodium-proton exchange inhibitor such as disclosed in DE 19622222; an LDL-receptor inducer or a steroidal glycoside such as disclosed in U.S. Pat. No. 5,698,527 and GB 2304106; an anti-oxidant such as beta-carotene, ascorbic acid, α-tocopherol or retinol as disclosed in WO 94/15592 as well as Vitamin C and an antihomocysteine agent such as folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E; isoniazid as disclosed in WO 97/35576; a cholesterol absorption inhibitor, an HMG-CoA synthase inhibitor, or a lanosterol demethylase inhibitor as disclosed in WO 97/48701; a PPAR δ agonist for treating dyslipidemia; or a sterol regulating element binding protein-I (SREBP-1) as disclosed in WO 2000/050574, for example, a sphingolipid, such as ceramide, or neutral sphingomyelenase (N-SMase) or fragment thereof. Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, pitavastatin and rosuvastatin, as well as niacin and/or cholestagel.
  • The compounds of the present invention may be employed in combination with anti-hypertensive agents. Examples of suitable anti-hypertensive agents for use in combination with the compounds of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and/or T-type; e.g. diltiazem, verapamil, nifedipine, amiodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates.
  • Cannbinoid receptor modulators could be useful in treating other diseases associated with obesity, including sleep disorders. Therefore, the compounds described in the present invention could be used in combination with therapeutics for treating sleep disorders. Examples of suitable therapies for treatment of sleeping disorders for use in combination with the compounds of the present invention include melatonin analogs, melatonin receptor antagonists, ML 1 B agonists, GABA receptor modulators; NMDA receptor modulators, histamine-3 (H3) receptor modulators, dopamine agonists and orexin receptor modulators.
  • Cannabinoid receptor modulators may reduce or ameliorate substance abuse or addictive disorders. Therefore, combination of cannabinoid receptor modulators with agents used to treat addictive disorders may reduce the dose requirement or improve the efficacy of current addictive disorder therapeutics. Examples of agents used to treat substance abuse or addictive disorders are: selective serotonin reuptake inhibitors (SSRI), methadone, buprenorphine, nicotine and bupropion.
  • Cannabinoid receptor modulators may reduce anxiety or depression; therefore, the compounds described in this application may be used in combination with anti-anxiety agents or antidepressants. Examples of suitable anti-anxiety agents for use in combination with the compounds of the present invention include benzodiazepines (e.g., diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam), 5HT1A receptor agonists (e.g., buspirone, flesinoxan, gepirone and ipsapirone), and corticotropin releasing factor (CRF) antagonists.
  • Examples of suitable classes of anti-depressants for use in combination with the compounds of the present invention include norepinephrine reuptake inhibitors (tertiary and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, fluvoxamine, paroxetine and sertraline), monoamine oxidase inhibitors (MAOIs) (isocarboxazid, phenelzine, tranylcyprornine, selegiline), reversible inhibitors of monoamine oxidase (RIMAs) (moclobemide), serotonin and norepinephrine reuptake inhibitors (SNRIs) (venlafaxine), corticotropin releasing factor (CRF) receptor antagonists, alpah-adrenoreceptor antagonists, and atypical antidepressants (bupropion, lithium, nefazodone, trazodone and viloxazine).
  • The combination of a conventional antipsychotic drug with a CB-1 receptor antagonist could also enhance symptom reduction in the treatment of psychosis or mania. Further, such a combination could enable rapid symptom reduction, reducing the need for chronic treatment with antipsychotic agents. Such a combination could also reduce the effective antipsychotic dose requirement, resulting in reduced probability of developing the motor dysfunction typical of chronic antipsychotic treatment.
  • Examples of suitable antipsychotic agents for use in combination with the compounds of the present invention include the phenothiazine (chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine), thioxanthine (chlorprothixene, thiothixene), heterocyclic dibenzazepine (clozapine, olanzepine and aripiprazole), butyrophenone (haloperidol), dipheyylbutylpiperidine (pimozide) and indolone (molindolone) classes of antipsychotic agents. Other antipsychotic agents with potential therapeutic value in combination with the compounds in the present invention include loxapine, sulpiride and risperidone.
  • Combination of the compounds in the present invention with conventional antipsychotic drugs could also provide an enhanced therapeutic effect for the treatment of schizophrenic disorders, as described above for manic disorders. As used here, schizophrenic disorders include paranoid, disorganized, catatonic, undifferentiated and residual schizophrenia, schizophreniform disorder, shcizoaffective disorder, delusional disorder, brief psychotic disorder and psychotic disorder not specified. Examples of suitable antipsychotic drugs for combination with the compounds in the present invention include the antipsychotics mentioned above, as well as dopamine receptor antagonists, muscarinic receptor agonists, 5HT2A receptor antagonists and 5HT2A/dopamine receptor antagonists or partial agonists (e.g., olanzepine, aripiprazole, risperidone, ziprasidone).
  • The compounds described in the present invention could be used to enhance the effects of cognition-enhancing agents, such as acetylcholinesterase inhibitors (e.g., tacrine), muscarinic receptor-1 agonists (e.g., milameline), nicotinic agonists, glutamic acid receptor (AMPA and NMDA) modulators, and nootropic agents (e.g., piracetam, levetiracetam). Examples of suitable therapies for treatment of Alzheimer's disease and cognitive disorders for use in combination with the compounds of the present invention include donepezil, tacrine, revastigraine, 5HT6, gamma secretase inhibitors, beta secretase inhibitors, SK channel blockers, Maxi-K blockers, and KCNQs blockers.
  • The compounds described in the present invention could be used to enhance the effects of agents used in the treatment of Parkinson's Disease. Examples of agents used to treat Parkinson's Disease include: levadopa with or without a COMT inhibitor, antiglutamatergic drugs (amantadine, riluzole), alpha-2 adrenergic antagonists such as idazoxan, opiate antagonists, such as naltrexone, other dopamine agonists or transportor modulators, such as ropinirole, or pramipexole or neurotrophic factors such as glial derived neurotrophic factor (GDNF).
  • The compounds described in the present invention could be used in combination with suitable anti-inflammatory agents. Examples of suitable anti-inflammatory agents for use in combination with the compounds of the present invention include prednisone, dexamethasone, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, aspirin, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha-4 beta-7 integrin antagonists, cell adhesion inhibitors, interferon gamma antagonists, ICAM-1, tumor necrosis factor (TNF) antagonists (e.g., infliximab, OR1384, including TNF-alpha inhibitors, such as tenidap, anti-TNF antibodies or soluble TNF receptor such as etanercept (Enbrel®), rapamycin (sirolimus or Rapamune) and leflunomide (Arava)), prostaglandin synthesis inhibitors, budesonide, clofazimine, CNI-1493, CD4 antagonists (e.g., priliximab), p38 mitogen-activated protein kinase inhibitors, protein tyrosine kinase (PTK) inhibitors, IKK inhibitors, and therapies for the treatment of irritable bowel syndrome (e.g., Zelnorm® and Maxi-K®0 openers such as those disclosed in U.S. Pat. No. 6,184,231 B1).
  • Exemplary of such other therapeutic agents which may be used in combination with cannabinoid receptor modulators include the following: cyclosporins (e.g., cyclosporin A), anti-IL-2 receptor (Anti-Tac), anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, monoclonal antibody OKT3, agents blocking the interaction between CD40 and gp39, such as antibodies specific for CD40 and/or gp39 (i.e., CD154), fusion proteins constructed from CD40 and gp39 (CD40Ig and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG), gold compounds, antiproliferative agents such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil, cytotoxic drugs such as azathiprine and cyclophosphamide, anticytokines such as antiIL-4 or IL-4 receptor fusion proteins and PDE 4 inhibitors such as Ariflo, and the PTK inhibitors disclosed in the following U.S. patent applications, incorporated herein by reference in their entirety: Ser. No. 09/097,338, filed Jun. 15, 1998; Ser. No. 09/094,797, filed Jun. 15, 1998; Ser. No. 09/173,413, filed Oct. 15, 1998; and Ser. No. 09/262,525, filed Mar. 4, 1999. See also the following documents and references cited therein and incorporated herein by reference: Hollenbaugh, D., Et Al, “Cleavable CD40Ig Fusion Proteins and the Binding to Sgp39”, J. Immunol. Methods (Netherlands), 188 (1), pp. 1-7 (Dec. 15, 1995); Hollenbaugh, D., et al, “The Human T Cell Antigen Gp39, A Member of the TNF Gene Family, Is a Ligand for the CD40 Receptor: Expression of a Soluble Form of Gp39 with B Cell Co-Stimulatory Activity”, EMBO J (England), 11 (12), pp. 4313-4321 (December 1992); and Moreland, L. W. et al., “Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (P75)-Fc Fusion Protein, ” New England J. of Medicine, 337 (3), pp. 141-147 (1997).
  • The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
  • The compounds of formula I of the invention can be administered orally or parenterally, such as subcutaneously or intravenously, as well as by nasal application, rectally or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, in an effective amount up to 1 gram, preferably up to 200 mg, more preferably to 50 mg in a regimen of single, two or four divided daily doses.
  • The compounds of the formula I can be administered for any of the uses described herein by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The present compounds can, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds can also be administered liposomally.
  • Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The compounds of formula I can also be delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
  • Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • Exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor.
  • Exemplary compositions for rectal administration include suppositories which can contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
  • It will be understood that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
  • It should be understood that while this invention has been described herein in terms of specific embodiments set forth in detail, such embodiments are presented by way of illustration of the general principles of the invention, and the invention is not necessarily limited thereto. Certain modifications and variations in any given material, process step or chemical formula will be readily apparent to those skilled in the art without departing from the true spirit and scope of the present invention, and all such modifications and variations should be considered within the scope of the claims that follow.

Claims (56)

1. A compound of formula I
Figure US20050014786A1-20050120-C00259
including all pharmaceutically acceptable salts and stereoisomers,
wherein:
R1 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, halo, CF3, CN, nitro, OR11, NR12R12a, COOR12 and CONR12R12a;
R3 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R4 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R5 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, COOR13 and CONR13R13a;
R6 and R6a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
R7 and R7a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
R8 is selected from the group consisting of hydrogen and alkyl;
R9 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R10 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R11 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, CHF2 and CF3;
R12 and R12a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R12 and R12a taken together can form cycloalkyl or heterocyclyl;
R13 and R13a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R13 and R13a taken together can form cycloalkyl or heterocyclyl;
X is selected from the group consisting of (CR14R14n)n, CO, COO, S(O)2, SO2N(R12) and CON(R12);
or R5 and R12 taken together can form cycloalkyl or heterocyclyl;
Y is selected from the group consisting of S(O)2, SO2N(R15) and C(O)C(O);
R14 and R14a are each independently selected from the group consisting of hydrogen, alkyl;
R15 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
n is an integer of 0, 1, or 2, with the following provisos:
R5 is not imidazole or substituted imidazole;
when X is (CR14R14a)n, n is 1, R14 is H and R14a is alkyl, R5 is not cycloalkyl, aryl or heteroraryl;
when Y is —S(O)2—, R10 is not a seven-membered lactam; and
when Y is —S(O)2NR15—, neither R10 nor R15 is a seven-membered lactam.
2. The compound of claim 1, including all pharmaceutically acceptable salts and stereoisomers, wherein:
R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, halo, CN;
R5 is selected from the group consisting of alkenyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R6 and R6a are each independently selected from the group consisting of hydrogen and alkyl;
R7 and R7a are each independently selected from the group consisting of hydrogen and alkyl;
R8 is hydrogen;
R9 is hydrogen;
R11 is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CHF2 and CF3;
X is CH2;
Y is selected from the group consisting of S(O)2, and SO2N(R15);
R15 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
n is an integer of 0, or 1.
3. The compound of claim 1, including all pharmaceutically acceptable salts and stereoisomers, wherein:
R1 is hydrogen;
R2 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo and CN;
R3 is hydrogen;
R4 is hydrogen;
R5 is selected from the group consisting of aryl and heteroaryl;
R6 and R6a are each hydrogen;
R7 and R7a are each hydrogen;
R10 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R15 is selected from the group consisting of hydrogen, alkyl;
or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
n is an integer of 1.
4. The compound of claim 1, including all pharmaceutically acceptable salts and stereoisomers, selected from
(S)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(R)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
(S)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-N-methyl-benzenesulfonamide
(R)—N-(6-Cyano-1-thiazol-5-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-N-methyl-benzenesulfonamide
(S)—N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(R)—N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S)—N-[1-(2-Chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)—N-[1-(3-Chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(R)—N-[1-(3-Chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)—N-[1-(4-Chloro-benzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)—N-(6-Cyano-1-pyridin-2-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S)—N-(6-Cyano-1-pyridin-3-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S)—N-(6-Cyano-1-pyridin-4-ylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-[6-Cyano-1-phenylethyl-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)—N-(6-Cyano-1-cyclohexylmethyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
Pyridine-3-sulfonic acid[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
Pyridine-2-sulfonic acid[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
Thiophene-2-sulfonic acid[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
(S)-2-Chloro-N-[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)-3-Chloro-N-[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
(S)-4-Chloro-N-[1-(3-chlorobenzyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-(6-Chloro-1-(pyrazin-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(6-Chloro-1-(thiazol-4-ylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-(thiozol-5-ylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((6-methoxypyridin-3-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((1-ethyl-1H-pyrazol-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((4-hydroxy-3-phenylisothiazol-5-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((2,4-dimethylthiazol-5-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((tetrahydrofuran-3-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzo[d][1,3]dioxol-5-ylmethyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Fluorobenzyl)-6-Chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Chloro-2-fluorobenzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3,5-Difluorobenzyl)-6-Chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(2,4-Difluorobenzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(5-Fluoro-2-methoxybenzyl)-6-chloro-1,2,3,4-tetrahydro quinolin-3-yl)benzenesulfonamide
N-(1-(3-Cyanobenzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(2-Cyanobenzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(4-Cyanomethyl)benzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-(2-cyano-2-phenylethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(4-(3-(Dimethylamino)propoxy)benzyl)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-(cyclopentylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-(cyclopropylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-isopentyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(6-Chloro-1-butyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N,N-Dimethylamino-1-sulfonic acid (1-benzyl-6-chloro-1,2,3,4-tetra hydroquinolin-3-yl)-amide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)ethanesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-2,2,2-trifluoroethanesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-2-(naphthalen-1-yl)ethanesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-propylbenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-ethylbenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-(2-cyanoethoxy)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-bromobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-2,5-dimethylbenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-2-(trifluoromethoxy)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-2-cyanobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3-cyanobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3-fluorobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-fluorobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluorobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-dichlorobenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,4-dimethoxyl benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3-methylbenzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-methylsulfonyl)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-acetamido)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4-(pyrrolidine-1-carboxamido)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)benzo(c)[1,2,5]thiazole-4-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3-(5-methyl-1,3,4-oxadizol-2-yl)benzenesulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-5-bromothiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4,5-dibromothiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-4,5-dichlorothiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-1-methyl-1H-imidazole-4-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-1,2-dimethyl-1H-imidazole-4-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-dimethyisoxazole-4-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-thiophene-3-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-thiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-5-(oxazol-5-yl)thiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-5-bromo-6-chloro pyridine-3-sulfonamide
N-(1-Benzyl-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-6-morpholino chloro pyridine-3-sulfonamide
(S)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(R)—N-(1-Benzyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S) N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(R) N-(1-Benzyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
(S) N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-(2-oxopyridin-1(2H)-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-pyridin-2-yl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-pyridin-3-yl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-pyridin-4-yl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-[1-Benzyl-6-(3-fluoro-phenyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-(1-Benzyl-6-thiophen-2-yl-1,2,3,4-tetrahydro quinolin-3-yl)-benzene sulfonamide
N-(1-Benzyl-6-thiophen-3-yl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-vinyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(6-Allyl-1-benzyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-(4-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(6-methoxypyridin-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(4-(benzyloxy)-3-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(2-oxopyrrolidin-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(2-oxopiperidin-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(1H-imidazol-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(1H-pyrazol-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(3-fluoro-4-hydroxyphenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(6-hydroxypyridin-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
(R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-hydroxybenzenesulfonamide
(R)—N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-(dihydrogen phosphate)benzenesulfonamide
N-(1-(3-Cyanobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-2-acetamido-4-methyl thiazole-5-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-dimethylisoxazole-4-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-1-methyl-1H-imidazole-4-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-5-chloro-1,2-dimethyl-1H-imidazole-4-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-1,2-dimethyl-1H-imidazole-4-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-5-(oxazol-5-yl)-thiophene-2-sulfonamide
N-(1-Benzyl-6-(4-fluoro phenyl)-1,2,3,4-tetrahydro quinolin-3-yl)-5-(isoxazole-3-yl)thiophene-2-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-5-chlorothiophene-2-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-5-methyl-2-(trifluoromethyl)furan-3-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)pyridine-2-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)pyridine-3-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-5-(trifluomethyl)pyridine-2-sulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-fluorobenzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-chlorobenzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-methylbenzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-cyanobenzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluorobenzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methanesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)(pyridin-3-yl)methanesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)(pyridin-4-yl)methanesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)(pyridin-2-yl)methanesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-2-phenylethene sulfonamide
N-(1-(3-Chlorobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Fluorobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Methylbenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Methoxylbenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Chlorobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl))-3,5-difluorobenzene sulfonamide
N-(1-(3-Chlorobenzyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl))-3-cyanobenzenesulfonamide
3-Benzenesulfonylamino-1-benzyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid amide
3-Benzenesulfonylamino-1-benzyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid
N-[1-Benzyl-6-(morpholine-4-carbonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-[1-Benzyl-6-(piperidine-1-carbonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-[1-Benzyl-6-(pyrrolidine-1-carbonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-3-methyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
(S)—N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
(R)—N-(1-Benzyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-7-chloro-1,2,3,4-tetrahydroquinolin-3-yl)-3,5-difluorobenzenesulfonamide
N-(6-Cyano-1-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-(3-Chlorophenyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S)-Piperidine-1-sulfonic acid (1-benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-amide
Morpholine-4-sulfonic acid [1-(3-chloro-benzyl)-6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl]-amide
N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-2-oxooxazolidine-3-sulfonamide
N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-cyclohexylamino-3-sulfonamide
N-(1-Benzyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-anilinyl-3-sulfonamide
(S)—N-(1-Benzoyl-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
(S)—N-[1-(3-Chloro-benzoyl)-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl]-benzenesulfonamide
N-(1-Benzoyl-8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzoyl-8-bromo-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-8-chloro-6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-8-bromo-6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide
N-(1-Benzenesulfonyl-6-bromo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzenesulfonyl-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide
N-(1-Benzyl-6-phenoxy-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(8-Phenoxy-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
N-(1-Benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-2-oxo-2-phenylacetamide
Ethyl 2-(1-benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-ylamino)-2-oxoacetate
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical combination comprising a compound of claim 5 and a therapeutic agent selected from anti-obesity agents; appetite suppressants; anti-diabetic agents; anti-hyperlipidemia agents; hypolipidemic agents; hypocholesterolemic agents; lipid-modulating agents; cholesterol-lowering agents; lipid-lowering agents; HDL-raising agent, anti-hypertensive agents; agents used to treat sleep disorders; agents used to treat substance abuse and addictive disorders; anti-anxiety agents; anti-depressants; anti-psychotic agents; cognition enhancing agents; agents used to treat cognitive disorders; agents used to treat Alzheimer's disease; agents used to treat Parkinson's disease; anti-inflammatory agents; agents used to treat neurodegeneration; agents used to treat arteriosclerosis; agents used to treat respiratory conditions; agents used to treat bowel disorders; cardiac glycosides; and anti-tumor agents.
7. A pharmaceutical combination of claim 6 wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of the pharmaceutical composition of claim 5.
8. A pharmaceutical combination of claim 6 wherein the anti-obesity agent is selected from melanocortin receptor (MC4R) agonists; melanin-concentrating hormone receptor (MCHR) antagonists; growth hormone secretagogue receptor (GHSR) antagonists; galanin receptor modulators; orexin antagonists; CCK agonists; GLP-1 agonists and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonists; NPY2 and NPY4 modulators; corticotropin releasing factor agonists; histamine receptor-3 (H3) modulators; aP2 inhibitors; PPAR gamma modulators; PPAR delta modulators; acetyl-CoA carboxylase (ACC) inhibitors; 11-β-HSD-1 inhibitors; adiponectin receptor modulators; beta 3 adrenergic agonists, including AJ9677, L750355 and CP331648 or other known beta 3 agonists; thyroid receptor beta modulator; lipase inhibitors, including orlistat and ATL-962; serotonin receptor agonists, including BVT-933; monoamine reuptake inhibitors or releasing agents, including fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetarnine, phentermine, phenylpropanolamine and mazindol; anorectic agents, including topiramate; ciliary neurotrophic factor, including Axokine; brain-derived neurotrophic factor; leptin and leptin receptor modulators and other cannabinoid-1 receptor antagonists, including SR-141716 and SLV-319.
9. A pharmaceutical combination of claim 6 wherein the anti-diabetic agent is selected from insulin secretagogues; insulin sensitizers; anti-hyperglycemic agents; biguanides; sulfonyl ureas; glucosidase inhibitors; aldose reductase inhibitors; PPAR γ agonists including thiazolidinediones; PPAR α agonists, including fibric acid derivatives; PPAR δ antagonists or agonists; PPAR α/γ dual agonists; 11-β-HSD-1 inhibitors; dipeptidyl peptidase IV inhibitors; SGLT2 inhibitors; glycogen phosphorylase inhibitors; meglitinides; insulin; glucagon-like peptide-1; glucagon-like peptide 1 agonists; and protein tyrosine phosphatase-1B inhibitors.
10. A pharmaceutical combination of claim 9 wherein the anti-diabetic agent is an oral antihyperglycemic agent selected from the biguanides, metformin, phenformin, metformin HCl and other salts thereof.
11. A pharmaceutical combination of claim 10 wherein the other therapeutic agent is a biguanide and the compound of claim 1 will be administered in a weight ratio to the biguanide within the range from about 0.001:1 to about 10:1.
12. A pharmaceutical combination of claim 11 wherein the other therapeutic agent is a biguanide and the compound of claim 1 will be administered in a weight ratio to the biguanide within the range from about 0.01:1 to about 5:1.
13. A pharmaceutical combination of claim 9 wherein the sulfonyl ureas are selected from glyburide, glibenclamide, glimepiride, glipizide, gliclazide, chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells.
14. A pharmaceutical combination of claim 13 wherein the combination of the compound of claim 1 and the sulfonyl urea is administered in the same or separate oral dosage forms.
15. A pharmaceutical combination of claim 9 wherein the glucosidase inhibitor is selected from acarbose and miglitol.
16. A pharmaceutical combination of claim 15 wherein the combination of the compound of claim 1 and the glucosidase inhibitor is administered in the same or separate oral dosage forms.
17. A pharmaceutical combination of claim 9 wherein the PPAR γ agonist is a thiazolidinedione oral anti-diabetic agent.
18. A pharmaceutical combination of claim 9 wherein the insulin sensitizer is selected from rosiglitazone, pioglitazone, MCC-555, GL-262570, englitazone, darglitazone, isaglitazone; JTT-501, L-895645, R-1 19702, NN-2344, and YM-440.
19. A pharmaceutical combination of claim 9 wherein the PPARα/γ dual agonists are selected from MK-767/KRP-297, tesaglitazar and muraglitazar.
20. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is an HMG CoA reductase inhibitor selected from mevastatin; compounds related to mevastatin; lovastatin; mevinolin; compounds related to lovastatin and mevinolin; pravastatin and compounds related to pravastatin; simvastatin and compounds related to simvastatin; fluvastatin; cerivastatin; atorvastatin; pitavastatin; nisvastatin; itavastatin; rosuvastatin; visastatin; compounds related to rosuvastatin and visastatin; pyrazole analogs of mevalonolactone derivatives; indene analogs of mevalonolactone derivatives; 6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivatives thereof; SC-45355; 3-substituted pentanedioic acid derivative; dichloroacetate; imidazole analogs of mevalonolactone; 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives; 2,3-disubstituted pyrrole, furan and thiophene derivatives; naphthyl analogs of mevalonolactone; octahydronaphthalenes; keto analogs of lovastatin and mevinolin; quinoline and pyridine derivatives; and phosphinic acid compounds.
21. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is a squalene synthetase inhibitor selected from α-phosphono-sulfonates; isoprenoid (phosphinyl-methyl)phosphonates; terpenoid pyrophosphates; farnesyl diphosphate analog A and presqualene pyrophosphate analogs; phosphinylphosphonates; and cyclopropanes.
22. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is a fibric acid derivative selected from fenofibrate; gemfibrozil; clofibrate; bezafibrate; ciprofibrate; clinofibrate; probucol; and compounds related to probucol.
23. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is a bile acid sequestrant selected from cholestyramine; colestipol; DEAE-Sephadex; Secholex; Policexide; cholestagel; lipostabil; E-5050; N-substituted ethanolamine derivatives; imanixil; tetrahydrolipstatin; istigmastanylphos-phorylcholine; aminocyclodextrin; AJ-814; azulene derivatives; melinamide; 58-035; CL-277,082; CL-283,546; disubstituted urea derivatives; nicotinic acid; niacin; acipimox; acifran; neomycin; p-aminosalicylic acid; aspirin; poly(diallylmethylamine) derivatives; quaternary amine poly(diallyldimethylammonium chloride; ionenes; and other known serum cholesterol lowering agents.
24. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is an acyl CoA:cholesterol O-acyl transferase inhibitor selected from substituted N-phenyl-N′-[(1-phenylcyclopentyl)methyl]ureas; TS-962; F-1394; CS-505; F-12511; HL-004; K-10085; and YIC-C8-434.
25. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is an upregulator of LDL receptor activity including MD-700.
26. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is a cholesterol absorption inhibitor including ezetimibe.
27. A pharmaceutical combination of claim 6 wherein the lipid-modulating agent is a cholesteryl transfer protein inhibitor selected from CP-529,414; SC-744; SC-795; CETi-1; and JTT-705.
28. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is an ileal Na+/bile acid cotransporter inhibitor.
29. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is an ATP citrate lyase inhibitor.
30. A pharmaceutical combination of claim 6 wherein the lipid-modulating agents are selected from a phytoestrogen compound selected from isolated soy bean protein, soy protein concentrate, soy flour, isoflavone, genistein, daidzein, glycitein or equol, or phytosterols, phytostanol and tocotrienol; a beta-lactam cholesterol absorption inhibitor; an HDL upregulator selected from an LXR agonist, a PPAR α-agonist and an FXR agonist; an LDL catabolism promoter; a sodium-proton exchange inhibitor; an LDL-receptor inducer; steroidal glycoside; an anti-oxidant selected from beta-carotene, ascorbic acid, α-tocopherol, retinol, Vitamin C antihomocysteine agent, folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E; isoniazid; a cholesterol absorption inhibitor; an HMG-CoA synthase inhibitor; a lanosterol demethylase inhibitor; a PPAR δ agonist for treating dyslipidemia; a sterol regulating element binding protein-I selected from a sphingolipid, ceramide, neutral sphingomyelenase or fragment thereof.
31. A pharmaceutical combination of claim 6 wherein the hypolipidemic agent is selected from pravastatin; lovastatin; simvastatin; atorvastatin; fluvastatin; pitavastatin; rosuvastatin; niacin and cholestagel.
32. A pharmaceutical combination of claim 6 wherein the anti-hypertensive agents is selected from beta adrenergic blockers; L-type channel blockers selected from diltiazem, verapamil, nifedipine, amlodipine and mybefradil; T-type calcium channel blockers selected from diltiazem, verapamil, nifedipine, amlodipine and mybefradil; diuretics selected from chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride and spironolactone; renin inhibitors; ACE inhibitors selected from captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril and lisinopril; AT-1 receptor antagonists selected from losartan, irbesartan and valsartan; ET receptor antagonists selected from sitaxsentan and atrsentan; Dual ET/All antagonists; neutral endopeptidase inhibitors; vasopepsidase inhibitors and dual NEP-ACE inhibitors selected from omapatrilat and gemopatrilat; and nitrates.
33. A pharmaceutical combination of claim 6 wherein the agent used to treat sleep disorders is selected from melatonin analogs; melatonin receptor antagonists; ML 1 B agonists; GABA receptor modulators; NMDA receptor-modulators; histamine-3 (H3)receptor modulators; dopamine agonists and orexin receptor modulators.
34. A pharmaceutical combination of claim 6 wherein the agent used to treat substance abuse and addictive disorders is selected from selective serotonin reuptake inhibitors; methadone; buprenorphine; nicotine; and bupropion.
35. A pharmaceutical combination of claim 6 wherein the anti-anxiety agent is selected from benzodiazepines selected from diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam; 5HT1A receptor agonists selected from buspirone, flesinoxan, gepirone and ipsapirone; and corticotropin releasing factor antagonists.
36. A pharmaceutical combination of claim 6 wherein the anti-depressant agent is selected from norepinephrine reuptake inhibitors selected from tertiary and secondary amine tricyclics; selective serotonin reuptake inhibitors selected from fluoxetine, fluvoxamine, paroxetine and sertraline; monoamine oxidase inhibitors selected from isocarboxazid, phenelzine, tranylcypromine and selegiline; reversible inhibitors of monoamine oxidase including moclobemide; serotonin and norepinephrine reuptake inhibitors including venlafaxine; corticotropin releasing factor receptor antagonists; alpha-adrenoreceptor antagonists; and atypical antidepressants selected from bupropion, lithium, nefazodone, trazodone and viloxazine.
37. A pharmaceutical combination of claim 6 wherein the anti-psychotic agent is selected from phenothiazine selected from chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine; thioxanthine selected from chlorprothixene and thiothixene; heterocyclic dibenzazepine selected from clozapine, olanzepine and aripiprazole; butyrophenone, including haloperidol; dipheyylbutylpiperidine, including pimozide; indolone and molindolone classes of anti-psychotic agents; loxapine; sulpiride; risperidone; dopamine receptor antagonists; muscarinic receptor agonists; 5HT2A receptor antagonists, 5HT2A/dopamine receptor antagonists and partial agonists selected from olanzepine, aripiprazole, risperidone and ziprasidone.
38. A pharmaceutical combination of claim 6 wherein the cognition-enhancing agent is selected from acetylcholinesterase inhibitors, including tacrine; muscarinic receptor-1 agonists, including milameline; nicotinic agonists; glutamic acid receptor modulators; and nootropic agents selected from piracetam and levetiracetam.
39. A pharmaceutical combination of claim 6 wherein the agent used to treat Alzheimer's disease and the agent used to treat cognitive disorders are selected from donepezil; tacrine; revastigraine; 5HT6; gamma secretase inhibitors; beta secretase inhibitors; SK channel blockers; Maxi-K blockers; and KCNQs blockers.
40. A pharmaceutical combination of claim 6 wherein the agent used to treat Parkinson's disease is selected from levadopa with or without a COMT inhibitor; antiglutamatergic drugs selected from amantadine and riluzole; alpha-2 adrenergic antagonists including idazoxan; opiate antagonists including naltrexone; other dopamine agonists and transportor modulators including ropinirole; and pramipexole or neurotrophic factors including glial derived neurotrophic factor.
41. A pharmaceutical combination of claim 6 wherein the anti-inflammatory agent is selected from prednisone; dexamethasone; cyclooxygenase inhibitors including COX-1 and COX-2 inhibitors selected from NSAID's, aspirin, indomethacin, ibuprofen, piroxicam, Naproxen, Celebrex and Vioxx; CTLA4-Ig agonists and antagonists; CD40 ligand antagonists; IMPDH inhibitors including mycophenolate; integrin antagonists; alpha-4 beta-7 integrin antagonists; cell adhesion inhibitors; interferon gamma antagonists; ICAM-1; tumor necrosis factor antagonists selected from infliximab, OR1384, TNF-alpha inhibitors including tenidap, anti-TNF antibodies or soluble TNF receptors including etanercept; rapamycin selected from sirolimus and Rapamune; eflunomide; prostaglandin synthesis inhibitors; budesonide; clofazimine; CNI-1493; CD4 antagonists including priliximab; p38 mitogen-activated protein kinase inhibitors; protein tyrosine kinase inhibitors; IKK inhibitors; and agents for treatment of irritable bowel syndrome selected from Zelnorm and Maxi-K openers.
42. A pharmaceutical combination of claim 6 wherein the other therapeutic agent is selected from cyclosporins; cyclosporin A; anti-IL-2 receptor; anti-CD45RB; anti-CD2; anti-CD3 (OKT-3); anti-CD4; anti-CD80; anti-CD86; monoclonal antibody OKT3; agents blocking the interaction between CD40 and gp39; antibodies specific for CD40 and/or gp39; CD 154; fusion proteins constructed from CD40 and gp39; CD40Ig; CD8gp39; nuclear translocation inhibitors of NF-kappa B function; deoxyspergualin; gold compounds; antiproliferative agents selected from methotrexate, FK506, tacrolimus, Prograf and mycophenolate mofetil; cytotoxic drugs selected from azathiprine and cyclophosphamide; anticytokines selected from antiIL-4 or IL-4 receptor fusion proteins; PDE 4 inhibitors including Ariflo and PTK inhibitors.
43. A method for the treatment or prevention of diseases and disorders associated with G-protein coupled cannabinoid receptor activity, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in formula 1.
Figure US20050014786A1-20050120-C00260
including all pharmaceutically acceptable salts and stereoisomers, wherein:
R1 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, halo, CF3, CN, nitro, OR11, NR12R12a, COOR12 and CONR12R12a;
R3 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R4 is selected from the group consisting of hydrogen, alkyl, halo and CN;
R5 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, COOR13 and CONR13R13a;
R6 and R6a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
R7 and R7a are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl;
R8 is selected from the group consisting of hydrogen and alkyl;
R9 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R10 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R11 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, CHF2 and CF3;
R12 and R12a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R12 and R12a taken together can form cycloalkyl or heterocyclyl;
R13 and R13a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R13 and R13a taken together can form cycloalkyl or heterocyclyl;
X is selected from the group consisting of (CR14R14n)n, CO, COO, S(O)2, SO2N(R12) and CON(R12);
or R5 and R12 taken together can form cycloalkyl or heterocyclyl;
Y is selected from the group consisting of S(O)2, SO2N(R15) and C(O)C(O);
R14 and R14a are each independently selected from the group consisting of hydrogen, alkyl;
R15 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R10 and R15 taken together can form cycloalkyl or heterocyclyl;
n is an integer of 0, 1, or 2.
44. A method for the treatment of diseases or disorders associated with the activity of the CB-1 receptor, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
45. A method for the treatment of bulimia, obesity or any disease resulting in the patient becoming overweight, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
46. A method for the treatment of metabolic disorders, eating disorders and appetitive disorders, including treatment of the conditions associated with those disorders, such as obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders, hyperlipidemic conditions, bulimia nervosa and compulsive eating disorders, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
47. A method for the treatment of obesity due to genetic or environmental causes, including overeating and bulemia, polycycstic ovary disease, craniopharyngeoma, Prader-Willi Syndrome, Frohlich's Syndrome, Type II diabetes, growth hormone deficiency, Turner's Syndrome and other pathological states characterized by reduced metabolic activity or reduced energy expenditure, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
48. A method for the treatment of psychiatric disorders selected from substance abuse, addictive disorders, depression, anxiety, mania and schizophrenia, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
49. A method for the improvement of cognitive function and memory impairment, including the treatment of diseases selected from dementia, Alzheimer's disease, short term memory loss and attention deficit disorders; neurodegenerative disorders, Parkinson's Disease, cerebral apoplexy and craniocerebral trauma; hypotension, hemorrhagic and endotoxin-induced hypotension; Parkinson's disease; Huntington's disease; Pick's disease; Creutzfeld-Jakob disease; head trauma; and age-related cognitive decline, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
50. A method for the treatment of diseases associated with dysfunction of brain dopaminergic systems including Parkinson's Disease and substance abuse disorders, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
51. A method for the treatment of diseases selected from catabolism in connection with pulmonary dysfunction and ventilator dependency; cardiac dysfunction, valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure; transplant rejection; rheumatoid arthritis; multiple sclerosis; inflammatory bowel disease; lupus; graft vs. host disease; T-cell mediated hypersensitivity disease; psoriasis; asthma; Hashimoto's thyroiditis; Guillain-Barre syndrome; cancer; contact dermatitis; allergic rhinitis; and ischemic or reperfusion injury, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
52. A method for the treatment of substance abuse or dependence disorders in which substances of abuse or dependence include alcohol, amphetamines, amphetamine-like substances, caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, phencyclidine-like compounds, sedative-hypnotics, benzodiazepines, other known or unknown substances, or combinations of the substances of abuse, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
53. A method of treatment of claim 52 wherein the substance abuse or dependence may occur without physiological dependence.
54. A method of treatment of drug or alcohol withdrawal syndromes and substance-induced anxiety or mood disorder with onset during withdrawal, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
55. A method for the treatment of leukocyte activation-associated disorders including rejection due to organ transplant, acute transplant, xenotransplant, heterograft and homograft; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; rheumatoid arthritis, psoriatic arthritis and osteoarthritis; multiple sclerosis; chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, and acute respiratory distress syndrome (ARDS); inflammatory bowel disease, ulcerative colitis and Crohn's disease; systemic lupus erythematosis; graft vs. host disease; T-cell mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy and Celiac disease; psoriasis; contact dermatitis; Hashimoto's thyroiditis; Sjogren's syndrome; autoimmune hyperthyroidism, such as Graves' Disease; Addison's disease; autoimmune polyglandular disease or syndrome; autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases; glomerulonephritis; serum sickness; uticaria; asthma, hayfever, allergic rhinitis and skin allergies; scleracierma; mycosis fungoides; acute inflammatory and respiratory responses, including acute respiratory distress syndrome and ishchemia/reperfusion injury; dermatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis palmoplanteris; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic schlerosis; and morphea, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
56. A method for the treatment of inflammatory diseases, including arthritis, inflammatory bowel disease and autoimmune glomerulonephritis, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 43.
US10/889,274 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators Abandoned US20050014786A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/889,274 US20050014786A1 (en) 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/108,616 US7884113B2 (en) 2003-07-11 2008-04-24 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/984,628 US8119808B2 (en) 2003-07-11 2011-01-05 Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48677403P 2003-07-11 2003-07-11
US10/889,274 US20050014786A1 (en) 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/108,616 Continuation US7884113B2 (en) 2003-07-11 2008-04-24 Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
US20050014786A1 true US20050014786A1 (en) 2005-01-20

Family

ID=34079298

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/889,274 Abandoned US20050014786A1 (en) 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US10/889,268 Expired - Lifetime US7276608B2 (en) 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/108,616 Expired - Lifetime US7884113B2 (en) 2003-07-11 2008-04-24 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/984,628 Expired - Lifetime US8119808B2 (en) 2003-07-11 2011-01-05 Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/889,268 Expired - Lifetime US7276608B2 (en) 2003-07-11 2004-07-12 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/108,616 Expired - Lifetime US7884113B2 (en) 2003-07-11 2008-04-24 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US12/984,628 Expired - Lifetime US8119808B2 (en) 2003-07-11 2011-01-05 Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Country Status (3)

Country Link
US (4) US20050014786A1 (en)
EP (2) EP1644335A4 (en)
WO (2) WO2005007628A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
WO2007096489A1 (en) * 2006-02-17 2007-08-30 Trimaran Limited Novel pharmaceutical compositions for optimizing replacement treatments and broadening the pharmacopeia for the overall treatment of addictions
WO2007079470A3 (en) * 2006-01-03 2007-12-06 Algebra Inc Therapeutic amine-arylsulfonamide conjugate compounds
US20080045583A1 (en) * 2006-08-18 2008-02-21 David Delmarre Stable levetiracetam compositions and methods
US20080221160A1 (en) * 2007-03-06 2008-09-11 Wyeth Sulfonylated heterocycles useful for modulation of the progesterone receptor
US20090048232A1 (en) * 2007-04-11 2009-02-19 Roberto Ciccocioppo Compositions and methods for prophylaxis and treatment of addictions
US20090137556A1 (en) * 2004-08-18 2009-05-28 Ace Aps Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
US20100190986A1 (en) * 2005-06-09 2010-07-29 Antonini Enrico A Method for Separation and Purification of Naltrexone By Preparative Chromatography
US20100234413A1 (en) * 2007-04-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN101367761B (en) * 2008-09-24 2011-05-11 中国科学院上海有机化学研究所 6,7- substituted-2,2,4-trimethyl-tetrahydroquinoline-1-carboxylic acid aryl amide, synthesis and uses thereof
CN102985402A (en) * 2010-04-20 2013-03-20 罗马大学 Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2
EP2727915A1 (en) 2007-09-13 2014-05-07 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders
US20170155159A1 (en) * 2014-07-02 2017-06-01 Volkswagen Ag Fuel cell device having a water-transferring anode gas path, and method for operating a fuel cell
US9909178B2 (en) 2013-03-27 2018-03-06 Hoffmann-La Roche Inc. Dalcetrapib for therapeutic use
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 A cellular model based on exogenous histamine detection and its application
CN110016145A (en) * 2019-05-08 2019-07-16 北京工业大学 Porous metal-organic framework material, preparation method and adsorption and separation application thereof
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10584385B2 (en) 2014-07-30 2020-03-10 Hoffmann-La Roche Inc. Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
EP3870292A1 (en) 2018-10-26 2021-09-01 The Research Foundation for The State University of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12257307B2 (en) 2019-06-24 2025-03-25 Diverse Biotech, Inc. β-lactam-cannabinoid conjugate molecules
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014786A1 (en) * 2003-07-11 2005-01-20 Chongqing Sun Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060025448A1 (en) * 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
EP1929310A2 (en) * 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
EP1986638A2 (en) * 2006-02-21 2008-11-05 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
EP2013182B1 (en) * 2006-03-13 2013-09-04 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as gsk-3 inhibitors
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
KR101019455B1 (en) * 2006-07-26 2011-03-07 테바 파마슈티컬 인더스트리즈 리미티드 Synthesis method of O-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
KR20090047458A (en) 2006-08-08 2009-05-12 사노피-아벤티스 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, methods of preparation thereof, medicaments comprising these compounds and uses thereof
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
WO2008079316A1 (en) * 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20090036426A1 (en) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
BRPI0816798A2 (en) 2007-09-11 2016-10-11 Activx Biosciences Inc compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
CN101855229A (en) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 Spirocyclic aminoquinolones as GSK-3 inhibitors
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CN101423513B (en) * 2007-10-29 2013-03-27 中国医学科学院药物研究所 Amine pyrimidine derivates, and production method thereof, and medicament composition and use
EP2242745A1 (en) * 2008-02-07 2010-10-27 Sanofi-Aventis Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof
DK2241564T3 (en) * 2008-02-08 2014-05-19 Zeria Pharm Co Ltd 3,8-DIAMINOTETRAHYDROQUINOLIN DERIVATIVE
WO2009128734A1 (en) * 2008-04-18 2009-10-22 Vialactia Biosciences (Nz) Limited Marker assisted identification of mammals for desired phenotypic trait
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AT507187B1 (en) 2008-10-23 2010-03-15 Helmut Dr Buchberger INHALER
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2011009414A (en) 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cycloalkylaminoquinolones as gsk-3 inhibitors.
WO2010146488A1 (en) * 2009-06-18 2010-12-23 Pfizer Inc. Bicyclic and tricyclic compounds as kat ii inhibitors
JP2013503135A (en) 2009-08-26 2013-01-31 サノフイ Novel crystalline heteroaromatic fluoroglycoside hydrate, pharmaceutical comprising the compound and use thereof
FR2950055A1 (en) * 2009-09-17 2011-03-18 Sanofi Aventis SUBSTITUTED 3-AMINO-CINNOLIN-4 (1H) -ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CN102639700A (en) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
JP2013509434A (en) * 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
USD655868S1 (en) * 2009-11-19 2012-03-13 Venus Jones Pooper scooper glove
KR101409554B1 (en) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. Crystal forms of o-desmethylvenlafaxine fumarate
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
EP2646417A1 (en) * 2010-12-01 2013-10-09 Pfizer Inc Kat ii inhibitors
MX2013005773A (en) * 2010-12-01 2013-06-18 Pfizer Kat ii inhibitors.
CA2726085A1 (en) * 2010-12-20 2012-06-20 Bernard Le Foll User of marihuana and compounds therein for treating obesity
CN103491815B (en) 2011-02-11 2016-01-20 巴特马克有限公司 Inhalator assembly
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
ES2450746B2 (en) * 2012-03-14 2015-01-26 Universidad Complutense De Madrid Preparation and cytotoxicity of 2-quinolones
WO2013166015A1 (en) * 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9266835B2 (en) 2014-02-27 2016-02-23 Janssen Pharmaceutica Nv Quinoline derivatives useful as CB-1 inverse agonists
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
EP3227279B1 (en) * 2014-12-02 2019-02-13 Eli Lilly and Company 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
TWI767896B (en) 2015-12-22 2022-06-21 美商英塞特公司 Heterocyclic compounds as immunomodulators
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
GEP20227428B (en) 2016-12-22 2022-10-25 Incyte Corp Heterocyclic compounds as immunomodulators
MA47099A (en) 2016-12-22 2021-05-12 Incyte Corp BICYCLIC HETEROAROMATIC COMPOUNDS USED AS IMMUNOMODULATORS
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CR20200520A (en) 2018-03-30 2021-03-09 Incyte Corp Heterocyclic compounds as immunomodulators
PT3790877T (en) 2018-05-11 2023-05-10 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN112007156A (en) * 2019-05-30 2020-12-01 复旦大学 Application of cannabinoid receptor drug in preparation of drug for treating myocardial cell necrotic apoptosis
CN110420180A (en) * 2019-07-24 2019-11-08 西北农林科技大学 A kind of nanoemulsion medicine and preparation method thereof containing vitamin E
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20230407A1 (en) 2019-11-11 2023-03-07 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022204014A1 (en) * 2021-03-25 2022-09-29 Per Os Biosciences, Llc. Compositions and methods for treating coronavirus
EP4543437A1 (en) * 2022-06-23 2025-04-30 The Cleveland Clinic Foundation 3-?hsd1 inhibitors and compositions and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107252A (en) * 1996-05-02 2000-08-22 Bayer Aktiengesellschaft Substituted phenyl uracils and their use as herbicides
US20010021709A1 (en) * 1997-02-13 2001-09-13 Merck Patent Gesellschaft Mit Beschrankt Patents Bicyclic amino acids
US6387926B1 (en) * 1997-07-02 2002-05-14 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6541661B1 (en) * 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
US20030232804A1 (en) * 2001-12-04 2003-12-18 Pinto Donald J.P. Glycinamides as factor Xa inhibitors
US20040002495A1 (en) * 2002-05-20 2004-01-01 Philip Sher Lactam glycogen phosphorylase inhibitors and method of use
US20040082798A1 (en) * 2001-03-07 2004-04-29 Cristina Alonso-Alija Novel amino dicarboxylic acid derivatives with pharmaceutical properties

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554737A (en) 1949-07-22 1951-05-29 Geigy Ag J R Basically substituted tetrahydroquinoline derivatives
DE3163199D1 (en) 1980-07-17 1984-05-24 Sandoz Ag Novel pentapeptides, processes for their production, pharmaceutical compositions comprising said pentapeptides and their use
US4371720A (en) 1980-09-19 1983-02-01 Pfizer Inc. 2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives
US5068234A (en) 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013387A (en) 1990-04-10 1991-05-07 Monarch Marking Systems, Inc. Hand-held labeller
DE69206725T2 (en) 1991-09-10 1996-05-02 Zeneca Ltd Benzenesulfonamide derivatives as 5-lipoxygenase inhibitors
IL101927A0 (en) 1992-05-19 1992-12-30 Yissum Res Dev Co Probe for cannabinoid receptors
GB2272439A (en) 1992-11-13 1994-05-18 Merck & Co Inc Benzo-fused lactams that inhibit the release of growth hormone
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
AU5772396A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2735774B1 (en) 1995-06-21 1997-09-12 Sanofi Sa USE OF HUMAN CB2 RECEPTOR AGONIST COMPOUNDS FOR THE PREPARATION OF IMMUNOMODULATORY DRUGS, NOVEL CB2 RECEPTOR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
NZ332073A (en) 1996-03-29 2000-05-26 Dimensional Pharm Inc Substituted hydrazinecarboximines as non-peptidic protease inhibitors
US5773203A (en) 1996-05-16 1998-06-30 Fuji Photo Film Co., Ltd. 4-(N,N-dialkylamino)aniline compounds, photographic processing composition containing the same and color image-forming method
CA2283797A1 (en) 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
WO1999002499A1 (en) 1997-07-11 1999-01-21 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
JP2001513560A (en) * 1997-08-28 2001-09-04 ブリストル−マイヤーズ スクイブ カンパニー 4-Aryl-3-aminoquinolin-2-one derivative potassium channel regulator
ID28692A (en) 1998-09-09 2001-06-28 Ishihara Sangyo Kaisha BENZENA HOLIDAYS ARE USED AS HERBISIDES
CN1129582C (en) 1998-12-04 2003-12-03 布里斯托尔-迈尔斯斯奎布公司 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
JP2000256323A (en) * 1999-01-08 2000-09-19 Japan Tobacco Inc 2-oxoquinoline compound and its medicinal use
AU2001255408A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005507875A (en) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット Novel pyrazole analogues acting on cannabinoid receptors
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
ES2252524T3 (en) 2001-09-24 2006-05-16 Bayer Pharmaceuticals Corporation PREPARATION AND USE OF DERIVATIVES OF 1,5,6,7-TETRAHYDROPIRROLO (3,2-C) PIRIDINE FOR THE TREATMENT OF OBESITY.
JP2005532982A (en) 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン Production and use of pyrrole derivatives for the treatment of obesity
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
SE0104330D0 (en) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
MXPA03000966A (en) 2002-02-28 2003-09-04 Pfizer Prod Inc Antidiabetic agents.
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
WO2004015130A2 (en) 2002-08-07 2004-02-19 Exelixis Modulators of rabggt and methods of use thereof
US20050014786A1 (en) * 2003-07-11 2005-01-20 Chongqing Sun Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US8554512B2 (en) 2006-06-13 2013-10-08 Nike, Inc. Athletic performance data system and method
US8897586B2 (en) 2012-06-15 2014-11-25 Comcast Cable Communications, Llc Dynamic generation of a quantization matrix for compression of a digital object

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107252A (en) * 1996-05-02 2000-08-22 Bayer Aktiengesellschaft Substituted phenyl uracils and their use as herbicides
US20010021709A1 (en) * 1997-02-13 2001-09-13 Merck Patent Gesellschaft Mit Beschrankt Patents Bicyclic amino acids
US6559144B2 (en) * 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
US6387926B1 (en) * 1997-07-02 2002-05-14 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6541661B1 (en) * 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
US20040082798A1 (en) * 2001-03-07 2004-04-29 Cristina Alonso-Alija Novel amino dicarboxylic acid derivatives with pharmaceutical properties
US20030232804A1 (en) * 2001-12-04 2003-12-18 Pinto Donald J.P. Glycinamides as factor Xa inhibitors
US20040002495A1 (en) * 2002-05-20 2004-01-01 Philip Sher Lactam glycogen phosphorylase inhibitors and method of use

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137556A1 (en) * 2004-08-18 2009-05-28 Ace Aps Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
US7709647B2 (en) 2005-01-18 2010-05-04 Bristol-Myers Squibb Company Tetrahydroquinoline cannabinoid receptor modulators
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
US7935821B2 (en) 2005-06-09 2011-05-03 Mallinckrodt Inc. Method for separation and purification of naltrexone by preparative chromatography
US20100190986A1 (en) * 2005-06-09 2010-07-29 Antonini Enrico A Method for Separation and Purification of Naltrexone By Preparative Chromatography
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
WO2007079470A3 (en) * 2006-01-03 2007-12-06 Algebra Inc Therapeutic amine-arylsulfonamide conjugate compounds
US7763612B2 (en) 2006-01-03 2010-07-27 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
WO2007096489A1 (en) * 2006-02-17 2007-08-30 Trimaran Limited Novel pharmaceutical compositions for optimizing replacement treatments and broadening the pharmacopeia for the overall treatment of addictions
US20080045583A1 (en) * 2006-08-18 2008-02-21 David Delmarre Stable levetiracetam compositions and methods
US7750038B2 (en) 2007-03-06 2010-07-06 Wyeth Llc Sulfonylated heterocycles useful for modulation of the progesterone receptor
US20080221160A1 (en) * 2007-03-06 2008-09-11 Wyeth Sulfonylated heterocycles useful for modulation of the progesterone receptor
US20090048232A1 (en) * 2007-04-11 2009-02-19 Roberto Ciccocioppo Compositions and methods for prophylaxis and treatment of addictions
US20100234413A1 (en) * 2007-04-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US10064850B2 (en) 2007-04-11 2018-09-04 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8426439B2 (en) 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2727915A1 (en) 2007-09-13 2014-05-07 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
CN101367761B (en) * 2008-09-24 2011-05-11 中国科学院上海有机化学研究所 6,7- substituted-2,2,4-trimethyl-tetrahydroquinoline-1-carboxylic acid aryl amide, synthesis and uses thereof
CN102985402A (en) * 2010-04-20 2013-03-20 罗马大学 Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2
US9909178B2 (en) 2013-03-27 2018-03-06 Hoffmann-La Roche Inc. Dalcetrapib for therapeutic use
US11549142B2 (en) 2013-03-27 2023-01-10 Hoffmann-La Roche Inc. CETP inhibitors for therapeutic use
US10711303B2 (en) 2013-03-27 2020-07-14 Hoffman-La Roche Inc. CETP inhibitors for therapeutic use
US20170155159A1 (en) * 2014-07-02 2017-06-01 Volkswagen Ag Fuel cell device having a water-transferring anode gas path, and method for operating a fuel cell
US12371748B2 (en) 2014-07-30 2025-07-29 Hoffmann-La Roche Inc. Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
US10584385B2 (en) 2014-07-30 2020-03-10 Hoffmann-La Roche Inc. Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
US11401554B2 (en) 2014-07-30 2022-08-02 Hoffman-La Roche Inc. Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders
US10039772B2 (en) 2015-11-13 2018-08-07 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12312375B2 (en) 2017-10-09 2025-05-27 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3870292A1 (en) 2018-10-26 2021-09-01 The Research Foundation for The State University of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 A cellular model based on exogenous histamine detection and its application
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11865126B2 (en) 2019-04-17 2024-01-09 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12447164B2 (en) 2019-04-17 2025-10-21 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN110016145A (en) * 2019-05-08 2019-07-16 北京工业大学 Porous metal-organic framework material, preparation method and adsorption and separation application thereof
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12257307B2 (en) 2019-06-24 2025-03-25 Diverse Biotech, Inc. β-lactam-cannabinoid conjugate molecules
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Also Published As

Publication number Publication date
US7884113B2 (en) 2011-02-08
WO2005007628A1 (en) 2005-01-27
EP1644370A2 (en) 2006-04-12
US8119808B2 (en) 2012-02-21
US7276608B2 (en) 2007-10-02
EP1644335A1 (en) 2006-04-12
WO2005007111A2 (en) 2005-01-27
EP1644370A4 (en) 2008-06-04
US20110104315A1 (en) 2011-05-05
US20050009870A1 (en) 2005-01-13
WO2005007111A3 (en) 2005-04-14
EP1644335A4 (en) 2008-06-04
US20080194625A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
US8119808B2 (en) Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7517900B2 (en) Pyrazole derivatives as cannabinoid receptor modulators
US7037910B2 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
US7517991B2 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7326706B2 (en) Pyrazine modulators of cannabinoid receptors
US7378418B2 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) Bicyclic heterocycles as cannabinoid-1 receptor modulators
EP1891074B1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
US7709647B2 (en) Tetrahydroquinoline cannabinoid receptor modulators
US7317012B2 (en) Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7220859B2 (en) Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) Bicyclic heterocycles as cannabinoid receptor modulators
US20060287342A1 (en) Triazolopyrimidine heterocycles as cannabinoid receptor modulators

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUN, CHONGQING;SITKOFF, DOREE;EWING, WILLIAM R.;AND OTHERS;REEL/FRAME:015090/0548;SIGNING DATES FROM 20040804 TO 20040816

AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUN, CHONGQING;SITKOFF, DOREE;EWING, WILLIAM R.;AND OTHERS;REEL/FRAME:016885/0956;SIGNING DATES FROM 20050907 TO 20050915

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE